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Dendritic cells (DC) are accessory cells distributed throughout non-lymphoid and
lymphoid tissues, and also found in the blood and afferent lymph. These cells represent
1-10% of the leucocytes in ovine afferent lymph, and can be purified using
pseudoafferent cannulation techniques. DC are essential as accessory cells for the
initiation of primary immune responses, and are also the most effective antigen
presenting cells for activation of T cells in the secondary response. However, the
mechanisms underlying the potent accessory capability of DC are currently poorly
understood. The aims of this thesis were to characterise DC surface markers and Fc
receptor expression in primary and secondary immune responses, and to investigate the
effect of enhanced antigen uptake via DC Fc receptors on T cell activation.
The phenotype of DC from the afferent lymph of sheep was investigated by flow
cytometry. MHC class I, class II and CD1 were observed at high levels on the DC
surface, while staining for immunoglobulins was variable. Cells obtained from the
afferent lymph of primed sheep on antigen challenge in vivo showed pronounced and
rapid modulation of surface markers, which may be required for processing and
presentation of antigen and migration to the draining lymph node.
Further characterisation of DC demonstrated staining with polyclonal antisera to
peptides of the bovine Fc receptor Type I for IgG. Western blot analysis of DC lysates
identified bands of the correct sizes for the Type I and II Fc receptors for IgG,
suggesting that both are expressed by ovine afferent lymph DC.
Functional studies were carried out to investigate the role of Fc receptors for IgG in the
uptake and presentation of antigen by DC. Specific antibody greatly increased the
response of CD4+ T cells to substimulatory concentrations of antigen presented by DC,
depending on the antigen/ antibody ratio. F(ab')2 portions of specific antibody and
intact irrelevant antibody were completely ineffective. These results suggest enhanced
presentation of antigen by DC following the uptake of immune complexes via Fc
receptors. Similar results, although with a smaller degree of potentiation, were obtained
using unfractionated peripheral blood mononuclear cells.
Fc receptors on DC would be important in secondary responses in vivo, in which
specific antibody of IgG isotype is present. The potentiation of T cell activation may
also play a role in diseases in which immune complexes are presented by DC.
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Dendritic cells (DC) are specialised accessory cells found in both lymphoid and non-
lymphoid tissues throughout the body. They are very efficient in the generation of T-
dependent immune responses, and are unique in their ability to activate resting T cells.
In recent years much research has concentrated on their distinctive functional
capabilities; however many key areas remain unclear.
DC have been identified in all non-lymphoid tissues with the exception of neural tissue.
Langerhans cells (LC) of the epidermis are probably the best characterised of these
interstitial dendritic cells (Schuler et al 1985). They are thought to act by capturing
antigens in the periphery and migrating to the T cell areas of lymph nodes or spleen, via
afferent lymphatics or the bloodstream. Here, DC interact with recirculating T cells,
activating those specific for the antigen carried (Kripke et al 1990).
DC are essential for the generation of the primary immune response to antigen (Inaba et
al 1990, Macatonia et al 1989). After the initial activation event, other antigen
presenting cells (APCs) such as macrophages and B cells can further stimulate
responding T cells for clonal expansion and effector function development (Metlay et al
1989). In spite of their potent accessory function, very little is known of the
mechanisms by which DC accumulate antigen. This knowledge would facilitate the
modulation of immune responses at a very early stage and may have implications for
vaccine development, and possibly autoimmune diseases in which responses are
mounted against self antigens.
DC from the afferent lymph of sheep form rosettes with IgG-coated erythrocytes, and
take up antigen with greater efficiency in the presence of specific antibody, suggesting
that immune complexes are attached to the DC surface via Fc receptors (FcR) for IgG
(Harkiss et al 1990). IgM is detected on the surface of a proportion of lymph DC, and it
is possible that this antibody could act as a concentrating mechanism for antigen in a
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primary response (Bujdoso et al 1990). In this project, therefore, the mechanisms
involved in the enhanced uptake of antigen by lymph DC, and the functional
consequences of this enhancement in terms of the efficiency of antigen presentation
were investigated.
1.2. Ontogeny: The DC Lineage
Although DC are known to arise from bone marrow progenitors, their development is
not well characterised. DC are not detectable in fresh preparations of bone marrow but
develop during short-term culture in serum-free medium (Steinman and Cohn 1974).
DC precursors do not express major histocompatibility complex (MHC) class II
molecules and are actively dividing in contrast to the functional progeny, which do not
divide and express high levels of MHC class II (Bowers and Berkowitz 1986).
DC and monocytes have some functional and phenotypic properties in common,
suggesting a common precursor (Austyn 1987). Tissue culture studies in human bone
marrow preparations support this theory, with monocytes and DC identified within
mixed colonies (Goordyal and Isaacson 1985, Reid et al 1990). A recent report by
Inaba et al (1993) describes a common origin for murine granulocytes, macrophages
and DCs. Colonies grown in semi-solid methylcellulose developed a small proportion
ofDC (1-2%) when cultures were supplemented with granulocyte/ macrophage colony-
stimulating factor (GM-CSF), a cytokine known to have beneficial effects on DC
viability in vitro (Witmer-Pack et al 1987, Macpherson 1989). DC, identified by
phenotype and functional properties, were not seen when cultures were supplemented
with the lineage-specific M-CSF or G-CSF.
Functional DC isolated from human blood express the myeloid markers CD 13 and
CD33 and the Fc receptors CD32 and CD64, although the latter are downregulated
when DC are cultured. However, the monocyte/ macrophage marker CD 14 is either
absent or expressed at low levels by freshly isolated or cultured DC, and these cells are
not capable of FcR-mediated phagocytosis (Thomas et al 1993a). Taken together with
the superior accessory functions exhibited by DC, these factors suggest that DC and
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monocytes share a common myeloid origin but differentiate along separate pathways
giving rise to their distinctive features.
Proliferating DC precursors have also been identified in murine and human blood
(Inaba et al 1992, Reid et al 1990). As in bone marrow cultures, supplementation with
GM-CSF is required for their development. Studies with human CD34+ haematopoietic
progenitor cells demonstrated the need for TNF-a in addition to GM-CSF for optimal
production of DC in vitro (Caux et al 1992). Mature DC resembled Langerhans cells
with the expression of CD la and Birbeck granules.
It is possible that DC progenitors from the bone marrow enter the blood, and
subsequently other tissues, and then proliferate extensively in these areas, undergoing
maturation in response to the cytokines produced by other cell types. Indeed, it has
recently been demonstrated that thymic DC develop from an intrathymic precursor
population in common with T cells, and do not arrive in the thymus fully differentiated
(Ardavin et al 1993). This also has implications for thymic selection (see below).
1.3. DC in The Induction of Immune Responses
1.3.1. Primary Responses
DC are extremely efficient accessory cells for T-dependent responses in vivo and in
vitro. There seems to be an absolute requirement for DC in the development of a
primary response where naive T cells must be activated (Austyn 1987, Metlay et al
1989, Ronchese & Hausmann 1993). DC were found to be necessary for initiation of
the primary allogeneic mixed leucocyte reaction (MLR); B cells, B blasts and MHC
class II-expressing peritoneal macrophages were ineffective (Inaba and Steinman
1984).
Priming of naive T cells in situ has been demonstrated in cattle and rodents. DC
collected from the afferent lymph of non-immune cattle were pulsed in vitro with
ovalbumin, and returned to the donor by intradermal injection after thorough washing.
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Antigen-specific responses were detected in PBMs from 1-5 weeks after DC
administration (McKeever et al 1992). In mice, lymphoid DC pulsed in vitro with
protein or peptide antigens and injected into the footpad led to the development of
antigen-specific CD4+ T cells in the draining lymph node (Inaba et al 1990, Levin et al
1993). Direct stimulation of host cells by antigen-bearing DC was shown by MHC
restriction; pulsed DC of parental strain were administered to F1 hybrid recipients, and
the T cells that were primed then responded to antigen in the context of the MHC class
II products of the donor DC. Antigen-pulsed B cells and macrophages were unable to
induce a primary response in vivo. DC obtained from thoracic duct cannulations of rats
following mesenteric lymphadenectomy were effective at inducing T cell responses in
naive animals, when antigen was acquired either in vivo or in vitro. (Liu &
Macpherson 1993). In the latter experiment, as few as 500 antigen-pulsed DC were
capable of sensitising specific T cells in vivo.
DC also act as APCs for CD8+ T cells in primary cytotoxic T lymphocyte (CTL)
responses in vitro (Macatonia et al 1989). Nair et al recently reported that DC pulsed
with antigen in vivo or in vitro could subsequently induce primary CTL responses in
vitro, while macrophages were ineffective (Nair at al 1993). Others demonstrated the
induction of CD8+ CTL by a single in vivo immunisation with peptide-pulsed DC
(Takahashi et al 1993).
Induction of the primary antibody response in vitro requires DC as accessory cells. DC
sensitise specific CD4+ T cells which can then stimulate antigen-carrying B cells (Inaba
et al 1985). Syngeneic DC pulsed with a soluble protein antigen in vitro can elicit an
antibody response in vivo when administered to naive mice, while pulsed B cells are
ineffective (Sornasse et al 1992). However, antibody can only be detected following
the injection of soluble antigen, at 12 days after DC administration, and therefore the
antibody detected may represent a secondary response. Antigen-bearing DC probably
sensitise specific CD4+ T cells, which can provide B cell help when soluble antigen is
injected subsequently. This correlates with the findings of Liu & Macpherson (1993),
where antigen-pulsed rat lymph DC did not produce a detectable antibody response on
in vivo administration, but weak secondary antibody responses were evident after
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boosting the animals with soluble antigen.
1.3.2. Secondary and Other Responses
DC are more efficient than macrophages or B cells in the generation of secondary
immune responses (Steinman 1991). Fewer DC are required to elicit a measurable
response due to their specialised antigen presenting functions, in several assay systems.
Thus antigen-pulsed DC from the afferent lymph of cattle are 10-100 times more
efficient than pulsed bovine monocytes in the stimulation of antigen specific T cells
(Mckeever et al 1991). DC are the most potent accessory cells for the allogeneic and
syngeneic MLR and T cell responses to foreign protein antigens in humans (Van
Voorhis et al 1982, Kuntz-Crow & Kunkl 1982, Van Voorhis et al 1983). In fact DC
are the only accessory cells capable of eliciting the syngeneic MLR in murine systems,
where T cells respond in the absence of exogenous antigen. Priming of mice with
antigen before carrying out the assay does not affect the response, and it is suggested
that a subpopulation of T cells is directly stimulated by DC; the mechanism may be
important in self-recognition in vivo (Nussenzweig & Steinman 1986).
DC accessory activity has also been demonstrated in oxidative mitogenesis assays; here
syngeneic T cells are pretreated with an oxidising agent such as sodium periodate then
APCs are added in the absence of exogenous antigen. DC were found to be the major
cell type capable of stimulating T cells in this system in rats (Klinkert et al 1982) and in
humans, where DC elicited a response three times greater than that seen with
macrophages or B cells as accessory cells (King & Katz 1989). In cloning studies,
antigen-specific T cells could be cloned with 80% efficiency in the presence of only
1000 DC, while B cells and monocytes were <1% as effective (Langhoff & Steinman
1989).
1.4. Adaptations for Accessory Function
The unique ability of DC to initiate primary T-dependent responses has not been fully
accounted for. However, contributing factors are likely to include the constitutive
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expression of high levels of MHC products involved in antigen presentation,
costimulatory/ adhesion molecules such as B7 (Young et al 1992), and possibly the
production of cytokines with costimulatory functions such as IL-1 and IL-6 (Matsue et
al 1992, Heufler et al 1992). Dendritic morphology and the decreased sialation of DC
surface molecules allows increased contact with lymphocytes, while the migration
patterns of DC from peripheral tissues to the T cell areas of lymphoid organs promote
subsequent interaction with numerous potential responder cells. These features are
covered in more detail below.
1.4.1. Surface molecules involved in accessory function
1.4.1.1. Antigen presentation
DC constitutively express MHC class II products, necessary for the presentation of
peptide antigens to CD4+ T cells, at high levels. I-A and I-E are found in the mouse,
while HLA-DP, DQ and DR are present on human DC (Steinman 1991). Ovine DC
express MHC class II products equivalent to the human DQ and DR (Dutia et al 1993).
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Antigen challenge in a primed sheep causes an increase in expression of MHC class II
molecules by afferent lymph DC. This correlates with enhanced ability of DC to present
a second antigen to specific T cells (Hopkins et al 1989). Addition of a monoclonal
antibody to MHC class II leads to total inhibition of T cell proliferation.
MHC class I molecules are also expressed at high levels by DC. These molecules are
expressed by many cell types compared with MHC class II molecules. Expression of
MHC class I products enables cells, including DC, to present endogenous antigens to
CD8+ T cells for the induction of CTL (Townsend et al 1986).
LC and DC from ovine afferent lymph also express CD1 (Bujdoso et al 1989), which
is similar in structure to MHC class I molecules and is associated with p2
microglobulin. In humans, five genes for CD1 have been identified and termed CDla-e
(Calabi et al 1991). Different cell types may express the product of one or more CD1
genes. Two genes for CD1 have been located in the mouse (Bradbury et al 1988).
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In sheep at least four genes have been identified (Ferguson 1993). It has been
suggested that the CD1 antigens form a family of non-classical MHC class I molecules
(Van de Rijn et al 1983). However, unlike MHC class I, CD1 does not show
significant polymorphism (Calabi et al 1991). CD1 molecules are thought to function in
the presentation of antigens to T cells bearing yd TCRs (Porcelli et al 1989, Haas et al
1993). CD lb has also been reported to restrict the response of human CD4-, CD8- T
cells expressing the a(3 TCR to a microbial antigen (Porcelli et al 1992). DC in afferent
lymph and epidermal LC are the major sites of expression of CD1 in the periphery, and
they may be involved in the presentation of antigen to the large numbers of of yd T
cells also present in afferent lymph (Mackay et al 1988a) or the epidermis (Kuziel et al
1987).
Other "non-classical" class I molecules, known as the class lb molecules, may also
play a role in antigen presentation (Germain & Margulies 1993). The MHC class lb
genes map to the MHC area, but their products are distinct from those of class I genes
in that they show limited polymorphism and restricted tissue expression, although in
common with class I molecules they are associated with (32 microglobulin. CD1 is not
included in the MHC class lb category, as its genes do not map to the MHC region
(Calabi et al 1991). Various murine yd T cell subsets recognise antigens presented by
the products of genes in the TL or H-2T regions, although the physiological relevance
of this recognition is at present unclear (Bluestone et al 1988, Van Kaer et al 1991).
One report describes TL products on the surface of murine LC (Rowolen et al 1983).
The class lb molecules have been proposed as a first line of defence against microbial
infections of epithelial linings, due to their localisation in these tissues and their
association with a restricted peptide repertoire (Sperling & Bluestone 1993).
Thus DC express all the presentational molecules required for interaction with both a|3
and yd T cells constitutively. In contrast, monocytes/ macrophages express variable
amounts of MHC class II products, and must be activated before optimal levels of class
II appear on the cell surface (Unanue 1984).
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1.4.1.2. Adhesion: cluster formation
Most APC types can form clusters with T cells in an antigen-dependent manner; the
unique feature ofDC is their ability to cluster resting T cells non-specifically. The initial
event is reversible enabling one DC to interact temporarily with many T cells to locate
the small number of those responsive to the antigen carried (Inaba & Steinman 1986).
Cluster formation is promoted by the dendritic morphology of DC; numerous processes
increase surface area and motile lamellapodia or 'veils' extend and retract to contact
neighbouring cells (Steinman 1991). DC surface molecules have a lower level of
sialation than other cells (Boog et al 1989), allowing a closer apposition between cell
surfaces due to reduced negative charge. The decreased degree of sialation is due to
biosynthesis, and is not the result of neuraminidase action at the DC surface. T cells
specific for peptides on the DC surface remain in the clusters and are activated, while
others are released.
Several molecules on the DC surface interact with ligands on responding T cells to
mediate adhesion: LFA-3 (CD58) with CD2, ICAM-1 (CD54) with LFA-1
(CD 1 la/CD18) and B7 with CD28 or CTLA-4 (Makgoba et al 1989, Young et al
1992). LFA-1, LFA-3 and CD2 are all expressed at greater levels on memory
compared with naive T cells, increasing their ability to interact with DC bearing ligands
for these molecules (Springer 1990). LFA-1 also undergoes a change from a low
avidity to a high avidity state after crosslinking of the TCR or signalling via CD2, thus
promoting intercellular adhesion. The increase in affinity correlates with protein kinase
C-dependent phosphorylation of serine residues in the (3 subunit (CD18) of LFA-1
(Valmu et al 1991), and occurs rapidly, with peak avidity between five and ten minutes
after TCR stimulation and a return to the low avidity state by thirty minutes (Springer
1990). The avidity of LFA-1 on the DC surface for ICAM-1 on the T cell may increase
in a similar manner.
Cluster formation with resting T cells is an active process, requiring a temperature of
37°C, an intact DC cytoskeleton and intracellular protein kinase activity (Scheeren et al
1991). Bidirectional interaction between LFA-1 and ICAM-1 seems to be the central
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event in binding; monoclonal antibodies (mAbs) to these surface molecules inhibit
cluster formation by 70%. However, the initial antigen-independent interaction is not
affected and the mAbs act by decreasing the stability of clusters after formation (Inaba
& Steinman 1987). Other ligand pairs must also be involved as binding is not
completely inhibited by mAbs specific for LFA-1 and ICAM-1. King and Katz
demonstrated a role for LFA-3/ CD2 adhesion molecules in the association of human
tonsillar DC with T cells (King & Katz 1989), but this was not confirmed in studies
involving blood DC (Scheeren et al 1991). Sheep afferent lymph DC express CD2 and
LFA-3 (Bujdoso et al 1990), therefore interaction of these molecules may occur to
facilitate homoadhesion between DC and T cells.
1.4.1.3. Costimulation
Contact of the TCR with antigen in the context of MHC products provides a signal to
the T cell but this is insufficient for its activation. Indeed, the absence of a second,
costimulatory signal provided either by a cytokine or surface molecule on the presenting
cell may lead to a state of anergy, preventing subsequent activation of the T cell
(Schwartz 1990). B7 is an important costimulatory molecule expressed by DC. Young
et al (1992) reported the constitutive expression of B7 by human blood DC, but a more
recent study suggests that B7 is expressed only after activation of DC, and is present on
IDC from lymphoid tissues but not on blood DC or LC (Hart et al 1993). B7 is also
found on activated B cells and monocytes (Dustin & Springer 1989, Freeman et al
1987). MAbs to the T cell ligands for B7, CD28 and CTLA-4, inhibited proliferation in
the allogeneic MLR. MAbs against T cell molecules CD2, CD4 and CDlla also
decreased proliferation in this assay (Young et al 1992). When added together the
blocking effect was synergistic and near total inhibition was achieved, indicating that all
these molecules are involved in T cell activation. The expression of costimulatory
molecules is also increased after antigen-specific interactions; B7 and ICAM-1 on the
DC surface are both upregulated, while the avidity of T cell LFA-1 is increased after
signalling through CD2 or CD3 as described above. Other DC accessory molecules
may also be important in T cell activation; for example the murine heat-stable antigen
provides a significant costimulatory signal from murine DC (Liu et al 1992). The
9
superior accessory function of DC may be partly explained by the high constitutive or
induced expression of costimulatory molecules compared with other APCs, enabling
DC to activate resting T lymphocytes. However, once sensitised, T cells may be
stimulated to respond to antigen by other APC types (Austyn 1987).
1.5. Cytokine production
Certain cytokines such as IL-1 and IL-6 have costimulatory properties for T cells
(Dinarello 1992), and in the past, macrophage release of IL-1 was considered essential
for the activation of T cells in the presence of specific antigen (Steinman 1991). The
production of cytokines by DC has not been comprehensively investigated, although
LC produce IL-1 and IL-6 (Matsue et al 1992, Enk & Katz 1992), and the expression
of IL-lp mRNA is upregulated on culture of these cells. The release of IL-ip by
murine splenic DC has also been reported (Heufler et al. 1992). IL-ip produced by
epidermal LC is essential for the induction of primary immune responses in the skin
(Enk et al. 1993). The accessory function of DC is enhanced in the presence of IL-1,
suggesting that DC must express receptors for IL-1 (Koide et al. 1987). The presence
of these receptors has been demonstrated by the binding of radiolabeled IL-1 to DC
from ovine afferent lymph (Fiskerstrand 1994).
In one study, DC and responding T cells were separated from T cells stimulated with
anti-CD3 mAbs by a 0.22|im filter. The latter cells should proliferate when a second
signal is supplied, as the TCR is already occupied by anti-CD3 mAbs. IL-2 was
produced and crossed the filter but the T cells did not respond, indicating that a surface-
bound molecule or molecules were necessary for activation (Inaba et al 1989).
A recent study demonstrates the effects of IL-10 on immune responses initiated by DC.
DC-induced production of gamma interferon (IFN-y) by both Thl clones and bulk
populations of CD4+ and CD8+ T cells was inhibited on the inclusion of IL-10 in in
vitro cultures, while proliferation of the responding T cells was not affected (Macatonia
et al 1993). This suggests a role for IL-10 in the inhibition of cell-mediated responses,




The methods employed by DC in the accumulation of antigens are not fully understood.
DC isolated from murine spleen are poorly phagocytic (Steinman 1991), while DC in
the afferent lymph of sheep can take up immune complexes (Hall & Robertson 1984).
FcR for IgG are found on murine and human Langerhans cells, and DC from murine
pulmonary tissue and human afferent lymph (Schuler et al 1985, Spry et al 1980, Astier
et al 1994), while those DC obtained from murine lymph nodes or spleen, or human
peripheral blood, do not express these molecules (Van Voorhis et al 1982). However,
the method of isolation employed may also be important, with more recent reports
showing low levels of FcR on the surface of DC obtained from murine spleen by a
rapid isolation technique (Crowley et al 1990), and on DC from human blood (Thomas
et al 1993a). Complement receptors are also present on DC; CDllb is detected on
>80% of human LC, but only a trace population of DC from lymphoid tissues and
afferent lymph, while CD1 lc is expressed by both DC and LC (Steinman 1991, Nestle
et al 1993). DC generally lack mannose-fucose receptors (Pugh et al 1983), although
freshly isolated LC from some strains of mice do express these receptors, which are
downregulated on culture (Reis e Sousa et al 1993). Other receptors such as those for
lipoproteins have not been identified.
Although the mechanism of antigen uptake is not clear, it is certain that DC do acquire
antigens in vivo and in vitro. Sheep afferent lymph DC draining the site of intradermal
antigen administration can activate specific T cells in vitro (Bujdoso et al 1989). A
similar effect has been demonstrated with pulmonary DC after application of antigen in
aerosol form (Holt et al 1987), and with DC in afferent lymph draining the intestine
after oral administration of antigen to rats (Liu & Macpherson 1991).
In a primary immune response, DC must acquire sufficient antigen for the activation of
resting T lymphocytes in the absence of specific antibodies. DC in the afferent lymph of
sheep bear surface immunoglobulins at variable levels (Miller & Adams 1977). Surface
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IgM, which is likely to be cytophilic, has been proposed as a concentrating mechanism
for antigen in a primary response (Bujdoso et al 1990). IgM antibodies may form
complexes with antigen and attach to the DC membrane via complement receptors or
receptors for IgM, facilitating the uptake of trace amounts of antigen. Alternatively,
non-specific pinocytosis may play a major role in the accumulation of antigen by these
cells in a primary response; DC are highly efficient in fluid-phase pinocytosis (Barfoot
et al 1989, Drexhage et al 1979). DC isolated from murine lymphoid tissues were
initially thought to have poor endocytic activity (Kapsenberg et al 1986, Inaba et al
1990). However, DC from murine spleen have recently been shown to be as
endocytically active as other APC types (Levine & Chain 1992). Endosomal traffic was
assessed by measurement of the accumulation and subsequent exocytosis of fluid-phase
markers in a flow cytometric assay. While these DC had a less active early endosomal
compartment than activated B cells or macrophages, the late endosomal compartment,
proposed as the site of antigen processing and association with MHC class II molecules
(Peters et al 1991) was equivalent in size and activity. A recent study demonstrated the
phagocytosis of mycobacteria by proliferating DC precursors from murine bone
marrow cultures, showing that these DC can also internalise particulate antigens for
subsequent presentation (Inaba et al 1993). Microorganisms such as yeast and bacteria
were phagocytosed by freshly isolated LC, although this capacity was downregulated
on culture in vitro (Reis e Sousa et al 1993).
Afferent lymph DC of sheep form rosettes with antibody-coated erythrocytes, and take
up antigen far more efficiently in the presence of specific antibodies of the IgG isotype
(Harkiss et al 1990). This enhanced uptake requires an intact Fc portion of antibody,
suggesting the involvement of Fc receptors for IgG on the DC surface. Such a
mechanism would be important in secondary responses in vivo, where specific
antibody is available, and in disease conditions where immune complexes are present,
especially if the increased uptake of antigen via FcR facilitated T cell activation.
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1.7. DC Migration and Maturation
1.7.1. Langerhans Cells
Although DC are present in most non-lymphoid tissues, the LC of the epidermis are the
best characterised. LC are thought to be the precursors of interdigitating DC (IDC) in
the lymph node, travelling via afferent lymph as veiled cells (Knight et al 1982). LC
have been identified in lymphatics draining the epidermis after application of contact
sensitising chemicals, and subsequently in the draining lymph node (Silberberg-Sinakin
et al 1976). LC migration from the epidermis to lymphatics in allografts and isografts
also occurs (Larsen et al 1990). In this study, LC migrated from epidermal cultures into
the surrounding medium, implying the involvement of local inflammatory stimuli in
migration. TNF-a has been proposed as a specific stimulus for the initiation of LC
migration in vivo (Cumberbatch & Kimber 1992).
DC bearing high levels of antigen can be isolated form the draining lymph node four
hours after skin-painting with fluorescein isothiocyanate (Macatonia et al 1987). These
cells carry antigen in immunogenic form and can elicit T cell responses in vitro and in
vivo (Moll et al 1993). Once present in the lymph node, DC do not emerge in the blood
or efferent lymph and probably die in the node (Fossum 1988).
Further evidence that at least a proportion of IDC are derived from epidermal LC is
provided by the phenotypic and functional maturation of LC which occurs during
culture and is thought to parallel the in vivo process (Pure et al 1990). Freshly isolated
LC are capable of processing and presenting native protein antigens, but cannot
sensitise resting T cells (Romani et al. 1989). After an in vitro culture period,
immunostimulatory capacity is increased significantly but LC become incapable of
presenting native antigens (Streilein & Grammer 1989). Phenotypic changes include
increases in the expression of MHC class II and class I, expression of the low affinity
receptor for IL-2, and downregulation of FcyRII (Shimada et al. 1987, Witmer-Pack et
al. 1988). Changes in culture are dependent on the presence of GM-CSF, and may be
increased by IL-1 (Witmer-Pack et al. 1987, Heufler et al. 1988). Cultured LC thus
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resemble DC isolated from lymphoid tissues in both phenotype and function.
The decline of antigen processing in cultured LC is not due to decreased uptake of
antigen; fresh and cultured LC accumulate a comparable amount of the pinocytic tracer
rhodamine-ovalbumin in perinuclear granules (Pure et al. 1990). MHC class II
expression is increased on culture, and cells can efficiently present peptides, which do
not require processing. However, the biosynthesis of MHC class II molecules
decreases dramatically on culture, with no synthesis detectable by 20 hours of culture
(Pure et al. 1990). Production of the invariant chain cannot be detected at this stage
either. This suggests that newly formed MHC class II molecules are required for
interaction with peptides in LC; in support of this, antigen processing in freshly isolated
LC is blocked by cyclohexamide which interferes with the synthesis of MHC class II
molecules. This correlates with the finding that nascent MHC class II molecules are
required for association with antigenic peptides in other APC types (Neefjes et al 1990,
Davidson et al 1991, Lanzavecchia et al 1992).
The disappearance of certain intracellular organelles of acidic pH also coincides with
the loss of processing ability by LC (Stossel et al 1990). These are largely late
endosomes and Birbeck granules and may be required for antigen cleavage and peptide
production. Although the exact site of peptide production and association with MHC
class II molecules has not been defined, the presence of an acidic compartment is an
essential requirement (Jensen 1990).
Once fresh LC have taken up an antigen they can retain it for up to two days in culture
(Pure et al 1990). This may be necessary in vivo to ensure that antigens captured in the
peripheral tissues are not displaced before they can be presented to specific T cells.
Indeed, the reciprocal antigen processing ability and immunostimulatory capacity of
fresh and cultured LC probably helps to ensure that antigen is presented in
immunogenic form at the site where interaction with specific T cells is most likely.
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1.7.2. The Role of DC in Antigen Transport in the Lymph Node
Follicular dendritic cells (FDC) in the lymph node retain antigen for long periods on
their cell membrane and are thought to be important in the maintenance of B cell
memory and the secondary antibody response (Gray & Skarvall 1988, Tew et al 1989).
In a secondary immune response, immune complexes in the afferent lymph may be
transported from the subcapsular sinus to the germinal centre by cells with dendritic
morphology; antigen is then transferred to FDC for interaction with B cells (Szakal et al
1989). The exact nature of these antigen transport cells is not known, but they may be
part of the DC lineage. FDC release antigen in the form of iccosomes, immune
complex-coated bodies which are subsequently taken up by B cells and stimulate the
production of antibody.
1.7.3. Transplantation
Because of their immunostimulatory ability and migratory properties, DC have been
proposed as important passenger leucocytes involved in the rejection of transplanted
tissues (Austyn & Larsen 1990). DC would act by sensitising host T cells to graft
antigens, thus initiating rejection. Depletion of DC from pancreatic islet grafts in mice
has proved effective in preventing rejection by allogeneic recipients (Faustman et al
1984). It is not known whether sensitisation to the graft occurs peripherally or in
lymphoid organs. One study of skin grafts in guinea pigs demonstrated a requirement
for intact lymphatic drainage for rejection to occur, suggesting that DC from the grafts
migrated to draining lymph nodes and initiated rejection centrally (Barker & Billingham
1968). However, Tilney & Gowans, using a similar model in rats, found that rejection
did occur but was delayed. They suggested that sensitisation of host T cells was taking
place in the graft itself (Tilney & Gowans 1970).
More recent studies have investigated fully vascularised organ grafts and the migration
ofDC via blood. Radiolabelled DC injected intravenously migrated only into the spleen
and liver, with the former the major site of radioactivity (Kupiec-Weglinski et al 1988).
In a rat cardiac allograft model, DC of donor origin were detected in the host spleen
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soon after transplantation. Appearance of donor DC in the spleen corresponded with
sensitisation to the graft (Larsen et al 1990). Further experiments showed that host DC
did not migrate into cardiac or skin allografts (Austyn & Larsen 1990). The
modification of grafting procedures involving depletion of donor DC or measures
preventing their migration to host lymphoid tissues could be a factor in the
improvement of graft survival.
1.8. Thymic DC and Tolerance
Selection of thymocytes bearing self MHC and the induction of tolerance to self
antigens is thought to occur in the thymus. DC are present in the thymus at the
corticomedullary junction where intermediate T cell stages between immature double-
positive and mature single-positive cells reside, and in the medulla (Inaba et al 1991).
Two populations of thymic DC were identified (Inaba et al 1988). One population
expressed MHC class II and represented 0.1-0.3% of thymus cells. These DC were
effective as accessory cells in thymocyte mitogenesis assays, with their stimulatory
function increasing on pre-incubation with IL-1. MHC class II-negative DC developed
class II expression and corresponding stimulatory activity when cultured in the
presence of IL-1, indicating that these class II-negative DC are precursors of the
mature, functional thymic DC.
A common precursor population in mouse thymus for both T cells and DC has been
reported (Ardavin et al 1993). This precursor did not express MHC class II, and DC
did not develop from later stages of the T cell lineage after gene rearrangement. As
thymic DC develop from an intrathymic precursor, newly formed T cells are likely to
interact with DC expressing only self antigens rather than DC having acquired
exogenous antigens before entering the thymus. Other mechanisms would be required
to generate tolerance to self antigens not present within the thymus.
The role of DC in tolerance induction was investigated by injection of minor
lymphocyte stimulating antigen (Mls)-incompatible APCs into the thymi of neonatal
mice (Inaba et al 1991). Responses were assessed by the demonstration of graft-
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versus-host-response (GVHR) following injection of thymocytes into the footpads of
Mis-incompatible recipients. Differences in the mode of tolerance induction by distinct
APC types were observed. Thymic B cells caused deletion of reactive thymocytes while
DC induced anergy; specific thymocytes were not deleted but GVHR did not occur.
Macrophages were completely ineffective and tolerance did not occur.
In a fetal thymus organ culture system, again with Mis as antigen, cooperation between
DC and Mis-expressing B cells was required for elimination of reactive T cell clones
(Mazda et al 1991). Thus B cells in this in vitro system could not tolerise T cells alone,
but probably passed Mis antigen to DC which in turn induced tolerance. This contrasts
with the previous in vivo work; however in the latter case it is possible that Mis-
incompatible B cells could transfer antigen to host DC after injection into the thymus,
with the latter cells then inducing tolerance.
1.9. Pathways of Antigen Processing and Presentation
Intracellular and extracellular antigens are generally processed and presented by distinct
pathways. Endogenous antigens produced in the cell cytoplasm, eg by viruses, are
usually presented to CD8+ T cells in association with class I MHC molecules. Many
cell types express class I products, and can potentially act as targets for CTL activity. In
contrast only a few specialised cell types carry the MHC class II molecules required for
the presentation of exogenous antigens to CD4+ T cells. These T cells are then activated
to provide B cell help in the production of antibodies specific for the extracellular
antigen. DC carry both MHC products and can therefore present intracellular and
extracellular antigens to CD8+ and CD4+ T cells respectively.
In mice, CD4+ "helper" T cells have been further divided into two subsets depending
on their cytokine profiles (Mosmann & Coffman 1989). Thl cells secrete IL-2 and
IFN-y on activation and thus promote macrophage activation and cell-mediated
responses such as delayed-type hypersensitivity (DTH), while Th2 cells produce IL-4,
IL-5 and IL-10, and stimulate the production of antibody including IgE by B cells. The
development of mast cells and eosinophils is also promoted by the Th2 subset. One Th
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subset characteristically dominates in the immune response to a particular antigen, and
each subset is able to suppress development of the other by the production of
cytokines. Thus the IFN-y produced by Thl cells inhibits proliferation of Th2 cells,
while Th2 cells in turn produce IL-10 which inhibits the production of IFN-y by the
Thl subset (Fiorentino et al 1989). In some diseases, the dominant subset determines
the outcome of the condition. In murine leishmaniasis, for example, a Thl response
with the production of IFN-y and induction of cell-mediated responses leads to an
effective immunity and healing of a localised lesion in resistant strains. In contrast, a
Th2 response characterised by IL-4 and antibody production occurs in susceptible
Balb/c mice, resulting in disseminated and often fatal disease (Heinzel et al 1989). Thl
and Th2 cells are thought to develop from a common precursor after TCR-mediated
activation (Coffman et al 1991). The properties of different APCs, cytokine production
by these or other cells, the amount of antigen available and epitope specificity have all
been proposed as factors potentially responsible for the differentiation of uncommitted
precursor cells into Thl or Th2 types (Coffman et al 1991, Wang et al 1993, Schmitz et
al 1993).
1.9.1. Processing of Endogenous Antigens
To be presented on MHC class I molecules for presentation to CD8+ T cells, antigens
must be located within the cytoplasm of the presenting cell. Peptides are produced by
protease cleavage of cytoplasmic proteins. The low molecular mass polypeptide (LMP),
a large proteolytic complex related to the proteasome, is thought to be capable of
producing multiple peptides simultaneously from a protein substrate. Peptides are then
delivered into the endoplasmic reticulum (ER) by a transporter for association with
class I molecules. The peptide transporter is thought to be the product of the genes Tap-
1 and Tap-2, which, with genes encoding the LMP, are found in the class II region of
the MHC (Trowsdale et al 1990).
Once inside the ER, peptides bind to newly synthesised class I molecules consisting of
a glycosylated heavy chain with three extracellular domains, non-covalently associated
with [32 microglobulin (Bjorkman et al 1987). A conformational change is induced on
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peptide binding, resulting in stabilisation of the molecule's structure. MHC class I
molecules without bound peptides dissociate rapidly at physiological temperatures. The
antigen-binding groove of class I is formed by the association of the 1st and 2nd
domains of the heavy chain, while the membrane proximal 3rd domain interacts with
CD8 (Germain & Margulies 1993). The antigen groove accommodates a peptide of nine
amino acids (Schumacher et al 1991), and there is some evidence that peptides of this
size are preferentially produced by the LMP (Brown et al 1991). The groove
incorporates a set of pockets extending between the floor and walls of the binding
domain (Garrett et al 1989). MHC class I molecules are highly polymorphic (Klein
1986), and this is evident in the differing shape and character of the pockets in the
binding groove, determining which peptides can be accommodated in the binding
region (Bjorkman et al 1987). Allele-specific motifs have been defined in peptides
eluted from MHC class I molecules of different haplotype, with amino acids commonly
found at a particular position being classified as anchor residues (Falk et al 1991). For
example, peptides eluted from HLA-B27 class I molecules were sequenced and the
motif of an arginine at position 2 and a basic residue at position 9 was identified
(Jardetzky et al 1991). Other work has demonstrated the importance of hydrogen bond
formation between the NH2-terminal amine of the peptide and conserved MHC residues
such as the tyrosines at positions 7, 59 and 171. The terminal carboxyl group, and the
first and penultimate amino acids of the peptide also form hydrogen bonds with other
conserved class I residues (Matsamura et al 1992, Zhang et al 1992). These conserved
bonds help to explain how polymorphic class I molecules can each bind a large number
of different peptide sequences (Germain & Margulies 1993).
Class I MHC molecules with bound peptides are exported to the cell surface via the
Golgi; during this process the pathway can be blocked by Brefeldin A, which prevents
movement of membrane proteins from the ER to the Golgi. This inhibitor of class I
presentation has no effect on the class II processing pathway (Nuchtern et al 1989).
1.9.2. Processing of Exogenous Antigens
Extracellular antigens enter endocytic vesicles of acid pH after internalisation. Antigens
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pass through early and late endosomes to lysosomes, and are at some point along this
pathway are cleaved by protease action to produce peptides. Treatment with
lysosomotropic agents such as chloroquine and ammonium chloride neutralises these
intracellular compartments and blocks the MHC class II processing pathway (Ziegler &
Unanue 1982), while the endogenous class I pathway is unaffected. It is uncertain how
the neutralisation of these acidic compartments blocks processing in the exogenous
pathway; the degradation of antigens to peptide form may be inhibited, or alternatively
dissociation of the invariant chain from the class II molecules to allow peptide binding
may fail to occur (Germain & Margulies 1993).
Class II molecules are assembled in the ER. Molecules consist of a non-covalently
associated a and (3 chain, each with two extracellular domains. The detailed structure of
the human MHC class II molecule HLA-DR1 has recently been determined, and is
similar to that of class I (Brown et al 1993). The a[3 heterodimers appear to associate as
dimers of dimers. This suggests that class II molecules at the cell surface are able to
form dimers at some stage, possibly during recognition by CD4 T cells. The resulting
structure could lead to an increased affinity for CD4, and cross-linkage of TCRs may
be important in stimulatory signalling in the responding T cells. There are also detailed
changes in the structure of the peptide binding region, which is formed by the
interaction of the al and (31 domains. The conserved residues in the class I peptide
groove which bind the peptide NH2 terminus and the C terminus are not found in class
II sequences (Brown et al 1993). The ends of the class II site are thus more open than
those of class I, and bound peptides are longer and more varied in size, projecting out
of the groove at each end. Peptides eluted from MHC class II molecules vary from
twelve to more than twenty amino acids in length (Rudensky et al 1991, Chicz et al
1992). Amino acid motifs for binding to particular class II molecules have been
identified, and these usually involve only two or three residues. These motif residues
are thought to occupy polymorphic pockets in the class II binding region, of a similar
type to those found in the class I binding groove (Germain & Margulies 1993). A
distinct pocket in the binding site of HLA-DR1 has been identified, which
accommodates a side chain of the bound peptide (Brown et al 1993). The site of
association between MHC class II molecules and CD4 has been determined as the [32
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domain, which is structurally analogous to the CD8-binding region in the a3 domain of
MHC class I molecules (Konig et al 1992, Cammarota et al 1992). If class II molecules
do exist in dimer form during interactions with T cells, the structure determined by
Brown et al suggests that CD4 might also contact a region of the a2 domain of one of
the class II molecules.
A third component, the invariant chain, associates with the a and P chains before
export of the class II molecule from the ER. The invariant chain has been proposed to
target class II molecules to the endocytic route and also to prevent the binding of self
peptides before class II molecules encounter exogenous peptides in endocytic vesicles .
On arrival in an endosomal compartment, the invariant chain is degraded (Germain &
Margulies 1993) to allow peptide binding to occur. MHC class II molecules are
expressed on the cell surface in mutants lacking the invariant chain, but expression is
impaired to a variable extent (Schaiff et al 1991). The invariant chain also seems to have
a role in the correct folding and conformation of the a(3 dimers (Anderson & Miller
1992), and the association of certain peptides with MHC class II dimers is dependent
on the prior association of the dimers with the invariant chain (Peterson & Miller 1990).
Binding of peptide to MHC class II molecules causes a conformational change leading
to increased stability of the class II dimer (Sadegh-Nasseri & Germain 1991). This is
similar to the situation with class I MHC molecules, where peptide association with the
heavy and microglobulin chains gives stability of the complex.
The exact site of association of MHC class II molecules with peptide is uncertain.
Processed antigen can be detected on the surface of APCs by specific T cells as little as
20 minutes after endocytosis, and in some studies with human and mouse APCs the
late endosomal compartment has been implicated as the site of association (Davidson et
al 1991, Guagliardi et al 1990). Others have suggested the involvement of lysosomes
(Pieters et al 1991, Harding & Geuze 1993).
A role for intracellular chaperone proteins in the transport of peptides and their
association with MHC class II molecules has been proposed. Pierce and colleagues
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suggested that molecules of the heat shock protein (hsp) 70 family, which possess
peptide-binding capacity, could scavenge partially degraded proteins from lysosomal
compartments and recycle them to the endosomes for binding to class II molecules at
this site (Pierce et al 1991). Homology does exist between the peptide-binding regions
of hsp70 and MHC class II molecules (Flajnik et al 1991), but there is no firm evidence
to support this transfer theory at present (Germain & Margulies 1993).
After peptide binding has occurred, MHC class II molecules are transported to the cell
surface, allowing interactions with responder cells specific for the antigen presented.
Recycling of class II molecules from the cell surface to an endosomal compartment has
been demonstrated (Salamero et al 1990, Reid & Watts 1990). However, this recycling
may be of limited functional importance, as only newly synthesised molecules seem to
associate with peptides derived from exogenous antigen (Davidson et al 1991,
Lanzavecchia et al 1992). MHC class II molecules can also present exogenously added
peptides without processing, if these are used at high enough concentrations. Added
peptides may displace those already present on MHC class II molecules, or alternatively
they may enter the antigen grooves of "empty" MHC class II molecules present on the
cell surface (Germain & Hendrix 1991).
1.9.3. Endogenous Antigens Presented By Class II Molecules
Although antigens produced endogenously are usually presented by class I molecules,
and exogenous antigens taken up by the cell follow the class II presentation pathway,
there are exceptions to this general rule. Exogenous antigens can be presented to CD8+
T cells on class I molecules (Rock et al 1990, Reddy et al 1991). This requires
penetration from the endocytic system to the cytoplasm, for example by osmotic shock
in in vitro studies (Moore et al 1988). However, in some cases, exogenous antigens
with no known method for entering the cytoplasm can elicit CD8 T cell responses
(Carbone & Bevan 1990, Collins et al 1992). Similarly, intracellular pathogens such as
Leishmania and Salmonella which reside in vacuoles and have no obvious access to
the cytoplasm, can still elicit class I-restricted T cell responses (Flynn et al 1990, Farrell
et al 1989). A recent report describes a novel class I processing pathway employed for
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the processing and presentation of phagocytosed bacteria. In this study, presentation by
class I molecules was not inhibited by either Brefeldin A or cyclohexamide, which
block the recognised class I pathway (Pfeifer et al 1993).
There is also evidence for the presentation of endogenously synthesised antigens by
class II molecules, particularly for cell surface or secreted proteins which can enter the
endosomal processing pathway (Weiss & Bogen 1989, Bikoff & Eckhardt 1989).
However, proteins that are produced in the cell cytoplasm and are not membrane-
associated or secreted can also be presented by MHC class II molecules, as can some
proteins which are retained in the ER and do not enter the cytoplasm in detectable
quantities (Brooks et al 1991). The mechanisms involved in each case are unclear,
however it is possible that a small amount of a protein with an ER retention signal could
leave the ER and enter the endosomal pathway, while cytoplasmic proteins are more
likely to be taken up into vacuolar compartments by autophagy, for processing in
endosomes or lysosomes (Brooks & McCluskey 1993). The pathway involved in the
presentation of endogenously synthesised antigens by class II molecules is inhibited by
chloroquine but not by Brefeldin A, indicating that it is separate from the class I
pathway for the processing of endogenous antigens (Jaraquemada et al 1990).
Antigens incorporated in immunostimulatory complexes (ISCOMS) may be presented
by both class I and class II molecules, potentially activating CD8 and CD4 T cells,
resulting in CTL and humoral responses against the given antigen (Takahashi et al
1990). A similar picture of T cell activation is seen following the administration of
antigen in the form of solid-matrix-antibody-antigen (SMAA) complexes (Randall &
Young 1991). This has implications in the development of vaccines to certain
pathogens where protective immunity is dependent on such a dual response.
1.10. Fc Receptors for IgG
The expression of Fc receptors for IgG by APCs such as macrophages and DC enables
them to take up antigen with increased efficiency in the presence of specific antibody,
as occurs in secondary immune responses in vivo. Enhanced presentation of antigen
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following its uptake via FcR has been demonstrated for different APC types (Section
1.11.1, below).
1.10.1. Structure
Fc receptors (FcR) for IgG have recently been the object of much investigation. There
are three types of FcyR; FcyRI (CD64) has high affinity for monomelic IgG and is
saturated with immunoglobulin (Ig) under physiological conditions, while FcyRII
(CD32) and FcyRIII (CD 16) bind only complexed IgG in detectable quantities
(Ravetch & Kinet 1991). All are members of the immunoglobulin superfamily
(Williams & Barclay 1988) and consist of a variable number of Ig-like extracellular
domains, a transmembrane section and cytoplasmic portion. FcyRI has three
extracellular domains while FcyRII and FcyRIII have only two (Fig.l). The first two
domains of FcyRI are structurally and functionally related to those of the low affinity
receptors; amino acid identity between murine FcyRI and FcyRII being 40% in this
region (Hulett et al 1991). It is thought that the third domain of FcyRI confers its
unique affinity for monomelic IgG (Ravetch & Kinet 1991). The cytoplasmic domain is
required for localisation of receptor and ligand into clathrin-coated pits and subsequent
internalisation (Miettinen et al 1991).
Soluble forms of FcyR have been demonstrated for all three classes in human sera.
These molecules lack transmembrane regions and may be generated by protease activity
and release from the cell surface (Huizinga et al 1990), or alternatively FcyR may be
synthesised without the necessary transmembrane region and subsequently exported
from the cell (Tartour et al 1993).
The area of FcyRII involved in interaction with the Fc portion of IgG was determined
in experiments with chimeric Fc receptors. Binding was shown to be dependent on the
second extracellular domain (ED 2); replacement of ED 2 of FceRI with the ED 2 of
FcyRII resulted in production of a chimera that bound IgG (Hulett et al 1991). The
binding area was identified more specifically as residues 146 to 169 of FcyRII.
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Figure 1
The schematic structure of the human FcyRs is illustrated. FcyRI may have an
associated y-y subunit, as shown; however it can also be expressed in the absence of
this dimer. FcyRIIIa may have a y-y, a or a y-£ dimer situated with it, while the
GPI-linked form, FcyRIIIb, has no associated subunits.













FcyRI is constitutively expressed by monocytes and macrophages and is inducible on
neutrophils and eosinophils (Van de Winkel & Capel 1993). Three homologous genes
have been identified in humans, encoding a receptor of molecular weight 72kD (Van de
Winkel & Anderson 1991). A single gene has been described in the mouse (Sears et al
1990), and a bovine gene for FcyRI has recently been cloned and sequenced (Symons
& Clarkson 1992). Amino acid sequences are conserved between these species, with
58% identity between the human, murine and bovine extracellular domains. In human
monocytes and U937 cells, a y-y subunit has been identified associated with FcyRI,
although this homodimer is not essential for expression of the receptor (Van de Winkel
& Capel 1993, Masuda & Roos 1993).
1.10.2.2. FcvRII
FcyRII is the most widely distributed of the Fc receptors for IgG and is often the only
type expressed by a particular cell. It is found on monocytes, macrophages,
neutrophils, basophils, eosinophils, B cells, platelets and LC as well as DC from
human blood (Thomas et al 1993a) and at low levels on DC from murine spleen
(Crowley et al 1990). The receptor has a molecular weight of 40kD and in humans
three genes have been identified encoding six isoforms (Qiu et al 1990). These are
almost identical in their extracellular sequence but differ in transmembrane and
cytoplasmic regions. Different genes may give rise to FcyRII of similar structure but
differing functions (see below). FcyRII was not thought to be associated with the y-y
subunits located with FcyRIII and sometimes FcyRI; however a recent study reports
the association of 20% of cell surface FcyRII with y-y homodimers in cultured human
monocytes (Masuda & Roos 1993).
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1.10.2.3. FcvRIII
In humans, FcyRIII is encoded by two genes giving rise to distinct products. The gene
FcyRIIIA encodes a receptor with a conventional transmembrane section and
cytoplasmic region. This form is located on macrophages, NK cells and a
subpopulation of T cells and monocytes. The FcyRIIIB gene product is expressed by
neutrophils and eosinophils and has a glycosyl phosphatidyl-inositol (GPI) linkage to
the cell membrane (Van de Winkel & Anderson 1991). FcyRIII is 50-80kD in size with
the range due to extensive glycosylation. FcyRIIIA is associated with various
disulphide-linked subunits associated as homo- or hetero-dimers (y-y, y-C, or C"C)>
which are necessary for expression of the receptor (Fig.l). In contrast, FcyRIIIB can
be found without these subunits (Kurosaki & Ravetch 1989). FcyRI is also associated
with y-y-homodimers but can be expressed in the absence of the subunit (Van de
Winkel & Capel 1993). These subunits are thought to have a role in signalling on
occupancy of the Fc receptor, and different combinations of y and £ chains could
represent alternative signalling pathways. y/C, subunits are related to those expressed
with FceRI and the T and B cell antigen receptors, suggesting that all these associated
chains may have a role in the internalisation of multimeric receptors.
FcR for different Ig classes were thought to be distinct; however one study reports that
murine FcyRII and FcyRIII can bind IgE with a similar affinity to IgG (Takizawa et al
1992). Binding of IgE was functional and resulted in mast cell activation and serotonin
release. In some parasitic diseases IgE-containing immune complexes are present in
situ; binding of these complexes to low affinity receptors for IgG could activate cells
such as macrophages, monocytes and lymphocytes.
1.10.2.4. FcyR Expression by T Lymphocytes
Reports of FcyR distribution on T cells have been contradictory; in general, these cells
are thought to express FcyR only after activation (Sandor & Lynch 1993). Thus
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FcyRII and FcyRIII have been detected on murine T cells (Daeron et al 1988).
Mantzioris and colleagues (1993) have recently demonstrated FcyRII on a subset of T
cells isolated from human peripheral blood. They found that 10-14% of CD4+ T cells
and 27-69% of CD8+ T cells stained with monoclonals to CD32, and mRNA for this
receptor was also demonstrated in CD8hish+ cells by polymerase chain reaction (PCR)
analysis. Regulation of B cell IgG production by FcyR-expressing T hybridoma cells
has been reported; the FcyRII on peripheral T cells could have a similar role. Soluble
FcyRII can act as a binding factor for IgG, and has also been detected in the
supernatants of T cell cultures (Sautes et al 1991).
1.10.3. Functions
Fc receptors are involved in many regulatory and effector mechanisms in the immune
response including phagocytosis, antibody-dependent cell-mediated cytotoxicity
(ADCC), the release of inflammatory mediators, regulation of Ig production and the
enhancement of antigen presentation (Anderson et al 1990, Fanger et al 1989, Anegon
et al 1988, Debets et al 1990, Klaus et al 1987). The latter is discussed in more detail
below.
Cross-linking of Fc receptors is required for the above functions; this can lead to
stimulatory or inhibitory signals depending on the cell type and perhaps the type or
isoform of FcyR. For example, cross-linking of FcyRII on macrophages delivers a
positive signal to the cell and the receptor and ligand are internalised for degradation
and subsequent presentation in immunogenic form (Macintyre et al 1988). In contrast,
occupation of the B cell FcyRII with ligand provides an inhibitory signal and the
receptor is not internalised. Indeed, cross-linkage of FcyR with membrane
immunoglobulin (mlg) on the B cell surface inhibits Ig production (Phillips & Parker
1984), and has been proposed as a regulatory mechanism for B cell responses.
A genetically determined polymorphism of human FcyRII has been demonstrated on
monocytes, macrophages and neutrophils. This was initially discovered by differences
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in the ability of cells from certain individuals to bind murine IgGl. Monocytes from
approximately 70% of Caucasians bound murine IgGl and supported T cell
mitogenesis induced by murine IgGl anti-CD3 monoclonal antibodies (high
responders, HR), while those from the remaining 30% did not (low responders, LR).
Only the LR receptor allotype is capable of binding human IgG2, while human IgGl
and IgG3 can be bound by both HR and LR (Van de Winkel & Capel 1993). The basis
of the polymorphism is a single amino acid change in the second extracellular domain
(Warmerdam et al 1990). The significance of this polymorphism is unclear, although an
effect on the immune response to bacterial polysaccharide antigens has been suggested,
as the antibodies produced against these antigens are mainly of the IgG2 isotype (Van
de Winkel & Anderson 1991).
The affinity of FcyRII on human monocytes for complexed IgG is markedly increased
by proteolysis, while the number of receptors on the cell surface remains constant.
IgG-mediated functions ofmonocytes, such as the release of TNF-cc, are also increased
by proteolysis (Debets et al 1990). It is therefore possible that proteases released by
cells such as granulocytes, activated T cells and macrophages in vivo could increase
the affinity of FcyRII especially at areas of inflammation, with a corresponding
increase in FcR-mediated functions (Tax & Van de Winkel 1990).
FcyRIII type A, found on NK cells and macrophages, is capable of mediating ADCC
and phagocytosis, while FcyRIIIB on neutrophils, with its GPI linkage, is not.
However, the latter may act synergistically with other FcR to mediate these functions,
or alternatively it could be a means of trapping immune complexes without subsequent
cell activation (Selvaraj et al 1988).
1.10.4. Signalling via FcR
Aggregation of FcyR is required before FcyR-mediated functions other than uptake
occur. An increase in the intracellular concentration of calcium ions occurs following
FcyR cross-linking (Van de Winkel et al 1990), although the events involved in
signalling on FcyR occupation have not been determined. Recent studies have
investigated signalling and internalisation of FcyRIII on different cell types. The y and
£ subunits situated with this FcyR do not possess intrinsic enzymatic activity but are
associated with a 70kD tyrosine phosphoprotein, and receptor triggering induces
increased association of this phosphoprotein with the C, subunit in both T and NK cells
(Vivier et al 1993). A similar protein located with the C, subunit in T cells has been
identified as a tyrosine kinase, and the authors suggest that the FcR-associated dimers
interact with this non-receptor tyrosine kinase in initiation of signalling and cell
activation. Greenberg and colleagues demonstrated the requirement for tyrosine
phosphorylation in FcR-mediated phagocytosis in mouse macrophages (Greenberg et al
1993). Localised areas of tyrosine phosphorylation were seen at points of attachment of
IgG-coated erythrocytes; increased concentrations of F-actin were seen in the same
locations. FcyRIII was thought to be responsible for phagocytosis, with the y or C,
subunits essential for signal transduction in FcR-mediated phagocytosis. Tyrosine
phosphorylation was also required for the internalisation of FcyRII and FcyRI in a
human monocytic cell line (Ghazizadeh & Fleit 1994). FcyRII was not tyrosyl
phosphorylated on FcyRI stimulation, suggesting that these two receptors employ
distinct signalling pathways.
The consequences of signalling via FcyR on neutrophils and macrophages include the
release of inflammatory mediators such as leukotrienes and prostaglandins, and the
inflammatory cytokines IL-1, IL-6 and TNF-a (Debets et al 1990, Krutmann et al
1990, Chantry et al 1989). The expression of cell surface molecules involved in
interactions with other cells and the extracellular matrix may also be regulated after
signalling through FcyR.
1.10.5. Regulation of FcyR Expression
Several cytokines have effects on FcyR expression. IFN-y upregulates FcyRI on
macrophages, although functions are differentially regulated with a decrease in
phagocytosis contrasting with enhanced effector functions such as the oxidative burst
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(Jungi et al 1989). IFN-y also induces expression of FcyRI on neutrophils, which do
not constitutively express this receptor (Fanger et al 1989).
FcyRII expression on macrophages is not increased by IFN-y, although functions are
affected as for FcyRI (Jungi et al 1991). The varying functional effects suggest a
divergence of the signal transduction pathway after ligand binding to the FcR, with
effector functions such as oxidative burst and ADCC promoted by IFN-y while
phagocytosis is inhibited. TNF-a and GM-CSF also enhance effector capabilities by
increasing the killing capacity of cultured monocytes through FcyRII (Erbe et al 1990).
1.10.6. Identification of FcyRs
There are currently several mAbs to each of the main Fc receptor types in humans and
mice, although none are available for sheep FcyRs. Anderson used IgG coupled to
Sepharose to affinity purify human FcyRs from lysates of alveolar macrophages and
U937 cells. Two molecules were eluted from the immunoabsorbent, of molecular
weight 40-43 and 72kD. These represented FcyRII and FcyRI respectively, and in
further experiments polyclonal antisera (Anderson et al 1985) and monoclonal
antibodies against FcyRI and FcyRII were raised (Anderson et al 1986).
1.11. Receptor-mediated antigen uptake
An accessory cell must be capable of taking up exogenous antigen, processing the
antigen to a form immunogenic for T lymphocytes, presenting the peptides generated in
a form recognisable by the TCR and providing the costimulatory signals necessary for
activation of the responding cell. The amount of antigen displayed on the accessory cell
surface is dependent largely on the ability of the cell to accumulate antigen and the
quantity of MHC class II products available for interaction with peptides produced by
processing (Lanzavecchia 1990). Non-specific methods of antigen uptake include
adsorption and fluid phase endocytosis; the efficiency of antigen capture is greatly
increased if a cell surface receptor is employed.
30
1.11.1. Enhancement of antigen presentation
The targeting of antigens to cell surface molecules can facilitate subsequent antigen
presentation. For example, Snider and Segal (1987) found that enhanced presentation
followed when antigen was targeted to class I and class II MHC molecules on B cells
and macrophages, and membrane IgD on B cells. Other surface molecules such as the
B cell differentiation antigen B220 were ineffective. This suggests that several surface
molecules can act as receptors for antigen uptake.
MIg on the B cell surface interacts with specific antigen which is then presented with
great efficiency to responder T cells. Internalisation ofmlg/ antigen and processing are
necessary before T cells can be activated in secondary responses (Lanzavecchia 1985);
mlg therefore acts only as a receptor. In contrast, B cells are poor presenting cells for
antigens taken up non-specifically, probably due to their low capacity for pinocytosis
(Chestnut et al 1982).
Antigen-specific antibody can target attached antigen to Fc receptors on the surface of
macrophages, B cells and DC. Celis and Chang (1984 a&b) found that T cell clones
specific for hepatitis B surface antigen (HBSAg) could be activated by 10-100 times
less antigen in the presence of specific antibodies and FcR-expressing APC. An intact
Fc portion of antibody was required for this enhancement. Similar evidence has been
reported by Schalke et al (1985) using the acetylcholine receptor as an antigen; in this
case the APC responsible was the splenic DC. Amigorena and colleagues transfected
FcyRIII into FcR-negative B lymphoma cells. These APC showed enhanced
presentation of antigen to specific T cells; 30-100 fold less antigen was required for T
cell activation when antigen was complexed with IgG (Amigorena et al 1992).
Studies by Marusic-Galesic et al (1991, 1992) investigated T cell responses to antigen
in immune complex form both in vitro and in vivo. In vitro, primed, polyclonal murine
T cells were cultured with human serum albumin (HSA) alone or complexed with
specific antibody. Up to 100-fold less HSA was needed for T cell activation in complex
form and mAbs to FcyR blocked the enhancement. In the in vivo work, the T cell
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response elicited by HSA in immune complexes was equivalent to that seen with five
times as much soluble antigen.
The antigen/ antibody ratio was shown to be important in that complexes at equivalence
or moderate antibody excess provided optimal T cell stimulation (Manca et al 1991). In
this case, extreme antibody excess did not potentiate T cell activation at suboptimal
antigen levels, and actually inhibited proliferation at stimulatory antigen concentrations.
Immune complexes were still taken up in antibody excess, and it was suggested that an
excess of polyclonal antibodies could prevent proteolytic degradation in vivo, acting as
a mechanism to regulate the T cell response.
1.11.2. Internalization of FcR-Ligand
Some surface receptors such as that for transferrin are internalised constitutively (Watts
1985), while others, including FcyR, first require a ligand binding signal (Ukkonen et
al 1986). The fate of immune complexes bound to FcyRII varies with cell type. In
mice, different isoforms of FcyRII are expressed by macrophages and B lymphocytes.
The macrophage receptor is internalised via clathrin coated pits when ligand binding
occurs, while the B cell receptor is not (see below).
The pathway followed by the receptor-ligand complex once internalised depends on the
ligand; while a monovalent Fab fragment of an anti-FcyR mAb is recycled to the cell
surface still bound to the receptor, multivalent ligands such as immune complexes do
not recycle and enter the late endosomal or lysosomal compartments for degradation
(Ukkonen et al 1986). Because the FcyR is also degraded, binding of ligand to FcyR
will result in a rapid downregulation of the receptor. Association of antigenic peptides
with MHC class II molecules may follow in the late endosomal or lysosomal
compartments (see above).
In contrast to the macrophage isoform of FcyRII, that found on murine B cells, which
differs in the cytoplasmic region, is not internalised upon ligand binding (Miettinen et al
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1989). While binding of ligand to FcyRII on macrophages provides a positive signal to
the cell, cross-linking of mlg and FcyRII on the B cell surface inhibits cell activation.
This may act as a regulatory mechanism in vivo to control the production of specific
antibodies.
Studies of FcyRII I have identified the area required for internalisation of this receptor.
This was found to be a cytoplasmic region of the y-y subunit containing a signal
sequence incorporating two tyrosine residues (Amigorena et al 1992).
1.12. Sheep Afferent Lymph DC
Cannulation of both efferent and afferent lymphatics of sheep has been performed
routinely for many years (Hall & Morris 1962, Miller & Adams 1977). DC are found
only in afferent lymph, but there are technical difficulties in obtaining these cells in any
quantity from the multiple afferent lymphatics which are much smaller in diameter than
the efferent lymphatics. Pseudoafferent cannulations give an improved lymph flow with
decreased risk of clotting, and are carried out after resection of the lymph node and a
time period to allow anastomosis of the former afferent and efferent ducts (Hopkins et
al 1989). The former efferent duct is then cannulated. The cannula is heparinised before
use to further reduce the possibility of clot formation, and lymph is collected into sterile
bottles containing heparin and antibiotics, as described in Chapter 2.
This procedure allows the direct investigation of immune responses in vivo by
analysis of phenotype and function of freshly isolated cells after the administration of
antigen into the drainage area of the cannulated duct. 1-10% of cells in afferent lymph
are DC, and these can be separated to a reasonable level of purity by one centrifugation
over metrizamide. A higher degree of purity can be achieved if a second metrizamide
separation is employed. Isolation is therefore simple, and does not require repeated
culture steps which could result in modification of DC morphology and function. With
an average of 5x104 DC per ml of afferent lymph, sufficient numbers of these cells for
functional assays can be obtained from an overnight collection. Lymph from one animal
can be obtained for several weeks .
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1.13. Aims of This Thesis
Previous work with afferent lymph DC of sheep has demonstrated their
immunostimulatory ability in the presentation of both soluble and alloantigens. After
antigen administration in a primed sheep, MHC class II is upregulated on the DC
surface, and this corresponds with increased ability of DC to present a second antigen.
CD1 expression is also increased (Hopkins et al 1989). DC take up fluorescent antigen
more efficiently in the presence of intact specific antibody, both in vitro and in vivo ,
and form rosettes with IgG-coated erythrocytes (Harkiss et al. 1990). Fc receptors for
IgG have thus been proposed as a mechanism of immune complex uptake by sheep
afferent lymph DC in secondary immune responses.
The aims of this thesis were:-
1) The characterisation of DC surface markers by flow cytometry analysis in primary
and secondary immune responses in vivo and in vitro, including molecules with
functions in antigen presentation, adhesion and costimulation. Any modulation of these
surface markers could be important in the migration of DC and subsequent activation
of antigen-specific T cells.
2) Investigation of the expression of FcyR by afferent lymph DC, from resting lymph
and after antigen challenge. This necessitated the generation of anti-ovine FcyR
antibodies for analysis of DC populations by flow cytometry and Western blot
techniques.
3) To determine the role of FcyR on DC in antigen uptake and presentation, by
measuring T cell proliferation in response to soluble or complexed antigen presented by
DC. From previous work, FcyR-bearing APCs would be expected to present antigen
in the form of immune complexes with increased efficiency; this was initially tested
with unfractionated ovine PBMs containing FcyR-expressing cells such as monocytes,




2. MATERIALS AND METHODS
2.1. Antigens
Ovalbumin (OVA) and human serum albumin (HSA) were obtained from the Sigma
Chemical Company, Poole, Dorset.
2.2. Animals and Surgery
2.2.1. Sheep
Finnish Landrace or Scottish Blackface sheep were obtained from the Moredun
Research Institute, Edinburgh. Animals were immunised with lmg OVA in complete
Freund's Adjuvant (CFA) administered subcutaneously and followed at four-weekly
intervals by 2 further injections of 200pg OVA in incomplete Freund's Adjuvant (IFA).
A similar procedure was used for priming sheep to HSA. Sera were tested for anti-
OVA or anti-HSA antibody activity by enzyme-linked immunosorbent assay (ELISA)
as described in section 2.7.2.
To obtain IgM anti-OVA antibodies, OVA was administered to sheep on rabbit
erythrocytes (Torrigiani & Roitt 1965). Rabbit erythrocytes were washed in PBS and
resuspended as a 50% solution in tannic acid, before mixing at room temperature for 20
minutes. After washing again, the erythrocytes were resuspended as a 10% solution in
PBS and 50mg OVA was added per 100ml of solution. The mixture was incubated at
37°C for 30 minutes, centrifuged at 400g for 5 minutes and resuspended in 20ml PBS.
6ml of cells in PBS was administered to sheep by the intravenous route, daily for three
consecutive days. Animals were bled to obtain serum on days 9, 10 and 11 after the
initial antigen administration.
Surgical procedures were carried out under general anaesthesia, induced with
intravenous alphaxolone/ alphadolone ("Saffan", Pitman-Moore, Crewe). Sheep were
then intubated and anaesthesia was maintained with halothane (Halothane-M&B, Rhone
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Merieux Ltd, Harlow) and nitrous oxide. Pseudoafferent cannulations of the
prefemoral ducts were carried out by Dr J. Hopkins (Hopkins et al 1985). Prefemoral
lymph nodes were resected and a period of at least six weeks was allowed for the
anastomosis of afferent lymphatics with the former efferent duct, which was then
cannulated. Initially untreated cannula was used (internal diameter 0.58mm, Portex,
UK), while in later experiments the same cannula was heparinised to reduce clotting
and improve lymph flow. Heparinisation was carried out as follows:- the cannula was
flushed with acetone, followed by 2% Vectabond (Vector Laboratories, Peterborough)
in acetone. The latter was left in the cannula for five minutes at room temperature before
a repeat flush with acetone. The cannula was then filled with neat heparin (5000iu per
ml, Leo Laboratories, Princes Risborough) and both ends were clamped. Before
insertion into a prefemoral duct, the clamps were released and the cannula was wiped
with absolute alcohol.
Cannulated animals were housed in metabolism cages, and lymph was collected into
sterile bottles containing 2.5x103 units of heparin and 2.5x104 units of penicillin and
streptomycin. Overnight collections were generally used for experiments with DC.
2.2.2. Rabbits
Rabbits were bred in the Department of Veterinary Pathology Animal House. Animals
were immunised with 250(ig of synthetic peptide antigens conjugated to OVA at a 1:1
ratio (section 2.10), and emulsified in Hunter's Titermax (Sigma). Antigen was
administered in several sites subcutaneously. Further injections of the same amount of
peptide/ OVA conjugate were given 10 and 17 days after the initial immunisation.
Rabbits were then bled from the ear vein to obtain sera for testing.
2.3. Separation of Cell Populations
2.3.1. DC from afferent lymph
DC were obtained from afferent lymph by centrifugation over metrizamide (Nycomed,
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Oslo). Afferent lymph cells were spun down and resuspended in RPMI medium
containing 10% FCS (Flow Laboratories, Herts). Cells were then layered over 14.5%
metrizamide in the same medium and centrifuged at 600g for 15 minutes at 4°C. The
cells collected from the interface were 60-80% DC by morphology when examined on
Leishmans-stained cytospins (Fig.l). Cells were washed twice in suitable medium
before further use.
A DC population of increased purity was obtained forWestern blot analyses, by adding
a second metrizamide separation. The interface cells were 90-95% DC by morphology
as above. These cells were used to make DC lysates for blots (section 2.7.6.).
2.3.2. Peripheral Blood Mononuclear Cells (PBMs)
Blood was defibrinated by shaking with glass beads, or collected into tubes containing
10 units of heparin per ml of blood, then diluted with phosphate-buffered saline (PBS).
Lymphoprep (Nycomed) was layered under the diluted blood and tubes were subjected
to centrifugation of 950g for 20 minutes at room temperature. PBMs were harvested
from the top of the Lymphoprep layer and washed twice by centrifugation at 500g in
medium before counting.
2.3.3. White Blood Cells (WBCs)
WBCs were obtained from whole blood by the lysis of erythrocytes. Three volumes of
lysis solution (0.14M NH4CI, 0.017M Tris, pH 7.2) were added to one volume of
defibrinated or heparinised blood at 37°C. After a 4 minute incubation, cells were spun
at 400g, washed by further centrifugation in medium and counted.
2.3.4. CD4+ T cells
PBMs were washed twice in PBS then resuspended in PBS at a concentration of 4x107
cells per ml. Biotinylated anti-CD4 monoclonal antibody was added to a predetermined
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Figure 1
Afferent lymph cells were washed and resuspended in RPMI medium containing
10% FCS. The cells were layered over 14% metrizamide and subjected to
centrifugation as described in section 2.3.1. The interface layer of cells was
collected and examined on cytospins stained with Leishman's solution. DC were
the larger cells with irregular shaped nuclei and abundant cytoplasm, with a veiled
or dendritic appearance. Lymphocytes were identified as smaller cells with regular
nuclei and only a small amount of visible cytoplasm.
FIGURE 1 Cytospin of DC Population Obtained After Separation Over Metiizamide
optimal concentration; cells were incubated on ice for 30 minutes. After one wash in
PBS, the cells were resuspended in 90|il PBS per 107 cells and streptavidin-labelled
magnetic MACS microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) were
added at 10p.l per 107 cells. Streptavidin-phycoerthrin (Sigma) was also added at this
stage to allow assessment of the purity of the selected population by flow cytometry. A
15 minute incubation on ice followed before cells were washed in PBS, resuspended in
500[il 1% bovine serum albumin (BSA) in PBS and added to the equilibrated MACS
column.
Columns were prepared by filling with ice-cold 1% BSA in PBS from the bottom and
tapping gently to remove air bubbles. After placing on the permanent magnet, three
column volumes of buffer were run through from the top of the column, using a 24
gauge needle to ensure the correct flow rate. Labelled cells were loaded onto the column
and followed by three volumes of buffer. Negatively stained cells passed through the
column matrix and were collected in a universal. The column was removed from the
magnet, and buffer was flushed from the syringe up through the column matrix to
dislodge the attached cells. After replacing the column on the magnet, buffer was
allowed to flow out through the matrix. A 22 gauge needle was substituted for the 24
gauge one used initially, and three volumes of buffer were used to wash the column
through from the top at an increased flow rate. The backflush and wash were repeated
three times before removing the column from the magnet, and eluting positively stained
cells by flushing with 20mls of 1% BSA in short pulses. Cells were spun down and
counted. The purity of the selected population was determined on a Becton Dickinson
FACScan (FACS). If <93% of cells were CD4+, they were passed through the column
a second time to increase the quality of the separation.
MACS columns were regenerated by washing with lOOmls sterile distilled water
(SDW) followed by lOOmls absolute alcohol, then dried under vacuum before storage.
Where selected cells were to be cultured, columns were autoclaved and all procedures
were carried out in a laminar flow hood.
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2.3.5. Alveolar macrophages
These cells were obtained from bronchoalveolar lavage fluid (BALF) of sheep post
mortem. Lungs were removed and lavaged with 1 litre HBSS containing 5mM
ethylene-diamine tetraacetic acid (EDTA), followed by 1 litre PBS also containing
EDTA. The resulting BALF was passed through a coarse wire mesh to remove mucus
before spinning to pellet the cells. After being resuspended, the cells were separated
over a 14.5% metrizamide gradient as described above for DC.
2.4. Monoclonal Antibodies and Flow Cytometry Analysis
2.4.1. Monoclonal Antibodies
The monoclonal antibodies used for surface phenotyping of cells in flow cytometry
analysis are shown in Table 1.
2.4.2. Cell Staining for Immunofluorescence Analysis
Cells were suspended in PBS containing 2% BSA and lOmM sodium azide (PBA),
and 106 cells in 50(il medium were added per LP2 tube. An equal volume of
monoclonal antibody or dilution of antiserum was added, and the tubes were kept on
ice for 30 minutes. After 3 washes by centrifugation in 500|il PBA, 50|il of relevant
fluorescein isothiocyanate (FITC) or phycoerythrin (PE)-labelled conjugate was added
at a predetermined optimal concentration. A further 30 minute incubation on ice was
followed by washes as above; the cells were then resuspended in 300(il PBS and
analysed on a FACS. Where cells could not be analysed immediately they were fixed in
0.5% paraformaldehyde in PBS and stored protected from light at 40C.
2.4.3. Conjugates for Immunofluorescence analysis
All of the conjugates used were obtained from Sigma:-
Sheep anti-mouse IgG FITC; goat anti-mouse IgG PE; goat anti-mouse IgM FITC;
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Table 1
The various monoclonal antibodies used in the immunofluorescence analysis of
ovine cells are listed in this table. SW73.2, RShyl, RShy2 and MS 121 are rat
monoclonals specific for ovine antigens, while all the other monoclonals are murine
Igs. The monoclonal antibodies were used either as supernatants, or as dilutions of
ascites. Where ascites preparations were used, they were titrated to obtain the
optimum staining of ovine cells. A reference or the source of the monoclonal
antibody is given in each case.
TABLE 1: Monoclonal antibodies used for cell surface phenotyping
Antibody Specificity Isotype Reference/ Source
VPM 6 Ovine IgG IgGl Jones 1988
VPM8 Ovine Ig light chain IgGl Jones 1988
VPM 13 Ovine IgM IgGl Moredun Research
Institute
VPM 18 Ovine LCA (CD45) IgGl Hopkins et al 1990
VPM 19 Ovine MHC Class I IgGl Hopkins et al 1990
VPM 36 Ovine MHC Class II (DQ a) IgGl Dutia et al 1990
VPM 53 Campylobacter IgGl McOrist et al 1987
SW73.2 Ovine MHC Class II IgG2a Hopkins et al 1986
17D Ovine CD4 IgGl Mackay et al 1988a
SBU-T8 Ovine CD8 IgG2a Maddox et al 1985
SBU-T6 Ovine CD1 IgGl Mackay et al 1985
135A Ovine CD2 IgGl Giegerich et al 1989
LI 80/1 Ovine LFA-3 IgGl Hunig et al 1985
F10/150/39 Ovine LFA-1 IgGl Mackay et al 1990
HP2/1 Human VLA-4 IgGl Sanchez-Madrid et al
1990
GoH3 Human VLA-6 IgG2a Hemler et al 1988
DF5 Human CD29 IgGl Ylanne et al 1989
25-32 Ovine CD44 IgGl Mackay et al 1988b
RShyl Ovine IgGl IgG2a S. Hobbs, Institute o
RShy2 Ovine IgG2 IgG2b Cancer Research,
MS121 Ovine IgA IgG2a Royal Marsden
Hospital, Sutton,
Surrey.
goat anti-rat IgG FITC and goat anti-rabbit IgG FITC; streptavidin-PE.
The conjugates were diluted in PBA and titrated to obtain optimum dilutions before
use.
2.4.4. Biotinylation of Monoclonal Antibodies
Approximately 2mls of ascites was applied to a Protein A-Sepharose column in order to
purify IgG. Columns were run in PBS, and bound IgG was eluted with 0.1M glycine/
HC1 buffer pH 2.5, then neutralised with 2M Tris as described below. The eluted
antibody was extensively dialysed into 0.1M sodium bicarbonate, pH 8.4, and its
protein concentration was determined from the optical density (OD) at 280nm. 2mg
biotin (Sigma) was dissolved in 1ml dimethyl sulphoxide (DMSO) immediately prior to
use; 75|ig biotin was then added per lmg IgG and the mixture was rotated at room
temperature for 4 hours. The antibody was dialysed into PBS/ azide and FACS analysis
of titrations was carried out to determine the optimal concentrations for cell staining.
The biotinylated antibody was stored in aliquots at -70°C until used.
2.4.5. Analysis of Flow Cytometry Data
Cells were prepared for flow cytometry as described above. A representative FACS
light scatter plot for afferent lymph cells is shown in Fig.2 (i). Side scatter, detected at
900 to the laser beam, is a result of reflection and refraction of the incident light, while
forward scatter due to diffraction is detected along the axis of the beam and depends on
the surface area of the cell. DC were gated on as cells with high forward and side
scatter due to their large size and complexity. A minimum of five thousand DC were
analysed per sample. The gate used for analysis of afferent lymphocytes is also shown
in Fig.2 (i). WBCs obtained from defibrinated blood after the lysis of erythrocytes
were used in some experiments; a scatter plot of these cells with the gates used for
analysis of granulocytes and lymphocytes is shown in Fig.2 (ii). The gates used for the
analysis of particular cell populations are difficult to set accurately; in each case there is
the possibility of a minor percentage of contaminating cells of another population being
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Figure 2
Afferent lymph cells were collected from a pseudoafferent cannulation of the
prefemoral duct, while WBCs were obtained from whole blood by ammonium
chloride lysis of erythrocytes. The cells were analysed by flow cytometry for their
forward (FSC) and side (SSC) light scatter profiles. The live gates used to analyse





included within the gate.
Negative controls were isotype-matched irrelevant monoclonals, second layer reagents
only, or, for rabbit sera, dilutions of the preinoculation serum. The percentage of DC
positive for each marker was assessed as the fluorescence staining over and above that
of the negative control. DC are a heterogeneous population of cells, and negative
control peaks often showed a "tail" of fluorescence as shown in Fig.3; this made it
necessary to set markers with 5-10% of cells in the negative control sample positive.
This percentage was then subtracted from the proportion of DC staining for each
marker tested. Lymphocytes and neutrophils gave a sharper negative control peak and
markers for these cells were set so that <1% of cells in the negative control peak
showed positive fluorescence (Fig.3).
2.5. Antigen Uptake by DC
2.5.1. Production of FITC-OVA
OVA was dissolved in 0.25M sodium carbonate pH 9, 0.1M sodium chloride to give a
protein concentration of 20mgmH. FITC in DMSO was added at 0.05mg per mg
protein, for a one hour incubation at room temperature. The mixture was then applied to
a Sephadex G-25 column equilibrated in PBS. Two coloured bands were visualised
and the heavier of these, representing conjugated OVA, was collected. FITC-OVA was
aliquoted and stored protected from light at -70°C.
2.5.2. In Vitro uptake of antigen
Antigen uptake was investigated in primary and secondary responses in vitro. In
experiments representing secondary responses, afferent cells were washed and
resuspended in PBA. lOOpl of afferent cells was then added to 50|il FITC-OVA
dilutions in PBA. To some tubes 50(0.1 of afferent lymph from an OVA-primed sheep
was added as a source of anti-OVA antibodies. Lymph was first tested by ELISA to
demonstrate the presence of anti-OVA antibodies of IgG isotype. In some experiments,
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Figure 3
Afferent lymph cells were stained with a second layer reagent only (anti-mouse Ig-
FITC) and analysed by flow cytometry on a FACScan. The DC and lymphocyte
populations were gated on as described, according to their forward and side light
scatter characteristics. Representative negative peaks are shown in (i) for DC and
(ii) for lymphocytes. The markers were set as shown for analysis; generally 5-10%
of DC were positive, and <1% of lymphocytes were positive, in the negative
control populations.
FIGURE 3 Negative Control Flow Cytometry Profiles Of DC and Lymphocytes
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affinity-purified antibodies (section 2.8.2.) were used instead of lymph fluid.
Incubation at room temperature for 30 minutes was carried out in LP2 tubes. After
washing three times in PBA, the cells were analysed by FACS for fluorescence. In
some experiments unlabelled OVA was used and the cells were subsequently incubated
with monoclonal antibodies to detect surface immunoglobulins. The uptake of FITC-
OVA by alveolar macrophages in the presence or absence of specific antibodies of IgG
isotype was also investigated using the above method.
To detect antigen uptake during primary responses, the above procedure was modified
to include IgM anti-OVA antibodies instead of IgG antibodies. Serum was collected
from sheep primed with OVA as described above, on days 9-11 of the primary immune
response. Unfractionated serum or purified IgM antibodies were added to afferent cells
with FITC-OVA as described above.
2.5.3. Antigen Uptake In Vivo
lmg FITC-OVA in PBS was injected intradermally into the drainage area of a
cannulated prefemoral pseudoafferent duct in a sheep repeatedly primed with OVA.
Lymph was collected at various time points and the cells were stained with monoclonal
antibodies followed by a phycoerythrin conjugate before analysis by FACS. In some
experiments unlabelled OVA was injected and the afferent cells were stained with
monoclonal antibodies followed by a FITC conjugate.
2.6. DC Phenotype Analysis After Antigen Stimulation
2.6.1. In Vitro Experiments
Unseparated afferent cells from a primed sheep were cultured with medium only, OVA
at l|igmH, or OVA at lpgml-1 and specific affinity purified antibodies at SOjigml-1.
Antigen and antibody were added to 24 well plates and incubated at 37°C for thirty
minutes to allow immune complex formation. Afferent cells were washed twice in
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medium before addition to wells at a concentration of 106 cells per ml. The cells were
stained for FACS analysis before culture and after 2 and 8 hour incubation periods; DC
were gated on as described above. The viability of the cells at each time point was
determined as >99% by Trypan Blue exclusion.
2.6.2. In Vivo Experiments
lmg of OVA in 1ml PBS was injected intradermally in two or three sites, into the
drainage area of a cannulated OVA-primed sheep. Afferent lymph was collected at
various time points after antigen administration, and the cells were washed and stained
for FACS analysis as described above. DC were gated on as before.
2.7 Protein Immunochemistry
2.7.1. Preparation of F(ab')2 Antibody Fragments
Affinity purified IgG anti-OVA antibodies were dialysed into 0.1M sodium acetate pH
4.5. Pepsin (Sigma) was made up in the same buffer and added at 3% (w/w). Digestion
took place overnight at 37°C, with constant rotation of the mixture; the digestion was
stopped by neutralisation with 2M Tris. F(ab')2 fragments were separated from residual
whole IgG by DEAE-cellulose ion-exchange chromatography (DE52, Whatman,
Maidstone). Antibodies were dialysed extensively into lOmM sodium phosphate pH
7.5 and applied to columns of equivalent pH and conductivity. Whole IgG molecules
were retained on the column while F(ab')2 fragments passed through and were
collected. The various fractions were analysed by sodium dodecyl sulphate
polyacrylamide-gel electrophoresis (SDS-PAGE) to ensure that no intact IgG molecules
remained (see Chapter 5). Antibody activity was confirmed by ELISA as described
below, and preparations were dialysed into RPMI before use in assays.
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2.7.2. Assessment of antibody activity and isotype by ELISA
Microtiter plates (Immulon 1, Dynatech Laboratories Ltd, Virginia) were coated
overnight with antigen in PBS at a concentration of 10|igml-L The plates were washed
in PBS / 0.5% Tween 20 before the addition of antibody dilutions in PBA. PBA alone
served as a negative control. After a one hour incubation at room temperature, the plates
were washed again then a second antibody or a relevant conjugate was added. For the
detection of sheep IgG, an anti-sheep IgG alkaline phosphatase conjugate at a dilution
of 1/1000 was the next layer, with a similar method used for rabbit IgG. To measure
the anti-OVA antibody activity of F(ab')2 preparations VPM 8 was employed to detect
sheep immunoglobulin (Ig) light chains, followed by an anti-mouse IgG alkaline
phosphatase conjugate. All of the conjugates were obtained from Sigma.
The antibody isotype in ovine preparations was investigated using the following second
layer monoclonals:-
RShyl against ovine IgG 1
RShy2 against ovine IgG2
VPM 13 against ovine IgM
These were followed by an appropriate alkaline phosphatase conjugate, with incubation
for 30 minutes at room temperature. The plates were washed once more, then alkaline
phosphatase substrate (Sigma 104 phosphatase substrate) , made in 0.1M glycine,
0.05M NaOH, 0.5mM MgC^, 0.5mM ZnCl2 was added as the final layer. The plates
were read after a 30 minute incubation at 37 °C protected from light, using a 405nm
filter. Positive results were those greater than the mean + 2 standard deviations of the
negative control wells.
2.7.3. Gel Electrophoresis
SDS-PAGE was used for protein analysis. 5% and 20% acrylamide solutions were
44
made in 0.38M Tris, 2mM EDTA pH8.8 with 0.13% SDS. To 4.2ml of each solution
was added 3|il N,N,N' ,N' -tetramethylethylenediamine (TEMED) (Stratagene, La
Jolla, California) and 30|il 10% ammonium persulphate, before pouring to form a
gradient slab gel.
The stacking gel was 2.5% acrylamide, 0.13M Tris pH 8, 0.1% SDS. 60p.l ammonium
persulphate and 20|il TEMED were added to lOmls of solution before pouring the
stack. The protein samples were boiled for three minutes in an equivalent volume of
SDS reducing buffer (25mM Tris, 2% SDS, 20% glycerol, 0.01% bromophenol blue
and 5% mercaptoethanol), before loading onto gels. Low molecular weight markers of
94, 67, 43, 30, 20.1 and 14.4 kD (Pharmacia, Uppsala, Sweden) were used. Gels
were run at 200V for 45 minutes in a tank buffer of 50mM Tris, 384mM glycine and
0.1% SDS, then stained to visualise proteins.
2.7.4. SDS-PAGE Staining
2,7.4.1 .Silver stain
The SDS-PAGE gels were fixed in 50% methanol, 10% acetic acid for 30 minutes,
then in 5% methanol, 7% acetic acid for the same period and finally in 10%
glutaraldehyde solution. After washing overnight with deionised water, 0.1% silver
nitrate was added for 15-30 minutes. The stain was rinsed off with deionised water
followed by developer (3% sodium carbonate with 50(il 37% formaldehyde per
100ml), then more developer was added. Once the protein bands were clearly visible
the reaction was stopped by the addition of solid citric acid.The gels were washed for at
least 30 minutes in deionised water, then fixed in 10% Ilfofix for 1 minute and dried
down immediately.
2.7.4.2. Coomassie blue stain
This stain was used where the amount of protein present was estimated to be at least
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5|ig per band. A solution of 0.25% coomassie blue, 20% methanol and 5% acetic acid
was prepared and filtered before use. The gels were stained for 30 minutes, rinsed in
deionised water and de-stained in 20% methanol, 5% acetic acid until protein bands
could be visualised. Drying of the gels was then carried out as above.
2.7.5. Western Blot Analysis
A semi-dry electric blotter (Ancos, Denmark) was used for this procedure. Six pieces
of 3mm chromatography paper (Whatman) were soaked in blotting buffer (25mM Tris,
40mM glycine, 20% methanol) and placed on the bottom carbon plate. A nitrocellulose
layer (Hybond C, Amersham) was placed on top, then the gel and finally another three
pieces of wet paper. Blotting was carried out at 150mA for two hours.
Prestained low molecular weight markers (BRL, Uxbridge) were removed and the rest
of the blot was blocked in PBS containing 3% BSA, 0.5% Tween 80 for at least 1
hour. Serum/ antibody dilutions in blocking buffer were added for an overnight
incubation. Several washes in PBS/ 0.5% BSA preceded the addition of the anti-rabbit
IgG alkaline phosphatase conjugate (Sigma) diluted 1/1000 in blocking buffer. After a
1 hour incubation and further washes in PBS/ 0.5% BSA, a final wash of 0.1M Tris
pH 9.5 was carried out before the addition of developer. Blots were developed with
nitroblue tetrazolium and bromo-chloro-indolyl phosphate (BCIP) in 0.1M Tris pH
9.5, with added magnesium chloride (Pluzek & Ramlau 1988). The reaction was
stopped by washing the blots with water.
2.7.6. Preparation of Alveolar Macrophage Lysate
Alveolar macrophages were obtained from the lungs of sheep at post mortem as
described above. The cells were washed twice in PBS and resuspended at 5xl07ml1
in lysis buffer of 1% NP-40 in PBS with the following protease inhibitors: 0.5mM
benzamidine, 5|igmH leupeptin, 2pgml-1 pepstatin and ImM polymethylsulphonyl
fluoride (PMSF). Cells were lysed on ice for 30 minutes before centrifugation at
12,000g for 30 minutes to remove cell debris. Sodium azide (lOmM) was added to
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supernatants which were stored at -70°C. The preparation of lysates of other cell types
(DC, lymphocytes) for use in Western blots was carried out using the same method.
2.7.7. Ouchterlony Double Gel Diffusion
This method was employed to ascertain equivalence points for antigens and specific
antibodies prepared from the sera of primed sheep. Gels of 1% agarose in PBS were
poured and wells of 4mm diameter cut in a radial pattern. Antigen was added to the
central well and dilutions of antibody to the outer wells. After overnight incubation in a
humidified atmosphere at 40C, equivalence was determined as the sharpest line of
precipitation between the central and an outer well.
2.8. Affinity Chromatography
2.8.1. Coupling proteins to Cyanogen bromide-activated Sepharose
This method was used to attach IgG, HSA, BSA and OVA to the Sepharose matrix.
The protein to be coupled was dissolved or extensively dialysed into coupling buffer
(0.1M NaHC03, 0.5M NaCl, pH 8.3). Cyanogen bromide (CNBr)-activated
Sepharose powder was washed in a sintered glass filter with 200ml ImM HC1/ g
powder. The protein was added at 5mg protein to 1ml Sepharose and the mixture was
rotated overnight at 40C to facilitate coupling. Excess protein was removed by washing
repeatedly with coupling buffer, the first wash being retained and its OD determined at
280nm to assess the efficiency of binding. Unreacted sites on the gel were blocked with
1M ethanolamine pH 9, mixing for one hour at room temperature. The Sepharose gel
with attached protein was finally washed alternately with 0.1M sodium acetate/ 0.5M
NaCl pH 4, and 0.1M Tris/ 0.5M NaCl pH 8 before pouring columns.
2.8.2. Purification of ovine antibodies
Columns were first flushed with ten volumes of PBS, then pre-eluted with ten
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volumes of 0.1M glycine pH 2.5. After a further ten volumes of PBS, samples of heat-
inactivated (56°C, 30 minutes) sera were applied to the columns and washed through
with running buffer. Bound antibodies were eluted with 0.1M glycine/ HC1 pH 2.5;
2ml fractions were collected and neutralised with 325|il 2M Tris per tube. Peak
fractions were pooled and the OD at 280nm measured to determine antibody
concentration, before the addition of 0.5% BSA to prevent aggregation during storage.
Antibody preparations were then dialysed into PBS or RPMI medium before use.
2.8.3. Purification of Rabbit anti-peptide antibodies
Fey receptor peptide 1 (see below) was conjugated to CNBr-Sepharose using the
above method. Serum from the rabbit primed with this peptide was then passed through
the column and the specific anti-peptide antibodies were eluted with 0.1M glycine pH
2.5, neutralised as above.
2.8.4. Affinity Columns for FcR Purification
BSA and sheep IgG were coupled to CNBr-Sepharose as described. 5ml columns were
poured and run at 4°C. The columns were first washed with 20 column volumes of
PBS, followed by 10 volumes PBS/BSA (0.5%). Pre-elution was carried out with 10
volumes of 0.5M acetic acid in 1% NP-40; then columns were re-equilibrated with 150
volumes 1% NP-40 in PBS.
The two columns were joined and the lysate from 108 alveolar macrophages was
applied to the BSA pre-column and then to the IgG affinity column. The sample was
recycled through both columns overnight. After washing with 150 volumes 1% NP-40
in PBS, the columns were eluted separately using 0.5M acetic acid in 1% NP-40. 1ml
fractions were neutralised with 350pl 2M Tris. The fractions were run on SDS-PAGE
reducing gels to assess their protein content.
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2.9. Proliferation Assays
2.9.1. DC and CD4+ T Cells
2.9.1.1. Response to antigen alone or immune complexes
DC and CD4+ T cells were separated as described above, counted and resuspended in
RPMI 1640 containing 10% FCS, 2mM glutamine, 5xl0 5M 2-Mercaptoethanol,
lOOU/ml benzyl penicillin and lOOU/ml streptomycin. DC were irradiated with 2500
rads from a caesium 137 source before use in assays. Antigen and antibody dilutions in
50|il volumes were added to the plates first, followed by an incubation of 30 minutes at
37°C to allow the formation of immune complexes. The cells were cultured with
antigen alone or with antigen and specific antibody in 96 well flat bottomed culture
plates (Nunclon, Denmark), in a final volume of 200|il. In each well, 5xl04 DC were
added to 1x10s responding CD4+ T cells.
The controls for these assays included DC or T cells alone, plated with antigen and
antibody. After 5 days of culture at 37°C in a humidified atmosphere containing 5%
CO2, plates were pulsed with lp.Ci of tritiated methyl thymidine (3H-Thymidine,
Amersham) per well and harvested 5 hours later onto filter paper using a semi-
automated cell harvester. The incorporation of 3H-Thymidine was assessed by
scintillation counting in a beta counter. All of the cultures were performed in triplicate.
2.9.1.2. Inhibition of proliferation
Inhibition of antigen-specific proliferation was assessed by the inclusion of F(ab')2
fragments of SW73.2, a rat monoclonal specific for ovine MHC Class II (obtained
from Dr J Hopkins), throughout the culture period. The control antibody for this
experiment was a F(ab')2 preparation of rat anti-mouse IgG (Pierce, Rockford,
Illinois).
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2,9.1.3. Inclusion of irrelevant antibody
Anti-HSA antibodies purified from sheep serum on affinity columns as described
above (sections 2.8.Land 2.8.2.) were included in some experiments as an irrelevant
control.
2.9.1.4. F(ab')2 preparations of specific antibody
F(ab')2 fragments of affinity purified antibodies specific for OVA were used in place of
intact antibody in some assays, to assess the importance of the Fc portion of the
antibody. Antibody activity against OVA was determined by ELISA before use.
2.9.2. PBMs
Unfractionated PBMs were obtained from defibrinated blood by centrifugation over
Lymphoprep. 105 cells per well were cultured with OVA and anti-OVA antibody as
described for DC and CD4+ T cells. Similar experiments with F(ab')2 portions of
specific antibody, intact irrelevant antibody and anti-MFIC Class II antibody were also
carried out (section 2.9.1.).
2.10. Fc Receptor Peptides
Peptides were selected from the protein sequence of the extracellular domains of bovine
FcyRI (Symons & Clarkson 1992), for their hydrophilicity and likely expression on
exposed surfaces of the Fc receptor. Peptide 1 is located in the second, and peptide 2 in
the first of the three extracellular domains. Both of the peptides incorporated a cysteine
amino acid at the N-terminus.
The peptides were synthesised by Douglas Thomson in the Department of Veterinary
Pathology, using standard fluoronylmethoxycarbonyl (FMOC) chemistry (Dryland &
Shepherd 1986). The peptides were desalted on a Sephadex G10 filtration column and
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purified by high pressure liquid chromatography (HPLC) using a C is reversed phase
column. Each peptide was freeze-dried and conjugated to OVA at a 1:1 ratio. OVA was
reacted with N-succinimidyl 3-[2-pyridyldithio]propionate (SPDP), to provide a thiol
group for subsequent formation of a disulphide link with the cysteine residue present at
the N-terminus of each of the synthetic peptides. OVA-peptide conjugates were
emulsified in Hunter's Titermax, and 100|ig of peptide-OVA conjugate was
administered subcutaneously in several sites to rabbits.
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CHAPTER THREE
PHENOTYPIC ANALYSIS OF DC
3. PHENOTYPIC ANALYSIS OF DC
3.1. Introduction
DC from the afferent lymph of sheep bear surface molecules important in antigen
uptake, intercellular adhesion, costimulation and the presentation of peptide antigens
(see Chapter 1). Expression of these various molecules contributes to the unique role of
DC in the initiation of primary immune responses and the activation of resting T cells.
The role of surface molecules such as Igs and Fc receptors for IgG has not been fully
investigated.
After intradermal administration of antigen in a primed, cannulated sheep, changes
occur in the phenotype and function of afferent lymph DC (Hopkins et al 1989).
Surface MHC class II is upregulated, reaching maximum levels five days after
challenge. CD1 is upregulated on a proportion ofDC after antigen administration. The
stimulatory capacity of DC for presentation of an unrelated antigen to T cells in vitro
increases with elevated class II expression.
In a primary response to antigen no alteration in MHC class II on the cell surface is
noted, although CD 1 expression is modulated and three different populations of DC
emerge transiently with varying intensity of expression. Changes in the expression of
surface molecules may enhance the immunostimulatory capacity of afferent lymph DC
for the subsequent activation of T cells in the draining lymph node.
In this chapter, phenotypic analysis of resting and in vivo or in vitro antigen-
stimulated DC was carried out. The expression ofmolecules involved in the uptake and
presentation of antigen and intercellular reactions was assessed by flow cytometry.
3.2. DC Phenotype in Resting Lymph
Cells were obtained from pseudoafferent cannulations of the prefemoral ducts of
Finnish Landrace or Scottish Blackface sheep as described. Lymph was collected in
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sterile bottles containing heparin and penicillin/ streptomycin, and a period of five days
was allowed before lymph cells were stained with a panel of monoclonals (details in
Table 1, Chapter 2) and analysed by flow cytometry as described in Section 2.4.5.
Representative fluorescence histograms are shown in Fig. 1.
3.2.1. Presentational Molecules
DC of afferent lymph form a heterogeneous population regarding both morphology and
the expression of surface molecules such as CD1 and FcyR (Bujdoso et al 1989,
Mackay et al 1988a, Harkiss et al 1990). In these experiments, resting DC expressed
high levels of MHC class II and class I products, while CD1, as detected by staining
with SBU-T6, was expressed by the majority of DC (Fig.l).
3.2.2. Surface Ig
Surface immunoglobulins have been reported on DC from sheep afferent lymph (Miller
& Adams 1977, Barfoot et al. 1989). Experiments in this chapter showed that DC
staining for surface IgM was variable (Table 1) both between animals and over the time
course of a particular cannulation. Addition of lymph to afferent lymph DC expressing
low levels of IgM and subsequent incubation at room temperature did not result in IgM
binding to DC (data not shown), suggesting that IgM in the lymph is not simply
adsorbed onto the DC surface. Staining with VPM8 to detect Ig light chain gave a
higher number of DC positive for this marker than for IgM alone, and a small
percentage (mean=9%, Table 1) of DC were routinely positive for IgGl. IgG2 and IgA
were not detected on DC. Representative flow cytometry profiles are shown in Fig.l.
The percentages of DC positive for each marker were assessed as described in Section
2.4.5.. However, with some surface molecules, including IgG, IgM and CD1, the
peaks for the negative control and stained cells overlapped considerably. This made it
difficult to set a marker to the right of the negative peak and obtain an accurate
percentage of cells positive. For example, the staining profile for IgG in Fig. 1 gave
15% DC positive for this molecule when a marker was set to the right of the negative
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Figure 1
The cells from afferent lymph were washed and stained with monoclonal antibodies
specific for immunoglobulins and molecules involved in the presentation of antigen.
The DC were gated on as the cells with high forward and side scatter in the scatter
profile of unseparated afferent lymph cells. The negative control peak shows
fluorescence where cells were stained with FITC conjugate only. Ten thousand
cells were analysed per sample, and representative fluorescence profiles are shown.













control peak. However, the whole peak has shifted to the right on staining with anti-
IgG mAb, therefore it is arguable that all the cells bear a low level of IgG.
3.2.3. Adhesion/ Costimulation Molecules
Many surface molecules involved in intercellular adhesion and costimulation were
expressed by the DC analysed. LFA-1 is thought to be necessary for the formation of
DC-T cell clusters from which activated T cells arise (Inaba & Steinman 1986), and is
also implicated in costimulation leading to T cell activation. LFA-1 was expressed by
DC from sheep afferent lymph, as was LFA-3, the ligand for CD2 on the T cell surface
(Fig.2 and Table 1). CD2 was also detected on a proportion ofDC; however it has been
suggested that this molecule could be passively acquired from T cells rather than
synthesised by the DC (Bujdoso et al 1990).
CD44 also plays a role in cellular interactions (Shimizu et al. 1989), and is expressed
by many cell types. Increased expression of this molecule occurs on T cell activation,
with memory cells expressing CD44 at high levels. MAbs specific for CD44 enhance
the CD2-LFA-3-mediated adhesion between T cells and monocytes, and induce
monocyte IL-1 production in vitro (Haynes et al 1989). CD44 is also important in
lymphocyte binding to high endothelial venules for subsequent extravasation (Jalkanen
et al 1988). As shown in Table 1, DC staining with anti-CD44 mAb was consistently
high. VLA-4, a (31 integrin, is present on T cells where it is involved in interactions
with ligands in the extracellular matrix as well as intercellular adhesion (Hemler 1990).
Binding of VLA-4 to its ligands, VCAM-1 or fibronectin, mediates adhesion and
delivers a stimulatory signal to the T cell. VLA-4 was found to be present on afferent
lymph DC (Fig.2). VLA-6, another (31 integrin found on T cells, was expressed only
by a proportion of DC (Table 1, Fig.2). The extracellular matrix ligand for this
molecule is laminin. CD29, the (31 integrin alpha chain, was present on afferent lymph
DC, correlating with the expression of VLA-4 by these cells.
CD4 on helper T cells is necessary for interaction with MHC class II molecules on
APCs in the presentation of peptide antigens. CD4 has previously been reported on the
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Figure 2
Afferent lymph cells were washed and stained for analysis by flow cytometry as
described in Chapter 2. The monoclonal antibodies used are detailed in Table 1,
Chapter 2. The DC population was gated on as described, and ten thousand cells
were collected per sample. Representative fluorescence profiles are shown. The
negative control peak illustrates DC stained with the FITC conjugate only .
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Table 1
Unfractionated afferent lymph cells were collected and stained with
monoclonals as described. After application of a FITC-labelled conjugate, cells
were analysed for fluorescence expression on a FACScan. DC were gated on
as cells with high forward and side scatter: ten thousand cells were analysed per
sample. Results are shown as the mean percentage of DC positive for FITC
flourescence over and above the fluorescence of the negative control, with the
range in brackets. Analysis was carried out on cells from at least five sheep for
each marker; several staining experiments were carried out with each
cannulation.
TABLE 1 Phenotypic Analysis of DC From Resting Afferent Lymph
DC % Positive for FL-1
Surface Molecule Mean (Range)
Class II 95 (80-100)














surface of sheep afferent lymph DC (Bujdoso et al 1990). In the phenotypic analysis
carried out in this chapter, CD4 was detected on the surface of a variable percentage of
the DC population (Table 1), where it may interact with MHC class II on responding
cells, providing an activational stimulus for the DC. In the flow cytometry profile
shown, a small subpopulation of brightly stained cells is present; these may be
contaminating T cells included in the DC gate (Fig.2). CD4-class II interactions will
also contribute to cell-cell adhesion (Doyle & Strominger 1987). CD45, the leucocyte
common antigen, was also expressed by afferent lymph DC.
3.3. Antigen Uptake
The uptake of antigens by afferent lymph DC has previously been investigated (Harkiss
et al. 1990). Enhanced accumulation of fluorescent antigen in the presence of specific
antibodies was demonstrated, suggesting the uptake of immune complexes via Fc
receptors for IgG on the DC surface.
Here antigen uptake by afferent lymph DC was compared with that by Fc receptor-
expressing macrophages. Surface Ig levels on DC were also investigated in antigen
uptake experiments.
3.3.1. In Vitro Uptake of FITC-OVA
Whole afferent cells were incubated with dilutions of FITC-OVA alone or with lymph
from a sheep primed to OVA as a source of anti-OVA antibodies. After incubation for
30 minutes at room temperature, the cells were washed three times and analysed by
flow cytometry. lOmM sodium azide was present in the incubation and washing
solutions in order to prevent phagocytosis and assess the uptake of immune complexes
via FcR. The fluorescence histograms of a representative experiment clearly
demonstrate the enhanced uptake of antigen in the presence of specific antibody
(Fig.3). At high concentrations of FITC-OVA (250|igml-i), over 80% of DCs were
positive for FITC fluorescence with added lymph (Fig.3 and Fig.4 (i)). Without
lymph, only 40% of DC took up antigen at the same FITC-OVA concentration.
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Figure 3
Unfractionated afferent cells were incubated with FITC-OVA at varying
concentrations for 30 minutes at room temperature in the presence or absence of
lymph from an OVA-primed sheep as a source of specific antibodies.
Representative fluorescence histograms are illustrated: the dotted lines show


















































Afferent cells were incubated with FITC-OVA alone, or with lymph as a source of
anti-OVA antibodies. The percentage of DC positive for FITC fluorescence is
shown. In (i), a lymph dilution of 1/2 was used, with a titration of FITC-OVA. In
(ii), serial lymph dilutions were used with a constant FITC-OVA concentration of
25pgmH.
FIGURE 4 DC Uptake of FITC-OVA In Vitro
(i) Fixed lymph concentration with FITC-OVA dilutions
Concentration of FITC-ova (ugml"l)
(ii) Fixed FITC-OVA concentration with lymph dilutions
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However, it was difficult to accurately obtain the percentage of DC positive for FITC
fluorescence, due to the overlap of cell populations. This was a greater problem with
DC incubated with FITC-OVA in the absence of lymph (Fig.3 (ii)), where the peaks
representing these cells were clearly shifted to the right, although there was a
considerable overlap with the negative control peaks.
In other experiments, a constant concentration of FITC-OVA ^Sfigml-1) and a range of
lymph dilutions were used. The percentage of DC showing positive fluorescence varied
with the concentration of lymph added, from a minimum of 34% at lymph dilution of
1/512 to 63% at a lymph dilution of 1/8 and 1/16 in the example shown (Fig.4 (ii)).
The highest concentrations of lymph used were not the most effective at causing
enhanced uptake of antigen. DC did take up some FTTC-OVA in the absence of specific
antibodies; in this case 24% of DC were positive for FITC fluorescence without added
lymph. Lymph alone had no effect on DC fluorescence.
Similar experiments were carried out with alveolar macrophages for comparison. Here
either lymph from a primed sheep or affinity purified anti-OVA antibodies were used as
a source of specific antibodies, with comparable effects on the enhancement of antigen
uptake. Fig.5 shows the percentage of macrophages positive for fluorescence after
addition of FITC-OVA at 20(lgml1 or 50flgml-i and either (i) lymph dilutions or (ii)
affinity purified antibodies. Only 10% of macrophages took up FITC-OVA alone at
20figml1; when the concentration was increased to 50(igml-i only 12% of
macrophages were positive for FITC fluorescence. Overlay fluorescence histograms
(Fig.6) illustrate the uptake of FITC-OVA in the presence of various lymph dilutions
compared with uptake in the absence of lymph. In one experiment, irrelevant affinity
purified anti-HSA antibodies were used as a control at the same dilutions as the specific




Alveolar macrophages were incubated in vitro with FITC-OVA in the presence or
absence of specific antibodies, before flow cytometry analysis for detection of
FITC fluorescence. In (i), FITC-OVA concentrations of 20 and 50pgml-i were
used with lymph from a primed sheep as a source of anti-OVA antibodies. In (ii),
affinity purified anti-OVA antibodies were used with FITC-OVA at 20pgml-i.
Irrelevant affinity purified antibodies specific for HSA were used as a control.
FIGURE 5 Uptake of FITC-OVA by Alveolar Macrophages
(i) Lymph of an OVA-primed sheep as a source of antibodies
Reciprocal Lymph dilution
Concentration of IgG antibodies (pgml"1)
Figure 6
Alveolar macrophages were incubated with FITC-OVA alone at a concentration of
20|igmH, or with FITC-OVA and lymph from a primed sheep at various dilutions
as a source of anti-OVA antibodies. Cells were analysed by flow cytometry for
FTTC fluorescence. The solid lines illustrate fluorescence in the presence ofFITC-
OVA and antibody, while the dotted lines show the fluorescense observed with
FITC-OVA only.
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3.3.2. DC Staining for Surface Ig After In Vitro Antigen Uptake
Assuming that the enhanced uptake described above is due to the accumulation of
immune complexes by DC FcyR, an increase in the levels of IgG on the DC surface
should be detectable. This was investigated using monoclonals specific for Ig isotypes.
Unlabelled OVA was used in these experiments as problems were encountered with
double staining using PE conjugates to monoclonals and the directly-labelled FITC-
OVA. Fig.7 illustrates the increase in slgG expression detected after in vitro incubation
ofDC with dilutions of OVA and lymph from a primed sheep as a source of antibodies.
Surface IgG was detected with both VPM6 and Rshyl, the latter being specific for
sheep IgGl. No DC staining was observed with RShy2, specific for sheep IgG2
(Fig.7). A maximum of 34% of DC were positive for slgG in these experiments. This
contrasted with slgG levels on incubation with BSA only, or with OVA only, which
were 4% and 6% of DC positive for fluorescence respectively.
3.3.3. In Vitro Uptake with IgM Anti-OVA Antibodies
In the primary immune responses for which DC are the crucial accessory cells, specific
antibodies of IgG isotype will not be available. Specific IgM antibodies are produced
during the primary response, while naturally-occurring antibodies of IgM isotype with
multiple specificities may play a role in the initial interaction with antigen (Casali &
Notkins 1989). IgM has been detected on the surface of afferent lymph DC, and has
been suggested as a concentrating mechanism for antigens in the primary response
(Bujdoso et al 1990, Harkiss et al 1990). This possibility was investigated by repeating
the antigen uptake experiments described above but substituting anti-OVA antibodies of
IgM isotype for those IgG antibodies previously used.
Serum from sheep immunised with OVA on rabbit erythrocytes, as described in
Chapter 2, was used as a source of IgM antibodies. Serum samples were collected on
days 9, 10 and 11 after initial immunisation. Antibody activity was assessed using
ELISAs with OVA-coated plates; IgM anti-OVA antibodies were detected with VPM13,
which is specific for ovine IgM, followed by an anti-mouse alkaline phosphatase
Figure 7
Unfractionated afferent lymph cells were incubated with dilutions of OVA, and
lymph from an OVA-primed sheep as a source of specific antibodies, for 30
minutes at room temperature. The cells were washed and stained with the anti-IgG
monoclonals VPM6, Rshyl, or RShy2, followed by an appropriate FITC
conjugate for FACS analysis. The results are the percentage of cells positive for
FITC fluorescence.
FIGURE 7 SIgG Levels on DC After In Vitro Incubation
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conjugate. The IgM anti-OVA titres of the sera used in the uptake experiments were
1/320 and 1/640. No anti-OVA antibody activity of the IgG isotype was detected by
ELISA, using VPM6 followed by an anti-mouse alkaline phosphatase conjugate.
There was no increase in the uptake of FITC-OVA by afferent lymph DC on the
addition of serum as a source of IgM anti-OVA antibodies. Sera from two different
sheep were used at a 1/2 dilution with a range of FITC-OVA concentrations; neither had
any effect on antigen uptake by DC. In the same experiment, lymph from a primed
sheep containing IgG anti-OVA antibodies was used as a positive control and caused
increased uptake of FTTC-OVA (Fig.8). Affinity purified IgM antibodies were obtained
from the sera of the primed sheep as described in Section 2.8. These antibodies had no
effect on the uptake of specific antigen by DC (data not shown).
3.3.4. In Vivo Uptake of FITC-OVA
lmg of FITC-OVA in PBS was injected intradermally into the drainage area of a
cannulated prefemoral pseudoafferent duct in a primed sheep. Afferent cells were
collected at time points following antigen administration and DC were analysed by flow
cytometry for fluorescence intensity. As shown in Fig.9, DC took up the antigen with a
maximum percentage of cells (90%) positive for FITC fluorescence three hours after
antigen administration. By 7 hours after antigen injection only 30% of DC showed
positive fluorescence. These results are in agreement with previous studies
demonstrating the uptake of FITC-OVA by DC in vivo (Harkiss et al 1990).
3.4. DC Phenotype After Antigen Administration
3.4.1. In Vivo Experiments
Modulation of DC surface molecules such as MHC class II and CD1 has been reported
after in vivo challenge with antigen (Hopkins et al 1989). In the following experiments
lmg of FITC-OVA or unlabelled OVA in PBS was injected intradermally into the
drainage area of a cannulated lymphatic in a primed sheep. Afferent cells were collected
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Figure 8
Unfractionated afferent cells were incubated for 30 minutes at room temperature
with FITC-OVA alone, or with added serum or lymph as a source of specific IgM
or IgG antibodies. The cells were washed three times in BSA before analysis for
FITC fluorescence expression by FACS. The DC were gated on as described.
FIGURE 8 DC Uptake of FITC-OVA is Enhanced
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lmg of FITC-OVA in PBS was injected intradermally into the drainage area of a
pseudoafferent cannulation in a primed sheep. Afferent lymph cells were collected
at various time points after antigen administration and washed before staining with
monoclonal antibodies and a PE-labelled conjugate. In this graph fluorescence
expression by DC is shown, representing uptake of FITC-OYA in vivo.
FIGURE 9 DC Uptake of FITC-OVA In Vivo In a Primed Animal
too
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and analysed by flow cytometry at various time points after antigen administration.
Five experiments with injection of unlabelled OVA were carried out, of which four
covered a range of time points up to 24 hours after antigen administration. The other
experiment included time points of 0 and 24 hours after antigen injection only. In these
experiments the cells were stained with monoclonals to surface markers followed by a
FITC-labelled conjugate for FACS analysis. A further experiment used FITC-OVA
instead of unlabelled OVA; the monoclonals were identified with a PE-labelled anti-
mouse Ig conjugate, and afferent cells were collected for analysis over a 7 hour period
after antigen administration. Marked changes in the expression of DC surface markers
were observed after the intradermal administration of antigen.
3.4.1,1. Surface Immunoglobulins
Fig. 10 demonstrates DC staining for slgs in five experiments. The results are difficult
to compare directly, as the initial percentage of DC positive for each surface molecule
varied between animals, and so are shown separately. Thus DC of sheep 19 showed
minimal staining with monoclonals specific for IgM and IgG at the beginning of the
experiment although the numbers of cells positive for both, and especially IgM,
increased over the seven-hour period monitored. DC from the other four sheep showed
considerable variation in immunoglobulin levels, with a transient rise in IgM in two
sheep followed by a decrease to around initial levels. Sheep 746N showed a dramatic
decrease in staining with VPM13 and VPM8 by 2 hours, followed by an increase in
both markers. There was thus an increase in the percentage of DC positive for IgM at
some point after antigen administration in all of the sheep except 150. DC from the
latter showed a decrease in the percentage of cells positive for IgM by 2 hours after
antigen injection which was maintained over the time course of the experiment.
In two of the five sheep (150 and 151), the number of DC bearing IgG increased over
the first two hours after antigen injection (Fig. 10). The increase was from 9 to 33 % of
DC showing positive staining for fluorescence in sheep 150, with a corresponding 11
to 28% increase in DC from sheep 151. This increase in IgG levels may be due to the
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Figure 10
lmg of OVA (or FITC-OVA in sheep 19) was injected intradermally into the
drainage area of pseudoafferent cannulations in primed sheep. Afferent cells were
collected at various time points after antigen administration and stained with
monoclonals specific for sheep Igs for FACS analysis. In sheep 741N, 746N, 151
and 150, a FITC-labelled conjugate was used while in sheep 19 a PE conjugate was
the second layer reagent. DC were gated on as cells with high forward and side
scatter; 10,000 cells were analysed for FITC or PE fluorescence per sample. All
experiments except for that with sheep 19 were carried out over a 24 hour period.
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presence of immune complexes containing IgG-anti-OVA antibodies attached to the DC
surface.
By 24 hours after antigen administration, three sheep showed numbers of DC staining
for slg similar to the initial percentages, while a substantial increase in the number of
DC bearing both IgM and IgG was seen with sheep 151. There was therefore a
transient decrease in the percentage of DC staining for both IgM and Ig light chain in all
of the 5 sheep used. This drop occurred at around 2 hours after antigen administration
in 4 sheep but not until 6-8 hours after injection of OVA in the remaining animal. Flow
cytometry histograms showing DC staining for IgM at various time points in the
experiment with sheep 151 are illustrated in Fig. 13.
3.4,1.2. Class II and CD1
All of the sheep showed an initial decrease in the percentage of DC expressing class II
and CD1 molecules (Fig 11). Sheep 151 showed the most dramatic transient decrease,
with a fall from 80% to 24% DC positive for class II at the four hour time point, while
the percentage of CD1+ cells decreased from an initial 50% to 22% ofDC at the same
time point. A gradual increase in the expression of both markers then occurred, with a
higher percentage of DC positive for both class II and CD1 24 hours after antigen
injection. In the experiment with sheep 150, the number of CD1+ DC decreased
steadily throughout the experiment, and had not returned to initial levels by the 24 hour
time point.
A substantial decrease in the percentage ofDC expressing both MHC class II and CD1
molecules therefore occurs, between 1 and 4 hours after antigen administration in vivo.
Recovery to initial levels takes place over a variable time period between sheep; in some
cases the number of cells positive is still below the initial level by 24 hours, while in
others the percentage of DC expressing CD1 or MHC class II has returned to initial
levels by around 4 hours after antigen injection. The kinetics of the alterations may be
affected by the exact site of antigen administration and the number of sites used for each
animal. Antigen was injected intradermally into the flank drainage area of the cannulated
60
Figure 11
Afferent cells were collected at time points after the intradermal injection of lmg
OVA in five primed sheep. The experiments are as described in the legend of
Fig. 10. The monoclonal antibodies used were SBU-T6 for CD1 and VPM36 for
MHC class II.
FIGURE 11 MHC Class II and CD1 Expression by DC After
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prefemoral duct, usually in two or three separate sites, but these were not necessarily
the same in each case. Flow cytometry profiles for CD1 and class II staining on the
afferent lymph DC of sheep 151 are shown in Fig. 12, and illustrate the marked
differences in both the proportion of cells positive for these molecules, and the
alteration in their levels of expression by DC at various time points.
3.4.1.3. Adhesion/ Costimulation Molecules
DC expression of adhesion molecules was investigated in three sheep. One experiment,
with sheep 150, followed changes in the expression of adhesion molecules over a 24
hour period, while another two experiments using sheep 151 and sheep 147 included 0
and 24 hour time points only. In addition, CD44 levels on DC from sheep 151 were
measured at several points over a 24 hour time scale (Fig. 13).
The percentage of DC staining for CD44 remained constant over the 24 hour time
course with sheep 150 (Fig. 14) and sheep 151 (Fig. 13), although a decrease in the
levels of CD44 expression did occur in both cases, as shown by the sequential
fluorescence profiles. In the experiment with sheep 147 where only a 24 hour time
point was taken, CD44 staining at 24 hours was slightly above the initial percentage
(Fig.15).
LFA-1 expression by DC from sheep 150 was fairly constant over the first four hours
but had decreased to only 37% of DC (compared with an initial 76%) by the 24 hour
time point (Fig. 14). DC of Sheep 147 showed a slight increase in expression of LFA-1
at 24 hours, while in sheep 151 the percentage of DC expressing LFA-1 had increased
from an initial 25% to 62% at 24 hours (Fig. 15).
The percentage of DC positive for LFA-3 in sheep 150 had decreased four hours after
the administration of antigen, and levels were still low compared with initial expression
by the 24 hour time point (Fig. 14). In agreement with this, LFA-3 was present on only
40% of DC at the 24 hour time point in sheep 147 compared to 82% before antigen
injection. However, in the experiment with sheep 151, LFA-3 expression increased
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Figure 12
lmg of OVA was injected intradermally in a primed sheep (Number 151). The
afferent cells were collected at various time points after antigen administration, and
stained for flow cytometry analysis. Fluorescence histograms for DC are shown for
CD1 and MHC class II expression . The faint lines show the negative control peaks
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Figure 13
Afferent cells were collected and prepared for flow cytometry analysis at various
time points after administration of lmg OVA into the drainage area of a cannulated,
primed sheep. Cells were stained with MAbs specific for CD44 and IgM. DC were
gated on as described. The faint lines show the negative control peaks representing
staining with VPM53.
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Figure 14
lmg of OVA was injected into the drainage area of a cannulated, primed sheep
(150). Cells were collected at 2,4 and 24 hour time points following antigen
administration, and stained for flow cytometry analysis with mAbs specific for
CD44, LFA-1 and LFA-3. DC were gated on as described, and negative control





































lmg OVA in PBS was administered intradermally into the drainage area of a
cannulated prefemoral pseudoafferent lymphatic, in each of two primed sheep.
Lymph was collected prior to antigen injection and 24 hours later. Cells were
prepared for FACS analysis, using MAbs specific for LFA-1, LFA-3, VLA-4 and
CD44, and DC were gated on as described. Staining profiles (solid lines) are
overlaid with the negative control peaks for each time point which represent















































































































from 28% at the start of the experiment to 55% of DC 24 hours after the administration
of antigen (Fig. 15). These results appear to be contradictory, but may reflect similar
changes in expression to those seen with CD1 and MHC class II, but with differences
between animals in the time scale over which variation takes place.
A decrease in DC staining for VLA-4 occurred in the experiment with sheep 147, from
an initial 76% of DC positive to only 46% at 24 hours. In contrast, VLA-4 was detected
on a greater proportion of DC at 24 hours in the experiment with sheep 151 (Fig. 15).
These changes may reflect a decrease and subsequent increase in the percentage of DC
expressing these molecules; the contradictory results between sheep may be attributable
to a different time scale over which changes occur. A full 24 hour experiment with
analysis of DC for VLA-4 expression at several time points would be required to
confirm this.
3.4.2. In Vitro Experiments
DC expression of surface markers was also examined after antigen administration in
vitro. In this experiment, unfractionated afferent lymph cells from an OVA-primed
sheep were cultured at a concentration of 106ml-i in 24 well plates. The culture was
carried out in medium alone, OVA at lpgml-i, or OVA at lpgmF1 and specific
antibodies at 30|lgml-i. Flow cytometry analysis was performed before the culture, and
after 2 and 8 hours incubation at 37°C. The viability of cells from each group was
analysed at each time point by Trypan Blue exclusion and was >99% in each case.
3.4.2.1. Surface Ig
Staining for all of the surface Igs investigated decreased over the culture period where
afferent cells were cultured in medium alone (Fig. 16). Initially 56% of DC were
positive for IgM; on culture in medium only this decreased to only 7% after 8 hours of
culture. A more rapid decrease in the percentage ofDC staining for IgM occurred where
cells were cultured with OVA, or OVA and specific antibody, but there was no
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Figure 16
Afferent lymph cells from an OVA-primed sheep (number 151) were cultured in
vitro in medium alone, OVA at l|igml-i, or OVA at l|igml-i and anti-OVA
antibodies at 30|igml-i (see key). The cells were harvested, washed and stained
with monoclonal antibodies specific for Igs; VPM8 for Ig light chain, VPM13 for
IgM and VPM6 for IgG. The viability of the cells was assessed for each culture by
Trypan Blue exclusion. DC were gated on as described.
FIGURE 16 DC Staining For SIg After In Vitro Culture
Time Al ter Antigen Administration in hours
difference between these two groups. Fluorescence profiles of DC staining for IgM are
shown in Fig. 17.
The number of DC positive for IgG as detected with VPM6 dropped from 25% to 4%
at the 8 hour time point for cells cultured with medium only (Fig. 16). When cells were
cultured with antigen, a similar decrease took place. In contrast, DC cultured with
antigen and antibody showed an initial decrease in expression of IgG at 2 hours of
culture, followed by a maintenance of this level to 8 hours after antigen administration.
This retention of IgG on the DC membrane is probably due to the presence of IgG anti-
OVA antibodies in immune complexes bound to DC FcyR. Ig light chain expression
over the culture period resembles that of IgM (Fig. 16), probably because more IgM
than IgG is present on the DC surface.
3.4.2.2. Class II and CD1 Expression
Over the eight hour culture period, the expression of MHC class II molecules by DC
remained more or less constant when the cells were cultured with medium or OVA.
However, on incubation with OVA and specific antibody at these concentrations, MHC
class II expression decreased from 95% to 70% of DC (Fig 18).
A similar result is seen with CD1 expression (Fig. 18). The percentage of DC positive
for CD1 as measured by staining with SBU-T6 decreased slightly on culture with OVA
or medium, but a much greater fall was seen after an 8 hour incubation with OVA and
specific antibody. The dramatic fall in the proportion of afferent lymph DC expressing
CD1 and MHC class II after in vitro culture with OVA and anti-OVA antibody is
similar to that which occurs in vivo after antigen administration in a primed sheep
(3.4.1.2.). Fluorescence histograms for CD1 and MHC class II staining of DC on in
vitro culture are shown in Fig. 19.
3.4.2.3. Adhesion/ Costimulation Molecules
The proportion of DC positive for CD44 remained fairly constant for those incubated
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Figure 17
Afferent lymph cells were cultured in vitro with medium only, OVA at l|igmH, or
OVA at l|igml-i and anti-OVA antibody at a concentration of 30|igml-i. Cells were
stained for flow cytometry analysis with VPM13, specific for ovine IgM, at 0, 2
and 8 hour time points; DC were gated on as described previously. Staining with
VPM13 is shown by the solid lines, while the dotted lines illustrate staining with








































































































Afferent lymph cells were cultured at 37°C with medium only, OVA at ljigml-i, or
OVA at lp.gml-1 with anti-OVA antibodies at 30|igml-i. The cells were harvested at
2 and 8 hour time points and stained with VPM36 for MHC class II and SBU-T6
for CD1, followed by a FITC conjugate. The DC were analysed by FACS for
expression of FITC fluorescence.
FIGURE 18 DC Expression ofMHC Class II and CD1 After In Vitro Culture













Afferent lymph cells were stained for flow cytometry analysis after in vitro
culture with:- (i) VPM36 to detect MHC class II expression and (ii) SBU-T6,
specific for CD1. DC were gated on according to their light scatter














































































































































with OVA or medium, while levels decreased substantially, from 98% to 76% of cells
positive, after eight hours of culture in the presence of OVA and anti-OVA antibodies
(Fig.20 and Fig.21). A similar change was observed in the expression of VLA-4 on
DC, with little variation where cells were cultured with either medium or OVA alone,
but a decrease from 97% to 62% of DC positive for VLA-4 after an eight hour culture
period with OVA and specific antibody (Fig.20). The number of DC positive for LFA-
1 and LFA-3 decreased on incubation for all of the culture conditions (Fig.20).
However, in both cases the greatest drop was seen where cells were incubated with
antigen and specific antibody. The alterations in the levels of these adhesion molecules
on afferent lymph DC after in vitro culture with OVA and anti-OVA antibody are
similar to the changes observed in the expression of MHC class II, CD1 and IgM on
DC under the same conditions.
3.7. Discussion
3.7.1. Resting Phenotype
DC in resting afferent lymph constitutively express surface molecules required for
antigen presentation and cellular interactions such as adhesion and costimulation. Flow
cytometry analysis demonstrated the presence of MHC class I and class II products,
necessary for presentation of antigen to CD8 and CD4 T cells respectively (Unanue
1984). CD1, which may be involved in the presentation of antigens to y5 T cells
(Porcelli et al 1989), was also present.
LFA-1 on the DC surface interacts with ICAM-1 and ICAM-2 on the T cell (Springer
1990). DC also express ICAM-1 and ICAM-2 which bind T cell LFA-1. Binding to
both LFA-1 and ICAM-1 delivers an activational signal to the T cell; this ligand pair is
important in costimulation. LFA-1, which increases in affinity for its ligands after being
phosphorylated on activation of the cell (Valmu et al 1991), was detected on DC from
sheep afferent lymph, but no monoclonals were available to investigate ICAM-1 and
ICAM-2 expression. LFA-1 and its ligands are thought to be involved in the initial
binding events in DC clustering and activation of resting T cells (Inaba & Steinman
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Figure 20
Afferent lymph cells from a sheep primed to OVA were cultured either in medium,
with OVA (lpgrnH), or with OVA (l(igml)-i and anti-OVA antibodies (30|igml-i).
DC were analysed for expression of the adhesion molecules CD44, VLA-4, LFA-1
and LFA-3 before culture, and at 2 and 8 hours of culture at 37 °C. The monoclonal
antibodies were detected with a FITC conjugate; the results are the percentage of
DC positive for FITC fluorescence at each time point.
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Figure 21
Afferent lymph cells were cultured in vitro as described, and stained with a
CD44-specific MAb at various time points. The negative control profile (dotted


























The Ig superfamily molecule LFA-3 and its ligand CD2 were both expressed by
afferent lymph DC. CD2 is usually restricted to T cells, where it is important in cell
activation (Dustin & Springer 1989). Costimulatory signals are provided to the T cell
on binding of CD2 with LFA-3 or certain anti-CD2 monoclonals. LFA-3 is more
widely distributed and is found on leucocytes and endothelial cells, suggesting a role in
cell migration. LFA-3 and CD2 are also important in DC-T cell clustering (King & Katz
1989). It is possible that DC acquire CD2 molecules passively by interaction with LFA-
3 (Bujdoso et al 1990). Alternatively, CD2 may be produced by DC and could play a
role in the activation of these cells. Analysis of mRNA should determine whether CD2
is synthesised by DC.
The (31 integrins VLA-4 and VLA-6 interact with ligands in the extracellular matrix and
facilitate cell migration and homing (Hemler 1990). VLA-4 binds fibronectin, while
VLA-6 binds laminin. VLA-4 also interacts with VCAM-1 on cells such as endothelial
cells, tissue macrophages and DC. Binding of ligands to the integrins on a T cell
delivers a costimulatory signal (Shimuzu et al 1990, Davis et al 1990). VLA-4 was
detected on DC from the afferent lymph of sheep by FACS analysis. It may be an
important molecule in the migration pathways of DC, and could also provide
activational stimuli on ligand binding. VLA-6 is probably also involved in migration
through the extracellular matrix, but is expressed only by a subset of DC in afferent
lymph.
CD44 is an adhesion molecule with widespread distribution, found on B and T cells,
monocytes and neutrophils as well as epithelial cells and fibroblasts. CD44 binds
hyaluronate; homotypic adhesion may also occur (Belitsos et al 1990). Binding of
ligand to CD44 provides an activational stimulus to the cell, and CD44 expression on
sheep lymphocytes is upregulated on culture/ activation in vitro (Mackay et al. 1988b).
In the experiments described here, CD44 was expressed at consistently high levels by
afferent lymph DC.
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CD4 was also found on sheep DC. This T cell marker has previously been reported on
ovine afferent lymph DC (Bujdoso et al 1990), and has recently been demonstrated on
DC from human blood (O'Doherty et al 1993). The role of CD4 on DC may involve its
interaction with MHC class II on activated T cells, mediating adhesion and providing
stimulatory signals to the DC.
Surface immunoglobulin was found on a variable proportion of DC in the experiments
described here, as has previously been reported (Miller & Adams 1977). This was
mainly of the IgM isotype, with a small proportion of DC positive for surface IgGl.
The significance of SIg on DC in resting afferent lymph is unclear. IgM antibodies may
act as a concentrating mechanism for the small amounts of antigen present in the
primary immune response, attaching to the DC membrane via p. Fc receptors or
complement receptors. However, IgM is not simply adsorbed onto the DC surface
when DC bearing low levels of SIgM are incubated in lymph in vitro before flow
cytometry analysis. The small percentage ofDC positive for IgG may reflect a low level
of expression of FcyRI by these cells (see Chapter 4), which would enable them to
bind uncomplexed IgG.
3.7.2. Antigen Uptake
When incubated at room temperature with FITC-OVA a small proportion of DC
accumulated antigen (generally <30%). Enhanced uptake of fluorescent antigen by DC
in the presence of specific antibody was demonstrated in vivo and in vitro. Similar
results were observed in experiments with alveolar macrophages, which are known to
express FcR for IgG. The degree of enhancement varied with the antibody/ antigen
ratio in both cases. An increase in DC surface IgG was also seen under conditions that
promoted antigen uptake, consistent with the detection of IgG antibody in immune
complexes on the DC membrane. No change in IgG levels was seen when these cells
were incubated with OVA alone. The percentage of DC positive for surface IgG was
less than the percentage which took up FITC-OVA in the presence of specific
antibodies; however the experiments were separate, and unlabelled OVA was used in
the IgG analysis. The fluorescent OVA was also directly labelled, while IgG on the cell
66
surface was indirectly labelled by two layers of reagents.
Anti-OVA antibodies of the IgM isotype did not enhance the uptake of antigen by
afferent lymph DC in vitro. Sheep serum containing these antibodies had no effect on
the uptake of FITC-OVA by DC, while in the same experiment lymph containing IgG
anti-OVA antibodies caused increased antigen uptake. Affinity purified IgM anti-OVA
antibodies were also ineffective. The reason for this is unclear; DC have variable
amounts of IgM on their surfaces, which may block further uptake. The method of
attachment of IgM to the DC has not been determined; a |i FcR or complement receptor
may be involved. If IgM is taken up via complement receptors, a lack of complement in
the in vitro experiment may explain the failure of these cells to take up IgM-OVA
immune complexes. Alternatively, it may be the 7S subunit of IgM rather than the 19S
molecule which is involved in antigen interactions with DC; these two molecules may
be taken up via different receptors and the monoclonal antibody VPM13 would not
distinguish between the two. Another possibility is that IgM antibodies do not play a
role in antigen uptake by DC and that DC acquire antigen by pinocytosis in the primary
immune response. Although no enhanced uptake of antigen was seen in the
experiments described above, in the experiments where OVA was administered into the
drainage area of a cannulated, primed sheep, increases in the percentage of DC staining
for IgM were observed at various time points in four of the five sheep used. This could
represent an antigen-induced mechanism of IgM attachment to the DC surface in vivo.
Further experiments would be required to ascertain whether an increase in the
percentage ofDC staining for IgM also occurs after antigen administration in a primary
response.
3.7.3. Changes in DC Phenotype After Antigen Administration
Alteration in the expression of several DC surface molecules was observed after antigen
challenge in a primed sheep. A marked decrease in the percentage of DC positive for
both MHC class II and CD1 occurred within three hours of intradermal antigen
injection. The percentage of DC positive for each marker then increased up to the 24
hour time point in three of five sheep. The levels of surface Igs were more variable
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between experiments, although an increase in numbers of DC positive for IgM and Ig
light chain did occur in four of the five sheep, as discussed above. A transient increase
in the percentage of afferent lymph DC positive for IgG occurred in two animals. This
probably represents IgG-anti-OVA antibodies in immune complexes attached to FcyR
on the DC surface. Not all of the surface molecules investigated showed a similar
decrease in expression; CD44 stayed at more or less constant levels on DC in the two
sheep used for this experiment.
These phenotypic changes may represent an actual decrease in the levels of surface
molecules on the DC present in afferent lymph, by downregulation of genes for
molecules such as class II and CD1, or by enzyme cleavage of surface molecules.
Alternatively, a different population of cells could be entering the lymph after antigenic
stimulation. If a decrease in the levels of markers on the same cell population is
responsible, this does not affect all surface molecules uniformly, as shown by the
minimal alteration in expression of CD44.
A similar decrease in the expression of surface markers on DC occurred during in vitro
culture. This effect was seen on culture in medium only for all of the markers
examined, although the decrease in expression of CD1 and MHC class II was slight.
However, a more pronounced decrease in expression, for some markers at least,
occurred on culture with antigen and specific antibody. Thus the proportion of DC
positive for CD1 and MHC class II after 8 hours was considerably less where cells
were cultured with OVA and antibody as opposed to medium or OVA only. In this
experiment, the proportion ofDC expressing CD44 also decreased, in contrast to the in
vivo experiment. Levels of VLA-4, LFA-3 and LFA-1 staining also fell. Staining for
IgG remained fairly constant on DC cultured in antigen and antibody, probably due to
IgG anti-OVA antibodies on the DC surface in the form of immune complexes. IgG
levels were decreased on cells incubated in medium or OVA.
The decrease in staining of DC for various surface molecules on in vitro culture with
OVA and anti-OVA antibody supports the theory that the same population of DC is
altering its phenotype after antigen is administered in a secondary response in vivo.
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Previous work has demonstrated an increase in MHC class II and CD1 expression on
afferent lymph DC 2-5 days after antigen administration in a primed animal (Hopkins et
al 1989). The increase in MHC class II expression correlated with more effective
accessory functions of the DC. The more immediate changes in expression of MHC
class II observed in the experiments described here may be a mechanism to turnover the
MHC molecules with peptides present on the DC surface at the time of antigen
administration, allowing newly synthesised MHC molecules to interact with and
present peptides of the administered antigen (i.e. OVA). A similar mechanism could
account for the alterations in CD1 expression.
The explanation for the decrease in expression of most of the adhesion molecules
examined is less clear. Dowflregulation of certain surface molecules may be required to
effect the movement of antigen-bearing DC from the dermal tissues to the draining
lymphatics. This is discussed further in Chapter 7.
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CHAPTER FOUR
EXPRESSION OF FCyR BY AFFERENT
LYMPH DC
4. EXPRESSION OF FcyR BY AFFERENT LYMPH DC
4.1. Introduction
The aim of the work described in this chapter was to investigate FcyR expression by
DC using Western blotting of cell lysates and flow cytometry analysis. As there were
no anti-sheep FcyR mAbs available, it was decided to raise rabbit antisera against each
of two peptide sequences from the extracellular domains of bovine FcyR I and an IgG-
Sepharose matrix with attached putative ovine FcyR. These antisera were then used in
Western blot analysis of afferent lymph DC and other ovine cells, and in flow
cytometry analysis of DC in resting lymph and following the administration of antigen
in vivo and in vitro.
4.1.1. R221 Antiserum
The R221 antiserum was raised against the column material produced in the attempt to
purify ovine Fc receptors for IgG from alveolar macrophage lysate. The experimental
details are in section 2.7.4. The lysate was passed repeatedly through a BSA-sepharose
pre-column followed by the specific IgG-sepharose column. This column was washed
and then acid-eluted. No protein was eluted from the IgG-sepharose column, as
assessed by SDS-PAGE analysis of the fractions collected (not shown). However,
when the column material was boiled in SDS reducing buffer and the supernatant was
run on a slab gel under reducing conditions, a protein doublet was visualised at around
40kD which was not seen with the BSA-sepharose column or IgG-sepharose which
had BSA only passed through it (Fig.l). This was the correct size for FcyRII, which in
humans and mice has a molecular weight of 40kD. IgG-sepharose with the attached
40kD protein was emulsified in Titermax adjuvant and used to immunise a rabbit as
described in Materials and Methods.
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Figure 1
IgG-Sepharose and BSA-Sepharose were made as described in Section 2.8.1. The
lysate prepared from alveolar macrophages was passed through these columns,
which were eluted at acid pH. The column materials were then boiled in SDS
reducing buffer and the supernatants run on SDS-PAGE gels. Track A shows the
IgG-Sepharose after recirculation of macrophage lysate, track B represents IgG-
Sepharose which has had only BSA passed through it, and in track C BSA-
Sepharose from the pre-column was run. The positions of the low molecular weight
markers are shown.
FIGURE 1 SDS-PAGE Analysis of IgG-Sepharose After
Passage of Alveolar Macrophage Lysate




The sequence for bovine FcyRI has recently been published (Fig.2; reference Symons
& Clarkson 1992), while no sequence data for ovine FcyRs is currently available.
There is approximately 60% homology at the amino acid level between the extracellular
domains of the murine, human and bovine FcyRI: it is therefore likely that a greater
degree of homology will exist between the ovine and bovine FcyRI, and that antisera
raised against peptides from the bovine sequence will cross-react with ovine FcyRs.
Rabbit 220 was immunised with FcR peptide 1 (FP1), a fifteen amino acid peptide
from a hydrophilic region of the second extracellular domain of bovine FcyRI with the
following sequence:-
Cys-Ser-Gly-Glu-Arg-Arg-Arg-Arg-Tyr-Thr-Ser-Ala-Gly-Gly-Ser
R220 antiserum was initially tested against FP1 by ELISA; a titre of 1/1280 was
obtained. Anti-FPl antibodies were affinity purified from the R220 antiserum using an
FPl-Sepharose column. The antibodies were tested by ELISA for anti-OVA activity,
and had a titre of 1/160.
4.1.3. R225 Antiserum
This serum was raised against FcR peptide 2 (FP2), a thirteen amino acid peptide from
the first extracellular domain of bovine FcyRI with the following sequence:-
Cys-Glu-Gly-Pro-His-Arg-Pro-Gly-Asp-Thr-Ala-Thr-Gln
The antiserum was tested by ELISA before use, and had an anti-FP2 titre of 1/640.
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Figure 2
The amino acid sequence of the extracellular portion of bovine FcyRI is shown
(Source: Symons & Clarkson 1992), with the regions of FP1 and FP2 outlined in

















4.2. Western Blots with R220 Antiserum
4.2.1. DC
Lysates of afferent lymph DC were prepared as described in section 2.7.6., from cell
populations that were > 92% DC by morphology on Leishmans-stained cytospins. The
lysates were fractionated by SDS-PAGE using 5-20% gradient gels, and 105 DC
equivalents were blotted with R220 FP1 antiserum and the preinoculation control at
1/100 dilutions in blocking buffer (Fig.3), as described in section 2.7.5.. Specific
bands were visible at 72 and 40kD, the latter band being more intense than the former.
There were also two fainter bands immediately above the 40kD band on the blot. The
two major bands were consistent with FcyRII (40kD) and FcyRI (72kD) as described
in other species (Van de Winkel & Anderson 1991). No bands were present on the
preinoculation serum control blot (Fig.3).
4.2.2. Alveolar Macrophages
These cells are known to express FcyRI and FcyRII in mice and humans (Unkeless et
al 1988), and the blot of the ovine alveolar macrophage lysate supports this, with an
intense band visible at 72kD and a less intense band at 40kD (Fig.3). In contrast to the
result obtained with the DC lysate, the alveolar macrophages in this sample seemed to
express more FcyRI than DC, but a comparable amount of FcyRII. As with the DC
blot, there were two fainter bands visible above the 40kD band. Some non-specific
bands were visible on the control blot with the preinoculation serum; these were of
intermediate size between the 40 and 72kD bands.
4.2.3. Lymphocytes
Although the DC populations from which lysates were prepared were > 92% DC by
morphology, a small percentage of cells (< 8%) were lymphocytes. The contribution of
these contaminating cells to the blot of the DC lysate in Fig.3 was assessed by blotting
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Figure 3
DC and macrophage lysates were prepared as described. 105 cell equivalents in
each case were fractionated by SDS-PAGE and analysed by Western blotting. R220
antiserum and the control preinoculation serum were used at a 1/100 dilution.
Antibodies were detected using an alkaline phosphatase conjugate and blots were
developed with NBT/ BCIP. Prestained low molecular weight markers were used
in these blots.
FIGURE 3 Western Blot Analysis of DC and
Macrophages with R220 FP1 Antiserum
R220 R220
Antiserum preinoculation
DC M0 DC M0
104 lymphocyte equivalents obtained from efferent lymph, i.e. the number of
lymphocytes that would be present if the DC population contained 10% lymphocytes.
There were no bands observed when this number of lymphocytes was blotted with the
R220 antiserum at a 1/100 dilution (Fig.4., track B). It is therefore unlikely that the
number of contaminating lymphocytes in the DC preparations contributed to the two
bands observed in Fig.3. Lymphocytes did react with this serum when they were used
in greater quantities: 105 efferent lymphocyte equivalents blotted with R220 antiserum
gave a faint but visible band at 40kD, indicating the presence of FcyRII on these cells
(Fig.4, track A). The source of the lymphocytes used above may be important; this is
discussed in section 4.7.
Further blots were carried out on the lysates of lymphocytes from a second source.
CD4+ T cells were separated from PBMs by positive selection on a MACS, as
described in Chapter 2. After lysis, 105 cell equivalents were run in track C of Fig.4,
and 104 cell equivalents in track D. A broad smear was visualised between 55-70kD in
track C, with a more discrete band in track D. This band may represent FcyRIII,
reported to be present on lymphocyte subsets in other species (Daeron et al 1988), with
the diffuse appearance due to the extensive glycosylation of the receptor. The 72 and
40kD bands observed on blots of DC and macrophage lysates were not present in the
lysates of the CD4+ T cells.
4.3. Western Blot Analysis of Ovine Cells with Affinity Purified Anti-
FP1 Antibodies
Anti-FPl antibodies were affinity purified on an FP-l-Sepharose column and dialysed
into PBS before use in blots. The control antibody for these blots was anti-OVA
antibody affinity purified from the serum of a rabbit primed to an irrelevant peptide
conjugated to OVA, and used at the same Ig concentration. Western blots with the
affinity purified antibodies were carried out on lysates of DC, alveolar macrophages,
efferent lymphocytes and CD4+ T cells (Fig.5). In track A of the blot with anti-FPl
antibodies, where 105 DC equivalents were run, bands were visible at around 40kD
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Figure 4
Lysates were prepared from efferent lymphocytes and CD4+ T cells separated from
PBMs. Varying numbers of cell equivalents were run on an SDS-PAGE gel for
subsequent Western blot analysis to assess the contribution of lymphocytes in DC
preparations to the results shown in Fig.3. The positions of prestained low
molecular weight markers are shown.
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Cell lysates of alveolar macrophages (105 cell equivalents), DC (105 cell
equivalents), efferent lymphocytes (104 cell equivalents) and CD4+ T cells (104
cell equivalents) were analysed byWestern blotting with affinity purified anti-FPl
antibodies. The controls for these blots were the same lysates blotted with affinity
purified rabbit anti-OVA antibodies. The positions of prestained low molecular
weight markers are shown.





B - 105 Macrophages
C - 104 efferent lymphocytes
D- 104CD4+T cells
and at 72 kD. The 72kD band is discrete, while the band at 40kD is diffuse and there
may in fact be more than one band present. 105 alveolar macrophage equivalents gave
the same pattern of bands (track B). These bands were the same sizes as those detected
with the R220 antiserum in Fig.3 and were specific, with no bands present on the
control blot. There were no bands in track C, in which the lysate of 104 efferent
lymphocytes was run to represent the contribution of the contaminating lymphocytes in
the DC preparation. In track C, 104 CD4+ T cells obtained from PBMs were blotted
with the affinity purified anti-FPl antibodies. A faint smeared band of approximate size
50-70kD was present, which could be FcyRIII as in Fig.4. The 72kD and 40kD bands
seen on the DC and macrophage lysates, which may represent FcyRI and FcyRII, were
not present in the CD4+ T cell lysate blot.
4.4. Western Blot Analysis of the Putative Ovine FcyR
The reactivity of R221 antiserum was investigated by Western blot analysis of the IgG-
Sepharose with attached putative FcyR. The supernatant obtained after boiling the
column material with the attached 40kD protein in SDS reducing buffer was
fractionated by SDS-PAGE and blotted with the R221 antiserum and preinoculation
control at 1/100 dilutions. The antiserum recognised bands of the correct sizes for the
IgG heavy and light chains and the 40kD doublet, while the preinoculation serum did
not react with any of these bands (Fig.6).
The R220 antiserum was also tested against the same antigenic material. Unexpectedly,
the R220 antiserum reacted with the IgG heavy and light chain bands as well as the
40kD doublet (track A, Fig.7). However, the preinoculation serum also reacted with
the IgG heavy and light chains, although to a lesser extent, therefore this may be a non¬
specific effect.
4.5. Cell Lysate Analysis by Western Blotting With R22I Serum
A series of blots was carried out on cell lysates using the R221 antiserum and
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Figure 6
Alveolar macrophage lysate was passed through an affinity column in an attempt to
purify FcyR. 50|il of IgG-Sepharose from the column was then boiled in SDS
reducing buffer and centrifuged to pellet the insoluble material. The supernatant was
fractionated by SDS-PAGE using gradient slab gels for subsequent analysis by
Western blot. In this blot, R221 antiserum was used at a 1/100 dilution, with the
preinoculation serum at the same dilution as the control.
FIGURE 6 Western Blot of The IgG-Sepharose Column Antigen
With R221 Antiserum
A - Antiserum
B - Preinoculation serum
Figure 7
Alveolarmacrophage lysate was passed through an IgG-Sepharose affinity column.
50p.l of IgG-Sepharose was boiled in SDS reducing buffer and run on an SDS-
PAGE slab gel for subsequent analysis by Western blotting. In this blot R220
antiserum and the preinoculation control serum were used at a 1/100 dilution.
FIGURE 7 Western Blot of The IgG-Sepharose Column Antigen
With R220 FP1 Antiserum
A - Antiserum
B - Preinoculation serum
preinoculation serum. Blotting of the DC lysate with R221 antiserum at a 1/100 dilution
gave a major band of molecular weight 40kD and a second at 23kD (Fig.8, track B).
No bands were present on the preinoculation serum control blot (track A). Bands of the
same weights were visualised on blots of alveolar macrophage lysates (Fig.9). The
40kD band may represent FcyRII, as for the blots of the same cell lysates with the
R220 antiserum (Fig.3) and the affinity purified anti-FPl antibodies (Fig. 5). The
efferent lymphocyte lysate did not react with this antiserum (Fig.9, track B), but a
smeared band is present in the CD4+ T cell lysate lane (track C). This band is of
molecular weight 80-90kD, and therefore is not the expected size for any FcyR.
4.6. Flow Cytometry Analysis of DC With Rabbit Antisera
The Western blot experiments described above clearly indicate the presence of FcyRs
on ovine afferent lymph DC. Flow cytometry analysis was carried out to further
investigate DC expression of FcyRs in resting lymph and after antigen administration in
vivo. Other cell types such as lymphocytes from afferent and efferent lymph and blood,
and neutrophils were also analysed for FcyR expression.
4.6.1. Analysis of ovine cells with R220 FP1 Antiserum
Strong staining of DC was observed with R220 antiserum, as shown in Fig. 10, where
the antiserum was used at a 1/10 dilution. 78% of DC were positive for FITC
fluorescence in this FACS profile; some showed very high levels of fluorescence. The
preinoculation serum at the same dilution was used as a negative control. A "tail" of
increasing fluorescence was present in the DC stained with the preinoculation serum.
To overcome this and to obtain a more discrete negative control peak, affinity purified
peptide-specific antibodies were used. After a ten-fold concentration in an Amicon
ultrafiltration apparatus to lSjigml1, anti-peptide antibodies were used in
immunofluorescence analysis of DC. Affinity purified anti-OVA antibodies were used
as a control at the same Ig concentration; the anti-OVA titre of this antibody preparation
was determined by ELISA as 1/1280.
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Figure 8
A lysate was prepared from DC as described. 105 cell equivalents were run on an
SDS-PAGE gel in each track; track A was then blotted with the preinoculation
control serum at a 1/100 dilution, and track B with the R221 antiserum at the
same dilution. The positions of the prestatined low molecular weight markers are
shown.








The cell lysates were prepared as described in Materials and Methods. 105
alveolar macrophage equivalents, 104 efferent lymphocytes and 104 CD4+ T cells
were each run in two tracks of an SDS-PAGE gel. The lysates were then blotted
with either the R221 preinoculation control serum at a 1/100 dilution, or the R221
antiserum at the same dilution. The positions of the prestained low molecular
weight markers are shown.
FIGURE 9 Western Blot Analysis of Ovine CellsWith R221 Antiserum
R221 R221
Antiserum Preinoculation
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Figure 10
Afferent lymph cells were stained for flow cytometry using rabbit antisera and the
relevant prebinoculation sera as controls. Antisera and controls were diluted 1/10 in
PBA before use. Rabbit 221 (R221) was immunised with the IgG-Sepharose plus
putative ovine FcyR, R220 with FcR peptide 1 and R225 with FcR peptide 2.
Overlay histograms show the staining observed with both prebinoculation sera and
antisera.
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As illustrated in Fig.l 1, the affinity purified anti-FPl antibodies stained most afferent
lymph DC while the control antibodies did not. Setting a marker to the right of the
negative control peak, the mean percentage of DC staining with the anti-peptide
antibodies staining was 56%, with a range of 38% to 76% DC positive for FL-1.
However, there was a large degree of overlap between the positive and negative peaks,
and it was therefore impossible to assess accurately the percentage of DC positive. In
Fig.l 1, the whole peak representing DC staining with anti-FPl antibodies has shifted
to the right compared with the negative control peak, indicating that all of the cells are
expressing FcyR at a low intensity.
Unfractionated R220 antiserum also stained lymphocytes from afferent and efferent
lymph and blood, and neutrophils (Fig. 12). It was therefore surprising that very little
staining of afferent lymphocytes was observed with the affinity-purified anti-FPl
antibodies (Fig.l 1).
4.6.2. Flow Cytometry Analysis with R221 Antiserum
The antiserum from rabbit 221 stained a large proportion of afferent lymph DC, afferent
lymphocytes, efferent lymphocytes and neutrophils. The background level of
fluorescence was determined by staining with the preinoculation control serum at the
same dilution (Fig. 10 and Fig.12). 85% of afferent lymph DC were positive for R221
serum staining in the FACS profile shown in Fig. 10, with both antiserum and prebleed
used at a 1/10 dilution. Some afferent lymph DC showed very high levels of FITC
fluorescence after staining with the R221 antiserum at this dilution (Fig. 10)..
The immunogen administered to the rabbit contained sheep IgG as well as the putative
FcyR, thus a proportion of the antibody present in the R221 antiserum was likely to be
directed against IgG. This could have contributed to the staining observed on DC,
although in repeated flow cytometry analysis of these cells the mean percentage ofDC
positive for IgG was only 9, with a range of 2-23% (Table 1, Chapter 3). The R221
antiserum may also have contained antibodies directed against sheep Ig light chain,
which could potentially account for more of the staining observed on DC; a mean of
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Figure 11
Afferent lymph cells were washed and stained with either affinity purified anti-FcR
peptide 1 antibodies or affinity purified anti-OVA antibodies at the same
concentration (18|igmH) as a control. The cells were then analysed by flow
cytometry, with the DC and lymphocyte populations gated on using the scatter
profiles of afferent lymph cells. Ten thousand cells were analysed per sample.
FIGURE 11 DC and Lymphocyte Staining With Affinity





Log 10 relative fluorescence intensity
Control antibody
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Figure 12
Ovine cells were prepared for analysis by flow cytometry, using the preinoculation
sera and antisera of rabbits 221 and 220. WBCs were obtained from whole blood by
ammonium chloride lysis of erythrocytes as described in Chapter 2, then neutrophils
(i) and lymphocytes (ii) were gated on according to their scatter profiles. In (iii),
staining of efferent lymphocytes by R221 preinoculation serum and antiserum and
afferent lymphocytes by R220 preinoculation serum and antiserum are shown. Ten
thousand cells were analysed per sample.












51% of DC expressed Ig light chain with a range of 12-85% (Table 1, Chapter 3). The
absorption of anti-IgG activity from R221 antiserum was attempted by its repeated
passage through an IgG-Sepharose column. The IgG-absorbed serum showed only
trace staining on afferent lymph DC (not shown). Western blot analysis of the IgG-
sepharose column material and putative FcyR with the unabsorbed R221 serum
showed activity against IgG heavy and light chains and the 40kD protein (Section 4.4),
while blots of the same material with the IgG-absorbed R221 antiserum demonstrated
residual anti-IgG activity, and reduced reactivity with the 40kD putative FcyR (not
shown). The absorption procedure therefore seemed to have non-specifically removed
antibodies directed against the putative FcyR, while failing to remove anti-IgG activity.
A Western blot of DC lysate with the unabsorbed R221 antiserum showed strong
reactivity with a 40kD protein, but little or no reactivity with IgG heavy chain or Ig light
chain (Section 4.5). It is therefore highly probable that the staining of DC demonstrated
by FACS analysis and shown in Fig. 10, is attributable to the presence of the 40kD
putative FcyR on the DC surface.
4.6.3. Flow Cytometry Analysis of DC with R225 Antiserum
Initial FACS analysis of DC showed a high background fluorescence with the
preinoculation serum. IgG was separated from both preinoculation and antiserum
samples by ion-exchange chromatography on a DE52 column in an attempt to decrease
non-specific staining. IgG concentrations were determined from OD readings at 280nm
and preinoculation and antiserum IgG were used at a concentration of 10|igml-i for
further FACS analysis. Positive staining of a large proportion of afferent lymph DC
was seen using the R225 antiserum IgG preparation (Fig. 10).
4.6.4. DC Staining with R220 Antiserum Following Antigen
Administration in vivo
The R220 FP1 antiserum was included in two phenotyping experiments (Fig. 13).
Each was used at a dilution of 1/100 in BSA, rather than at the 1/10 dilution used
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Figure 13
DC were collected at various time points after antigen injection into the drainage
area of two cannulated OVA-primed sheep (numbers 150 and 151), and stained
with rabbit antiserum 220 followed by a FITC-conjugate. Unfractionated afferent
cells were stained; DC were gated on as described in Chapter 2. The control was
preinoculation rabbit serum at the same dilution as the antiserum. The results are the
percentage of DC positive for FITC fluorescence above control staining.
FIGURE 13 DC Staining With Rabbit Antiserum to FcyR Peptide 1
After In Vivo Antigen Administration
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previously, in an attempt to obtain lower background staining with the prebleed control,
and lose the "tail" of increasing fluorescence observed on staining DC with the 1/10
dilution of the prebleed (Fig. 10). Serum was not absorbed against OVA. R220
antiserum showed very little initial staining on DC in both experiments, probably
because of the greater dilution of antiserum used. However, the percentage of DC
staining positive with the antiserum increased four-fold at the 4 hour time point in sheep
151, and two-fold by 24 hours after antigen administration in sheep 150. Increases in
the percentage of DC staining with R220 antiserum may reflect an upregulation of
FcyR on the DC surface after antigen injection; however, as the antiserum was not
absorbed against OVA, rabbit anti-OVA antibodies could be binding to OVA exposed
on the DC membrane and contributing to the increase detected. To determine the
contribution of the rabbit anti-OVA antibodies, the experiment could be repeated using
rabbit antiserum from which anti-OVA antibody activity had been removed.
4.7. Discussion
4.7.1. Western Blot Analysis With Rabbit Antisera
The R220 antiserum was raised against the peptide FP1, the sequence of which was
from the second extracellular domain of bovine FcyRI. This antiserum reacted with two
bands of molecular weight 40 and 72kD on the lysate of alveolar macrophages, a cell
type known to express FcyRI and FcyRII in mice and humans (Ravetch & Kinet
1991). The bands observed were of the correct sizes for FcyRII (40kD) and FcyRI
(72kD). Ovine afferent lymph DC also expressed these molecules, as demonstrated by
Western blot analysis of DC lysates. DC appeared to express a greater quantity of
FcyRII than FcyRI. The affinity purified anti-FPl antibodies reacted with antigens of
the same sizes as the R220 antiserum, on both DC and macrophage lysates, while the
control antibodies did not pick up these bands.
Afferent lymph cells were subjected to two separations over metrizamide to obtain a DC
population of sufficient purity for Western blot analysis. However, a proportion of
lymphocytes remained in the DC preparation used for the production of lysates. The
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DC population contained <8% lymphocytes, determined by cell morphology on
cytospins. Lymphocytes in other species express FcyR: FcyRII is found on B cells,
while FcyRII and FcyRIII have been reported on subsets of T cells (Lanzavecchia
1990, Daeron et al 1988, Mantzioris et al 1993). To assess the contribution of the
residual lymphocytes in DC preparations to these blots, the number of lymphocyte cell
equivalents that would be present if the DC population contained 10% lymphocytes was
blotted with R220 antiserum and the affinity purified anti-FPl antibodies. Efferent
lymphocytes were used because of the difficulty in obtaining a population of afferent
lymphocytes free of DC. There were no bands present on Western blots of efferent
lymphocytes with the R220 antiserum or the anti-FPl antibodies, and the contaminating
lymphocytes were therefore unlikely to affect the results of blots on DC lysates.
However, when the number of lymphocyte equivalents was increased 10-fold, a band
was visualised at 40kD, indicating the presence of FcyRII on these cells.
The source of the lymphocytes used in these control blots may be important. Efferent
lymphocytes were used in place of the afferent lymphocytes which would actually be
present in the DC samples. Afferent lymph T cells are memory cells and are activated,
while naive, unactivated T cells are found in resting efferent lymph (Mackay et al
1990). Although subsets of activated T cells in other species express FcyR, the
strength of the signal detected in the DC lysate and the small numbers of T cells present
make a significant contribution by contaminating cells to the bands observed highly
unlikely.
Lymphocytes from another source were also examined. Ovine afferent lymphocytes are
mainly T cells (Mackay et al 1992), so CD4+ T cells were obtained from PBMs by
MACS separation. Western blot analysis of these cells with R220 antiserum and anti-
FPl antibodies demonstrated the presence of a diffuse band of molecular weight 55-
70kD. This may be FcyRIII, reported on T cell subsets in humans (Sandor & Lynch
1993), with the smeared appearance of the band due to the extensive glycosylation of
the receptor (Van de Winkel & Capel 1993). The bands seen at 40 and 72 kD in blots of
DC lysates were not present; these CD4+ T cells therefore did not express FcyRII at
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detectable levels. The expression of FcyRIII by CD4+ T cells in humans has been
associated with activarion of these cells (Sandor & Lynch 1993). The positive selection
of CD4+ T cells from PBMs, involving the use of an anti-CD4 monoclonal antibody,
may provide an activational signal to the selected cells, causing an upregulation of
certain surface molecules. Further experiments, including flow cytometry of CD4+ T
cells with R220 and R221 antisera, and Western blot analysis of negatively selected
CD4+ T cells would be required to ascertain whether these cells constitutively express
FcyRIII.
The R221 antiserum, raised against IgG-Sepharose with the attached 40kD protein,
blotted with bands of molecular weight 40kD and 23kD on DC lysates. The 40kD band
is likely to be FcyRII, as discussed above for the blots with R220 antiserum and the
affinity purified anti-FPl antibodies. The identity of the 23kD band is unclear. Soluble
forms of FcyR have been reported, which lack transmembrane and cytoplasmic
portions (Sautes et al 1991). These are of lower molecular weight than the 40kD
FcyRII, and are present in serum (Fridman et al 1992) and probably also lymph . The
23kD band could therefore represent a soluble form of FcyR present in the DC lysate.
However, if this is the case it is surprising that the R220 antiserum did not react with
this band on the same cell lysates. Western blot analysis of ovine serum and lymph
proteins with the R220 and R221 antisera would be informative. The two bands were
also present on blots of alveolar macrophage lysate, but were not observed on blots of
efferent lymphocytes or CD4+ T cells. A 40kD band was seen on blots of the efferent
lymphocyte lysate with R220 antiserum, as described above; however in the blot with
the R221 antiserum fewer cell equivalents were used.
Western blot analysis of the immunogen administered to rabbit 221 with R221
antiserum revealed bands corresponding to the heavy and light chains of IgG, and the
40kD protein attached to the IgG-Sepharose matrix. Blotting of the same material with
R220 serum revealed the same pattern of bands, while the R220 preinoculation control
serum also reacted with the IgG bands but not the 40kD band. This suggests that the
R220 antiserum specifically recognises the 40kD putative ovine FcyRII.
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The above data therefore provide evidence for the expression of FcyRs by afferent
lymph DC. FcyRII, which binds complexed IgG efficiently but does not detectably
bind monomelic IgG, would be responsible for the enhanced uptake of antigen in
complex form described in Chapter 3, and the functional consequences in terms of
antigen presentation by DC (Chapter 6). The presence of FcyRI on the DC surface
could account for the low levels of IgG detected on DC from resting lymph by flow
cytometry analysis.
The R220 antiserum was raised against a peptide sequence from the second
extracellular domain of bovine FcyRI. This antiserum was expected to cross-react with
ovine FcyRI, as FcyRI is conserved between species, with the identity of the amino
acids in the three extracellular domains between the bovine, murine and human
receptors being 60% for the first domain, 58% for the second and 58% for the third
domain (Symons & Clarkson 1992). However, this antiserum also reacted with a band
of the correct size for FcyRII on macrophages, DC and lymphocytes. This indicates
that the antiserum cross-reacts with FcyRII, and it may also cross-react with FcyRIII
on CD4+ T cells. While FcyRI has three extracellular domains, FcyRII and FcyRIII
have only the first two (Unkeless et al 1988). The first two extracellular domains of
FcyRI show 40% identity with the extracellular domains of FcyRII and FcyRIII in
mice (Hulett et al 1991) and 50 % in humans (Allen & Seed 1989). The corresponding
region of the FP1 sequence in mice shows 40% identity, 60% similarity between
FcyRI and FcyRII, and 33% identity and 60% similarity between FcyRI and FcyRIII
(Fig. 14). These regions of murine FcyRII and FcyRIII have 87.5% identity and
similarity. In humans the identity between the different FcyR types in this region is
considerably less, with 27% identity and 47% similarity between FcyRI and FcyRII
and 27% identity and 40% similarity between FcyRI and FcyRIII (Fig. 14). The
corresponding data for the bovine FcyRs is unknown, but would probably relate more
closely to the situation in sheep. If the ovine FcyR types have a percentage identity in
the FP1 region similar that of the murine FcyRs, then this could account for the cross-
reactivity of the antiserum raised against the bovine FcyRI peptide.
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Figure 14
The amino acid sequences of human and murine FcyRs are compared in the region
of FP1. The sequences were obtained from the Swissprot database, and the
percentages for identity and similarity were calculated using the programme "Gap".
FIGURE 14 Sequence Comparisons of Human and Murine FcyRs in the
Region Corresponding to the FcR peptide 1 Sequence
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4.7.2. Investigation of FcyR Expression by Flow Cytometry
Afferent lymph DC showed strong staining with each of the three rabbit antisera, with
more than 70% of DC positive for fluorescence on staining with R220 FP1 antiserum.
Affinity purified anti-peptide antibodies also stained a large proportion of DC, and
control affinity purified antibodies gave a more discrete negative control peak than the
preinoculation serum control. These results suggest the presence on DC of FcyR but do
not distinguish between classes of FcyR. R220 serum also stained lymphocytes and
neutrophils, neither of which express FcyRI in other species. FcyRII is found on B
cells, while FcyRII and FcyRIII have been reported on subsets of T cells (Daeron et al
1988). Neutrophils express FcyRII and FcyRIII, although expression of FcyRI can be
induced by IFN-y (Van de Winkel & Anderson 1991). The reactivity of the serum with
these cell types suggests a cross-reactivity between FcyRI, FcyRII and FcyRIII, as
was also indicated by the results ofWestern blot analysis.
Surprisingly, the affinity purified anti-peptide antibodies did not stain afferent
lymphocytes although the unfractionated serum did. In contrast, the staining ofDC was
improved by affinity purification. This could be due to the loss of certain anti-peptide
antibodies during affinity purification, with high affinity antibodies retained on the
peptide column, and may suggest structural differences in FcyR on DC and
lymphocytes.
The R225 antiserum, raised against FP2, stained a large proportion of DC, again
suggesting the expression of an FcyR by these cells. The R221 antiserum, raised
against immunopurified ovine FcyR, stained DC, lymphocytes and neutrophils
strongly. However, when anti-IgG activity was absorbed on an affinity column, the
serum stained DC very weakly even when concentrated. Staining of lymphocytes was
also considerably reduced. This may be due to loss of anti-FcyR antibodies during
absorption on the affinity column. That the staining of DC observed with the
unabsorbed R221 serum is likely to be due to the presence of the 40kD putative FcyR
on the DC surface, rather than any anti-Ig activity in the serum, is demonstrated by
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Western blot analysis of DC lysate (Section 4.5).
Changes in DC staining with the R220 antiserum after antigen challenge in vivo may
reflect varying levels of FcyR expression by DC, although the antiserum would not
distinguish between FcyRI and FcyRII, and the expression of these two molecules
may be differentially regulated. The rabbit antiserum also contained anti-OVA
antibodies, which could bind to OVA on the DC surface and increase the percentage of
DC staining with rabbit antibodies. Removal of anti-OVA activity would be required to




EFFECT OF SPECIFIC ANTIBODY ON
PBM PROLIFERATION
5. EFFECT OF SPECIFIC ANTIBODY ON PBM PROLIFERATION
5.1. Introduction
Previous work has shown the enhanced presentation of antigen by FcR-expressing
APCs in the presence of specific antibody, by demonstrating potentiation of
proliferative responses (Chapter 1). To determine whether this was also the case for
ovine cells, experiments were carried out using unfractionated PBMs from sheep
primed to OVA as both APCs and responding cells. For the enhanced presentation of
antigen in immune complexes to occur, presenting cells must express Fc receptors.
Monocytes, known to express Fc receptors for IgG in other species, are likely to act as
APCs in these assays. Antigen-specific B cells are probably not present in sufficient
numbers to activate T cells, and B cells present non-specific antigens poorly. Antibody
also inhibits antigen presentation by specific B cells, with soluble antibodies competing
with B cell mlg for antigenic epitopes (Lanzavecchia 1987). Human PBMs also
contain a small percentage ofDC (Thomas et al 1993); it is possible that DC contribute
to antigen presentation in these assays.
5.2. Antibody Preparations
5.2.1. Antibody Activity and Isotype
Anti-OVA antibodies were affinity-purified from heat-inactivated antiserum. Activity of
the anti-OVA antibodies was confirmed by ELISA using the serum of a primed animal
as a positive control. The antibody isotype was also determined by ELISA, using
second layer monoclonals specific for sheep Ig isotypes; all anti-OVA activity was of
the IgGl isotype. The concentration of the antibody preparation was calculated from
OD readings at 280nm. The antibodies were dialysed into RPMI and filtered before use
in assays.
The antibody/ antigen ratio for affinity purified antibodies and OVA was measured
using Ouchterlony double gel diffusion. The equivalence point was taken as the
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sharpest line of precipitation between wells of OVA and dilutions of specific antibody
preparations. For the antibodies used in these experiments the antibody/ antigen ratio at
equivalence was found to be 10:1.
An irrelevant affinity-purified antibody was required as a control for proliferation
assays. Antibodies from the serum of a sheep primed to HSA were separated on an
affinity column, and anti-HSA activity assessed by ELISA. No cross-reactivity of these
antibodies against OVA was detected in an ELISA using OVA-coated plates (data not
shown). The isotype of the anti-HSA antibody preparations was also IgGl.
5.2.2. F(ab')2 Preparations
F(ab')2 fragments of OVA-specific antibody were obtained by pepsin digestion of the
intact antibody, followed by separation on an ion-exchange column. There was no
residual whole IgG in these preparations, as determined by the absence of heavy chain
on SDS-PAGE analysis (Fig.l, track 2). The other tracks show intact IgG (4),
unseparated pepsin digest (3) and material eluted from the DEAE column with 0.3M
NaCl (1). All of the residual heavy chain was present in the latter eluate. The anti-OVA
activity of the F(ab')2 antibody was evaluated by ELISA using a monoclonal specific
for sheep Ig light chain as a second layer reagent. F(ab')2 preparations had equivalent
titres to the intact antibody from which they were prepared (for the sample used in these
experiments both intact IgG and F(ab')2 fragments had an anti-OVA titre of 1/1600).
5.3. Effect of Specific Antibody on PBM Proliferation
Assays were set up as described in Chapter 2; 105 PBMs were plated per well, in a
final volume of 200pL After incubation at 37°C in 5% CO2 for five days, PBM
proliferation was determined by measurement of 3H-Thymidine incorporation over the
last five hours of culture. The cultures were carried out in triplicate, with the results
expressed as the arithmetic mean of cpm ± SD.
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Figure 1
Pepsin digestion of affinity purified anti-OVA antibodies was carried out in order to
obtain F(ab')2 fragments. After ending the reaction and dialysis into lOmM
phosphate buffer, the antibody was passed through an ion-exchange column to
separate the F(ab')2 portions from residual intact antibody. The F(ab')2 antibody
was expected to pass straight through the column, while the intact antibody was
retained and subsequently eluted with sodium chloride solution. These two
antibody samples, with unseparated antibody after pepsin digestion, and the
original affinity purified preparation, were analysed by SDS-PAGE on a 5-25%
gradient slab gel. The gel was silver-stained.
FIGURE 1 SDS-PAGE Analysis of A (Fab')2 Preparation
ofAnti-OVA Antibodies
1 - Material eluted from DE column
2 - F(ab')2 preparation
3 - Unseparated anti-OVA antibodies after pepsin digestion
4 - Anti-OVA antibodies before digestion
The proliferation of PBMs to OVA at suboptimal concentrations was enhanced
considerably by the addition of specific affinity purified antibodies (Fig.2). This
increase in proliferation was seen over a range of OVA dilutions but was greatest at
suboptimal concentrations. In the experiment shown in Fig.2, proliferation was
increased a maximum of 3.4 times above that seen with OVA alone. No significant
enhancement was seen at an OVA concentration of lOOpgml-t, where PBMs
proliferated optimally to OVA alone. When cultured with anti-OVA antibody alone, the
PBMs did not show any proliferative response above that seen with medium only.
Similar results, showing potentiation of the PBM response to suboptimal
concentrations of OVA on the addition of specific antibody, were obtained with five
sheep (Table 1). The changes in proliferation of PBMs observed on the addition of
specific antibody were statistically significant in each case, and ranged from a 1.8-fold
(sheep 23) to a 5.8-fold (sheep 82) increase. In each case, no proliferation over that
seen with medium only occurred where PBMs were cultured with anti-OVA antibody
alone.
5.4. Effect of F(ab')2 Anti-OVA Antibody on PBM Proliferation
F(ab')2 fragments of anti-OVA antibody were used in place of intact antibodies in one
experiment. The F(ab')2 antibodies did not cause any significant enhancement of the
PBM proliferation to OVA (Fig.3) although they retained anti-OVA activity as detected
by ELISA (section 5.2.). The requirement for an intact Fc portion of specific antibody
suggests the involvement of FcyR in the enhanced PBM response.
5.5. Effect of Irrelevant Antibody on PBM Proliferation
Irrelevant affinity purified antibodies were used as a control in two assays with PBMs.
A range of OVA dilutions was used, and specific or anti-HSA antibodies were added at
the same concentration. The activity of HSA-specific antibodies was confirmed in an
ELISA with HSA-coated plates before use (data not shown). While specific antibody
significantly increased the proliferation of PBMs to OVA, irrelevant antibody did not
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Figure 2
105 PBMs from a primed sheep were cultured with dilutions of OVA, with and
without specific antibody at 30|igml-i. After five days of culture, PBM proliferation
was assessed by measurement of 3H-Thymidine incorporation over the final five
hours. The results are the mean cpm of triplicate cultures. Statistical significance was
determined using a Two Sample T Test.
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PBMs from sheep primed to OVA were cultured with OVA at a concentration of
O.lfigml-1. Affinity purified anti-OVA antibody was added to some wells at a
concentration of 30|igml-i. Controls were DC and T cells cultured with medium
only, or with anti-OVA antibody only. The antibody and antigen dilutions were
added to the wells first and incubated at 37°C for 30 minutes to allow the
formation of immune complexes. PBM proliferation was assessed by
measurement of 3H-Thymidine incorporation over the last five hours of culture.
The results shown are the mean cpm of triplicate cultures ± SDs. The statistical
significance of the enhancement which occurred on the addition of specific













































































































PBMs from a sheep primed to OVA were cultured with dilutions of OVA alone, or
with added intact specific antibody at 30[igml-i, or F(ab')2 portions of specific
antibody at the same concentration. The antibody and antigen dilutions were
incubated at 37°C for 30 minutes to allow the formation of immune complexes before
the cells were added in a final volume of 200pl The cells were cultured for five days
before addition of 3H-Thymidine over the last five hours. The results are the mean
cpm of triplicate cultures ± SDs. Statistical analysis was carried out using a Two
Sample T Test.
FIGURE 3 An Intact Fc Portion of Specific Antibody
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(Fig.4). In fact, in one of the two experiments (sheep 151), anti-HSA antibody at the
concentration used decreased the proliferative response of PBMs to OVA. This
inhibition was statistically significant at the two points shown, as determined using a
Two Sample T Test. In the other experiment (sheep 77) the anti-HSA antibody had no
significant effect on the proliferation of PBMs to OVA.
5.6. Effect of Anti-Class II Antibody on PBM Proliferation
Exogenous antigens such as OVA are usually processed for presentation as peptides on
MHC class II molecules, for interaction with CD4 T cells (Unanue 1984). An anti-
MHC class II monoclonal antibody was included in a PBM assay to determine whether
the enhanced proliferation seen with OVA and specific antibodies involved MHC class
II. SW73.2 was used at 20|igmH and was present throughout the culture period
(Fig.5). A control antibody, rat anti-mouse IgG, was used at the same concentration.
The proliferation of PBMs to OVA and specific antibody was significantly reduced on
the inclusion of SW73.2, while the control antibody had no significant effect.
5.7. Effect of Altering the Antibody/ Antigen Ratio on PBM
Proliferation
The antigen/ antibody ratio affects the degree of enhancement of proliferation of
responding cells when antigen is presented by murine macrophages (Manca et al 1991).
In these experiments, the maximum enhancement of proliferation with specific antibody
occurred at moderate antibody excess in all five sheep. OVA was used at a
concentration of 0.1|igmH, with anti-OVA antibody at 30|igml-i, to give a 30-fold
antibody excess (Fig.6 (i)). PBM proliferation on the addition of specific antibody
increased from 1.8 to 5.8 times with these antibody and antigen concentrations.
Significant increases in PBM proliferation were observed in two of four sheep with
OVA at a concentration of 10 ngml-i and anti-OVA antibody at 30(igml-', representing
a 300-fold antibody excess (Fig.6 (ii)). At a 3000-fold antibody excess, with OVA at
lngml-1, significant enhancement of PBM proliferation on addition of specific antibody
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Figure 4
105 PBMs from each of two primed sheep were cultured with varying dilutions of
OVA alone, or with added specific antibodies at 30|igml-i, or anti-HSA antibodies
at 30|J.ml-i. Controls included cells incubated with each antibody alone, and
medium only. PBM proliferation was assessed after a five day culture period by
measuring the incorporation of 3H-Thymidine. The results are the mean cpm of
triplicate cultures ± SDs. The statistical significance of the difference between the
response to OVA alone and proliferation to OVA with added antibody was
determined using a Two Sample T Test.
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Figure 5
105 PBMs were cultured with
(i) OVA dilutions
(ii) OVA and specific antibody at 30|lgml-i
(iii) OVA, specific antibody and SW73.2 anti-class II antibody at 20|J.gmH.
(iv) OVA, specific antibody and rat anti-mouse IgG control antibody at 20|igml-i
Proliferation assays were carried out over a five day period. The results are the
mean cpm of triplicate cultures ± SDs. The statistical significance was determined
using a Two Sample T Test. The significance values shown for the proliferation to
OVA and specific antibody refer to the difference between the response of PBMs to
OVA only and to OVA and anti-OVA antibody. Those for the cultures including
SW73.2, indicate the significance of the difference between the proliferation to
OVA and anti-OVA antibody and that to OVA, anti-OVA antibody and SW73.2
antibody.
FIGURE 5 The Enhanced Proliferation of PBMs to OVA and Anti-OVA
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OVA and specific antibody dilutions were added to 96 well plates and incubated for
30 minutes at 37°C to allow the formation of immune complexes. 105 PBMs from a
primed sheep were added and incubated for five days before measurement of 3H-
Thymidine uptake over the last five hours of culture. In (i) the PBM proliferation to
OVA at 0.1|igml-i is shown with and without specific antibody at 30(J.gml-i,
representing a 30-fold antibody excess. In (ii), the OVA concentration is 10 ngml-i
with specific antibody at 30figml-i, representing a 300-fold antibody excess, and in
(iii) the OVA concentration is lngml-i with specific antibody at 30}lgml-i,
representing a 3000-fold antibody excess. The controls for this experiment included
PBMs cultured with medium only, or with anti-OVA antibody only. The results are
the mean cpm of triplicate cultures ± SD; statistical significance was determined
using a Two Sample T Test.
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were observed in three of five sheep (Fig.6 (iii)). Here, the maximum increase in the
PBM response occurred in sheep 21, where a 2.4-fold enhancement was observed
when specific antibody was included. The PBMs from sheep 23 showed some increase
in proliferation to OVA on addition of antibodies at extreme excess, but this was not
significant. No increase was seen at these concentrations with the PBMs from sheep
77.
To investigate the effect of antigen excess on PBM proliferation, CD4+ T cells were set
up in culture with antigen/ antibody complexes at ratios of 3.3-fold antigen excess, or 3
or 30-fold antibody excess. CD4+ T cells were separated from the PBMs of a sheep
primed to OVA on a MACS as described in Chapter 2. The unstained, CD4- population
of cells which came straight through the magnetised column was also collected and
used as a source of APCs after irradiation with 2500rads. A titration of CD4- APCs
was added to 105 CD4+ T cells per well, with three concentrations of OVA and a fixed
specific antibody concentration (Fig.7).
Where OVA was used at 10pgml-i (Fig.7(i)), i.e. at 3.3-fold antigen excess, specific
antibody inhibited the proliferative response of CD4+ T cells to OVA. The inhibition of
proliferation on the addition of antibody was found to be statistically significant using a
Two Sample T Test. Anti-OVA antibody alone had no effect on PBM proliferation (data
not shown). In (ii), the OVA concentration was lpgmH and anti-OVA antibody added
at 30pgml-i inhibited the proliferation of PBMs to OVA to a lesser extent. Indeed, the
decrease in the CD4+ T cell response when anti-OVA antibody was added was
significant at only one point. The latter concentration of antibody and antigen
represented a 3-fold antibody excess, and in the assays with unseparated PBMs specific
antibody enhanced proliferation to OVA at this ratio (Fig.2). The proliferation of CD4+
T cells to OVA at 0.1|igml-i was significantly enhanced by the addition of anti-OVA
antibodies at 30figmH, giving a 30-fold antibody excess (Fig.7 (iii)). The antigen/
antibody ratio is clearly important in these assays, as in the assays with unfractionated
PBMs. However, inhibition of proliferation to OVA was not observed on the inclusion
of anti-OVA antibodies in assays using unfractionated PBMs.
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Figure 7
CD4+ and CD4- cells were obtained from the PBMs of an OVA-primed sheep by
separation on a MACS. 105 CD4+ cells were cultured with varying numbers of
irradiated CD4- cells, with OVA only or OVA and specific antibodies.. In (i) OVA
was used at 10|!gml-i, in (ii) at lfigml1 and in (iii) at 0.1|igml-i. Anti-OVA
antibodies were included in some wells at 30p.gml-i. The cells were incubated at
37°C for five days; uptake of 3H-Thymidine was measured over the last five hours of
culture. The results are the mean cpm of triplicate cultures ± SDs. The statistical
significance was determined with a Two Sample T Test..
FIGURE 7 Effect of Anti-OVA Antibody on Proliferation of CD4+ T Cells
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5.8. Discussion
The proliferation of PBMs from primed sheep to substimulatory concentrations of OVA
was greatly enhanced in the presence of specific antibodies, although antibody alone
had no effect. A significant increase in PBM proliferation on the addition of anti-OVA
antibodies was observed in experiments with five sheep, and the greatest increase in the
PBM response occurred at suboptimal concentrations of OVA.
Intact specific antibody was necessary for potentiation of the proliferative response,
with F(ab')2 fragments being completely ineffective despite their retention of anti-OVA
antibody activity. An Fc portion of antibody was therefore required, presumably for
interaction with Fc receptors for IgG on the surface of the APC.
The requirement for specific antibodies capable of forming immune complexes with
OVA was demonstrated by the inclusion of irrelevant affinity purified antibodies at the
same concentration. Anti-HSA antibody was of the same isotype as the anti-OVA
antibodies (IgGl) and was active against HSA when tested by ELISA, but failed to
increase PBM proliferation to OVA. Indeed, the irrelevant antibody actually inhibited
the PBM response to OVA to a significant degree in the PBMs from one of the two
animals used (Fig.4). The mechanism by which inhibition occurs is not clear; OVA, in
the absence of specific antibodies, is probably taken up by pinocytosis and it is difficult
to see what effect non-specific antibodies would have on this. Uncomplexed anti-HSA
antibodies should not bind to FcyRII, but could bind to FcyRI. However, binding of
IgG to FcyRI provides an activational stimulus to the cell, and therefore should not
cause the inhibitory effect observed. FcyRI, with its high affinity for monomelic IgG,
should also be saturated with IgG under physiological conditions (Van de Winkel &
Anderson 1991).
The enhanced proliferation of PBMs to OVA-anti-OVA complex was significantly
inhibited by the inclusion of anti-MHC class II antibodies in the cultures. The
presentation of at least a proportion of antigen taken up via FcyR on the APC surface
was therefore dependent on an MHC class II pathway. CD4+ T cells, which recognise
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peptide antigens in the context of MHC class II molecules on the APC surface, are
likely to be the main responding cells in the PBM population. Some proliferation by
CD8+ cells and B cells may also be taking place.
The degree of increase in PBM proliferation on the addition of specific antibody was
dependent on the antibody/ antigen ratio, and was greatest in moderate (30-fold)
antibody excess. However, significant enhancement was also apparent at 300-fold
antibody excess in two of four sheep and at 3000-fold antibody excess in three of the
five sheep.
PBMs contain several cell types capable of acting as APCs. For the experiments
described here, APC requirements include the expression of FcyR, the ability to take
up and process antigen in complex form and to present peptides to responding T cells.
Monocytes are non-specific FcyR-expressing accessory cells, while B cells are efficient
APCs for specific antigen acquired via membrane Ig receptors. DC are also present in
the PBM population in low numbers; DC from human blood have recently been
reported to express FcyRI and FcyRII, and comprise 2-3% of PBMs (Thomas et al
1993). Although B cells also express Fc receptors for IgG, they are unlikely to play a
part in the enhancement of proliferation when specific antibody at excess and low levels
of antigen are present. While immune complex attachment to FcyRII provides
stimulatory signals to cells such as monocytes, cross-linkage of FcyRII and mlg on the
B cell surface delivers an inhibitory signal to the B cell (Klaus et al 1987). The murine
macrophage FcyRII is internalised on ligand binding while the B cell isoform remains
on the cell surface (Miettinen et al 1989). This mechanism has been proposed as a
means of preventing B cells from taking up immune complexes and acting as non¬
specific APCs (Lanzavecchia 1990). Monocytes (and possibly DC) are therefore more
likely to be functioning as APCs in these proliferation assays.
In order to separate the APC and responder cell populations, one experiment was
carried out using irradiated CD4- cells obtained from PBMs as APCs, with the
positively selected CD4+ T cells acting as responders. The proliferation of CD4+ cells
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to OVA was actually inhibited by specific antibody in antigen excess (Fig.7(i)) and, to a
lesser extent, at moderate (3-fold) antibody excess (Fig.7(ii)). A further ten-fold
antigen dilution was necessary before specific antibody increased proliferation to
antigen alone (Fig.7(iii)). This last concentration represented a 300-fold antibody
excess. These results are in contrast to the PBM assays, in which, although maximum
enhancement of proliferation was observed at moderate (3 to 30-fold) antibody excess,
significant inhibition of proliferation to OVA on the inclusion of specific antibody did
not occur.
To assess the relative contributions of monocytes and DC in the PBM population to
antigen presentation in these assays, purification of each cell type would be required.
However, purification procedures may involve culture and techniques which modify
the ability of the selected cells to present antigen and elicit a proliferative response from
T cells. A rapid isolation procedure with minimal culture steps would thus be necessary
to obtain unaltered DC and monocytes from fresh PBMs.
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CHAPTER SIX
THE EFFECT OF SPECIFIC ANTIBODY ON
ANTIGEN PRESENTATION BY DC
6. THE EFFECT OF SPECIFIC ANTIBODY ON ANTIGEN
PRESENTATION BY DC
6.1. Introduction
DC are known to be potent accessory cells for the induction of T cell responses. The
mechanisms involved in antigen uptake and processing by DC remain to be established;
DC are poorly phagocytic and the expression of Fc receptors for immunoglobulins is
variable depending on the source of the cells.
DC from sheep afferent lymph show greatly enhanced uptake of antigen in the presence
of specific antibody (Harkiss et al 1990); this increase is dependent on the presence of
an intact Fc portion of IgG, and varies with the antigen/ antibody ratio. DC are also
capable of rosette formation with IgG-coated erythrocytes; these data imply that DC
express FcyR which are involved in the efficient uptake of immune complexes. The
results in Chapters 3 and 4 demonstrated DC staining with antisera raised against
peptides of extracellular domains of an Fc receptor for IgG, and also with an antiserum
raised against a putative ovine FcyR. Western blot analysis demonstrated the presence
on DC of molecules of suitable size for FcyRI and FcyRII.
The functional significance of the enhanced uptake of antigen by DC in the presence of
antibody is unclear. Enhanced presentation of antigen in the form of immune complexes
has been shown for other APCs (see Introduction), and for unfractionated ovine PBMs
(Chapter 5), but not for afferent lymph DC. The experiments described in this chapter
were carried out to investigate the role of Fc receptors on DC in the presentation of
antigen to T cells. DC and T cells were obtained from sheep primed to OVA and
cultured in vitro with OVA only or OVA and specific antibodies. Proliferation of T
cells was used to measure antigen presentation by DC.
6.2. Purity of CD4+ Responder T Cells
CD4+ T cells at > 93% purity were obtained from PBMs of primed sheep by selection
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on a MACS as described in Chapter 2 (Fig.l). The purified CD4+ T cells were cultured
with OVA or OVA with specific antibodies to assess possible contamination with
APCs. No proliferation by CD4+ T cells above that with medium alone was seen in any
experiment unless DC were added.
6.3. Specific Antibody Enhances CD4+ T Cell Proliferation
For these experiments OVA and affinity-purified antibodies at varying concentrations
were added to plates for incubation at 37 °C to allow immune complex formation before
the addition ofDC and T cells. T cell proliferation in a representative assay is shown in
Fig 2. The cultures were carried out in triplicate with results expressed as the arithmetic
mean of counts per minute (cpm) +/- standard deviation (SD).
The proliferation of CD4+ T cells to suboptimal concentrations of OVA was greatly
enhanced by the addition of anti-OVA antibodies.The increased proliferation required
the presence of both OVA and specific antibodies; no proliferation above background
occurred when DC and T cells were cultured with antibody alone (Table 1 & 2). Both
DC and CD4+ T cells were required for proliferation to occur, control wells with DC or
T cells only cultured with medium, OVA or OVA and anti-OVA antibody never gave
counts of >300 (Table 1 and data not shown), indicating that T cells were not
contaminated with APCs and DC were not contributing to the proliferation observed.
This enhancement was observed in experiments with six sheep, with the effect of
specific antibody on the T cell proliferation to OVA ranging from a 5-fold to a 203-fold
increase (Table 2). The enhancement was found to be highly significant in each case,
using a Two Sample T Test. Irrelevant affinity purified antibodies specific for HSA
were included in experiments with two sheep, and had no stimulatory effect on T cell




PBMs were stained with biotinylated anti-CD4 monoclonal antibody followed by
streptavidin-labelled magnetic microbeads. Streptavidin-PE was also added at this
stage to enable assessment of the purity of the CD4+ selected population by flow
cytometry. The PBMs were then separated on a MACS. FACS profiles for
positively selected cells (i) and unselected cells which passed through the
magnetised column (ii) are shown. The percentage of cells positive for fluorescence
and therefore CD4 expression was 94% in (i) and 5% in (ii).
FIGURE 1 CD4 Expression of Cells Separated by MACS
(i) Positively Selected Cells
(ii) Unselected Cells
Logio Relative Fluorescence intensity
Figure 2
DC and CD4+ T cells from sheep primed to OVA were purified as described in
Materials and Methods. 5xlCM DC and 105 T cells were cultured with dilutions of
OVA in 200p.l volumes in 96-well plates. Specific antibody was included in some
wells at a final concentration of 30|J.gml-i. Antibody and antigen were added to the
wells first; incubation at 37 °C for 30 minutes allowed the formation of immune
complexes before addition ofDC and T cells. After a five day culture period, T cell
proliferation was assessed by measurement of 3H-thymidine incorporation. The
results are expressed as the mean counts of triplicate cultures ± standard deviations
(SD). Significance values were calculated using a Two Sample T Test.
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Table 1
DC and CD4+ T cells from an OVA-primed sheep were cultured with one of the
following:- OVA at lp-gml1; anti-OVA antibodies at SOflgml1; both OVA and
antibodies; or medium only. Each cell type was also cultured separately with the
range of additions as shown. The results are the mean cpm of triplicate cultures ±
SDs, and illustrate proliferation in a representative experiment.
TABLE 1 Proliferation Assay Controls
Cells Cultured With Mean cpm ± SD
DC + T OVA 17862 ± 3026
DC + T OVA + Ab 143106 ± 10500
DC + T Ab 288 ± 29
DC + T Medium 521 ±79
DC OVA 125 ± 35
DC OVA + Ab 198 ±32
DC Ab 226 ± 72
DC Medium 113 ± 6
T OVA 251 ±36
T OVA + Ab 140 ± 14
T Ab 188 ±40
T Medium 119 ± 5
Table 2
DC and CD4+ T cells from sheep primed to OVA were cultured with OVA only at
0.1|lgmH, or OVA at 0.1|igml-i and anti-OVA antibodies at 30|lgmH. The
antibody and antigen dilutions were added to the wells first and incubated at 37 °C
for 30 minutes to allow the formation of immune complexes. DC and CD4+ T
cells were then added, and cultured at 37°C for five days. T cell proliferation was
assessed over the last five hours of culture, by measurement of 3H-Thymidine
incorporation . The results are the mean cpm of triplicate cultures ± SDs. The
statistical significance of the difference between the T cell response to OVA alone































































































































Purified DC and T cells were added to wells containing OVA only, OVA and
specific antibody at 30|igml-i, or OVA and anti-HSA antibody at 30pgml-i (see
key). Both antibody preparations were affinity purified from sera of primed
sheep, and were of the same (IgGl) isotype. Anti-HSA antibodies showed no
cross-reactivity with OVA when tested by ELISA. Controls included DC and T
cells cultured with anti-HSA or anti-OVA antibody alone. Results are the means
of triplicate counts; standard deviations are shown by the error bars. Statistical
analysis was carried out using a Two Sample T Test and significant differences in
the proliferation of T cells are shown.
FIGURE 3 Irrelevant Antibody Does Not Potentiate
T Cell Proliferation to OVA
Key
OVA only
OVA and anti-HSA antibody
OVA and anti-OVA antibody
p < 0.05
p < 0.001
6.4. Effect of F(ab')2 Antibody on T Cell Proliferation
F(ab')2 fragments of specific antibody were used to investigate the role of DC Fc
receptors for IgG in the potentiation of T cell responses. While F(ab')2 preparations
retained anti-OVA antibody activity when tested by ELISA, they were completely
ineffective in these assays and did not increase CD4+ T cell proliferation above that
seen with OVA alone. This experiment was carried out with two sheep and the results
are shown in Fig.4.
6.5. Effect of Anti-MHC Class II Antibody on T Cell Proliferation
The presentation of antigen to CD4+ T cells involves peptides in the antigen-binding
grooves of MHC class II molecules on the DC surface interacting with the antigen-
specific TCR of the T cell. To determine whether the enhancement of T cell stimulation
that occurred with specific antibody was dependent on class II molecules, SW73.2, a
rat monoclonal with specificity for ovine MHC class II, was included in some wells
throughout the culture period of one experiment. Complete inhibition of proliferation to
OVA plus antibody occurred on addition of SW73.2 at 20|lgml-i, while the control
monoclonal (rat anti-mouse IgG), used at the same Ig concentration, had no significant
inhibitory effect (Fig 5).
6.6. Effect of Altering the Antigen/ Antibody Ratio on T Cell
Proliferation
The degree of enhancement of antigen uptake in the presence of specific antibody is
dependent on the antigen/ antibody ratio. Experiments were carried out with fixed,
suboptimal concentrations of OVA and added specific antibody in varying amounts to
investigate the role of the antigen/ antibody ratio in functional assays.
The extent of the increase in T cell proliferation seen in this experiment varied with the
antigen/ antibody ratio when DC were used as accessory cells (Fig 6). Maximal
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Figure 4
F(ab')2 fragments of anti-OVA antibody were obtained by pepsin digestion of intact
affinity purified antibody. Anti-OVA activity of the fragments was determined by
ELISA before use in assays. 5X104 DC were cultured with 105 CD4+ T cells in the
presence of OVA only, OVA and specific antibody at 30|igml, or OVA and F(ab')2
specific antibody at the same concentration (see key). The experiment was carried
out with cells from two sheep. The results shown are the mean counts of triplicate
cultures + SDs. The statistical significance of the difference between CD4+ T cell
proliferation to OVA only, and the response on addition of antibody, was assessed
using a Two Sample T Test.
FIGURE 4 T Cell Proliferation is Not Enhanced by
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DC and CD4+ T cells were purified as described and cultured with OVA dilutions
only or OVA plus specific antibody at 30|igml-i. Anti-MHC class II monoclonal
antibody, SW73.2, was added to some wells at 20p.gml-i, and was present
throughout the five day incubation period. Rat anti-mouse IgG, used at the same
concentration as SW73.2, served as a control. The results shown are the means of
triplicate cultures ± SDs. The statistical significance was assessed using a Two
Sample T Test. The proliferation of T cells to OVA and anti-OVA antibody was
compared with that to OVA only. The response to OVA, anti-OVA antibody and the
control antibody was compared with the proliferation to OVA and anti-OVA
antibody. T cell proliferation to OVA, anti-OVA antibody and SW73.2 was
compared with the T cell response to OVA and anti-OVA antibody.
FIGURE 5 Effect of Anti-MHC Class II Antibody on
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5xlCH DC and 105 CD4+ T cells were plated with fixed suboptimal concentrations
of OVA (1.6 or 0.4jigml-i), with or without added specific antibody at a range of
concentrations (see key). IgG from an unprimed sheep was used as a control over
the same range in concentration. Proliferation of triplicate cultures was assessed by
measurement of 3H-thymidine incorporation over the last five hours of culture.
Mean counts ± standard deviations are illustrated, with p values calculated using a
T Test as previously.
FIGURE 6 The Effect of Antibody/ Antigen Ratio






Concentration of immunoglobulin (ggmH)
Key
OVA 0.4figmH and anti-OVA antibody
OVA 1.6|igmH and anti-OVA antibody
A OVA 1.6|igmH and control IgG
f p < 0.05
* p < 0.001
enhancement of proliferation over that with OVA alone occurred at an antibody
concentration of SOpgml1, with OVA at 1.6 or 0.4 (igml-h These antibody and antigen
concentrations represent a 1.9-fold and a 7.5-fold antibody excess respectively (3pg of
OVA would be required for equivalence with 30|ig antibody). A smaller increase in
proliferation occurred when the antibody concentration was increased or decreased
from this level. The response of CD4+ T cells to OVA in the presence of IgG from an
unprimed sheep is shown in the same figure. No additional proliferation above that to
OVA alone occurred over the same concentration range of IgG.
Fig. 7 illustrates the results obtained in separate experiments with three sheep. Again
the greatest increase in T cell proliferation on the addition of specific antibody is seen at
moderate (30-fold) antibody excess (i), with highly significant 14-fold, 18.5-fold and
6.3-fold increases observed in sheep 150, 151 and 21 respectively. DC and T cells
were cultured with antibody at a fixed concentration of 30pgml-i, with OVA
concentrations ofO.lpgml-1 in (i), lOngmH in (ii) and lngml-1 in (iii). The increase in
proliferation with added specific antibody was significant in two of the three sheep in
(ii), representing a 300-fold antibody excess, but was not significant in any of the
sheep where OVA was used at lngmH (iii), which gave a 3000-fold antibody excess.
Experiments involving the addition of specific antibody at antigen excess were carried
out in three sheep; in one animal no increase in T cell proliferation was observed, while
in two sheep significant enhancement in the T cell response occurred at a 3.3-fold
antigen excess. However, higher concentrations of antigen were present than were used
in the experiments at antibody excess, with OVA at lOpgmH, and CD4+ T cells
proliferated strongly to OVA alone (Fig.2 and data not shown).
6.7. Effect of Altering DC Numbers on T Cell Proliferation
DC are potent accessory cells for the stimulation of T cells and are often effective in
smaller numbers than other APC types. Experiments were carried out with fixed levels
of OVA (O^pgrnl1) and specific antibody (30|igml-i), with a constant number of
CD4+ T cells and varying numbers of afferent lymph DC.
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Figure 7
DC and CD4+ T cells were cultured with OVA at suboptimal concentrations, or OVA
and anti-OVA antibodies at 30pgml-t. In (i), OVA concentration was O.lpgmH,
representing a 30-fold antibody excess; in (ii) OVA was used at 10ngml-i,
representing a 300-fold antibody excess, and in (iii) an OVA concentration of lngml-i
gave a 3000-fold antibody excess. The results are means of triplicate cultures ± SDs,
and the statistical significance values for the differences between proliferation to OVA
alone and response to OVA and antibody were determined using a Two Sample T
Test.
FIGURE 7 Antibody/ Antigen Ratios: Effect on
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As expected, the proliferation of T cells to OVA presented by DC decreased with the
number of DC added (Fig. 8). The enhanced T cell response in the presence of anti-
OVA antibody also decreased with DC number, but the difference between proliferation
to OVA alone and that to OVA and antibody was greatest at the lower numbers of DC.
Indeed at the smallest number of DC added, T cell proliferation to antigen alone was at
background levels yet on addition of specific antibody a 400-fold increase occurred.
6.8. Discussion
The experiments in this chapter were carried out to investigate the effect of specific
antibody on presentation of antigen by DC. The enhanced uptake of antigen in complex
form by these cells has already been demonstrated; however the functional
consequences with regard to effects on antigen presentation remain to be determined.
Proliferation of T cells was used as a measure of antigen presentation by DC, as there is
as yet no direct method of assessing the immunostimulatory functions of APCs. A
population of responding T cells free of APCs was required to investigate the
presentation of antigen by DC. This was obtained by the positive selection of CD4+ T
cells from PBMs using a MACS. Selected cells were analysed by FACS to ensure that
purity was at least 93% before culture with OVA or OVA and specific antibodies in the
absence of added APCs. CD4+ T cells showed no proliferation over that seen in
medium only when plated with stimulatory or suboptimal concentrations of OVA, or
OVA and specific antibodies, unless DC were added, indicating that the responding
cells were not contaminated with APCs.
The cells obtained after centrifugation of afferent lymph cells over metrizamide were
60-80% DC by morphological criteria on cytospins, with some lymphocytes also
present. Before use as APCs this cell population was irradiated with a dose of 2500
rads to prevent proliferation of lymphocytes and possible antigen presentation by B
cells. After irradiation the APCs showed no proliferation above background levels
when cultured with OVA or OVA plus antibody, thus the proliferative response
observed in these assays was due to the CD4+ responder cells.
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Figure 8
CD4+ T cells (105) were cultured with OVA at 0.2fj.gmH, with and without
specific antibody at 30|igml-i and varying numbers of DC. The. results are the
means of triplicate cultures ± SDs. Statistical analysis was carried out with a Two
Sample T Test.
FIGURE 8 Enhanced CD4+ T Cell Stimulation
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DC and CD4+ T cells from primed sheep were cultured with OVA at a range of
concentrations. At suboptimal levels of OVA, the addition of specific affinity purified
antibodies greatly enhanced T cell proliferation. This highly significant increase was
seen in experiments with six sheep. Although some enhancement was seen at higher
levels of OVA, the potentiation of the T cell response was greatest at concentrations of
OVA that caused little proliferation alone. The data suggests improved antigen
presentation by DC following uptake of OVA in the form of immune complexes.
To confirm the requirement for an intact Fc portion of antibody to interact with DC
surface Fc receptors, F(ab')2 fragments of specific antibody were used in place of
whole antibody molecules. No intact IgG remained in these preparations. F(ab')2
portions of specific antibody were found to be ineffective in these assays; no increase in
T cell proliferation occurred when digested antibody was used at the same concentration
as intact antibody. This was not due to reduction or loss of anti-OVA activity during
pepsin digestion, as F(ab')2 preparations had similar titres to intact antibodies when
tested by ELISA. An Fc portion of antibody is therefore required for the enhancement
of proliferation seen in these experiments, implicating Fc receptors for IgG in the
process.
To exclude any non-specific stimulatory effects of affinity purified antibodies, anti-
HSA antibodies prepared from the serum of a primed sheep on an affinity column were
used as a control in some experiments. These antibodies had anti-FtSA activity when
tested by ELISA, but had no stimulatory effect on T cell proliferation to OVA dilutions.
This result confirmed the requirement for specific antibody capable of immune complex
formation with OVA.
The degree of the increase in uptake of antigen by afferent lymph DC in the presence of
specific antibody varied with the antigen/ antibody ratio (Harkiss et al 1990);
experiments carried out in this chapter clearly show that the magnitude of the
enhancement of T cell proliferation on addition of anti-OVA antibody also depends on
this ratio. Maximum potentiation of the T cell response was seen when specific
antibody was present at moderate excess, while in extreme antibody excess or antigen
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excess smaller increases in proliferation occurred for the same OVA concentration.
Moderate antibody excess therefore provides the optimum conditions for the enhanced
presentation of antigen by DC in the presence of specific antibody. This could be
accounted for by the uptake of complexes being most efficient at moderate antibody
excess, or alternatively the processing and presentation pathway followed by the
immune complexes may function more effectively in conditions of moderate antibody
excess.
The results from the experiment including anti-MHC class II monoclonal antibody
indicated that the increased stimulation of T cells on addition of specific antibody at
suboptimal OVA concentrations was dependent on a class II presentation pathway. At
least some of the antigen taken in via the FcyR on the DC surface is therefore routed to
a class II processing pathway.
Very low numbers of DC were effective at inducing additional T cell proliferation in the
presence of antibody. In the experiment described, 1.6xl03 DC were sufficient to
cause a 400-fold increase in response to OVA when anti-OVA antibody was added in
moderate antibody excess. Indeed, greater increases were observed with the smaller
numbers of DC, while when 2xl05 DC were used as APCs T cells proliferated
strongly to OVA alone and no increase was seen on addition of antibody. This may
reflect the importance of limited numbers of antigen-carrying DC in vivo which will
encounter and activate specific T cells in secondary responses.
The enhancement of T cell proliferation by specific antibody but not by F(ab')2
fragments, and the effects of irrelevant antibody and anti-MHC class II antibody are
similar to those observed with unfractionated PBMs (Chapter 5). However, the degree
of increase in the proliferative response to antigen on the addition of specific antibody
was much greater in the DC/ CD4+ T cell assays than in experiments with PBMs. In
the PBM assays, the maximum enhancement was a 5.8-fold increase in proliferation,
compared with a maximum 400-fold increase in CD4+ T cell proliferation to antigen
presented by DC. DC are potent APCs for soluble protein antigens (Van Voorhis et al
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1983, Steinman 1991), and they may also be more efficient than monocytes, likely to
be the major APC population in the PBMs, in the uptake and presentation of antigen in
the form of immune complexes. Another difference between the results obtained in the
two assay systems related to the antibody/ antigen ratio. In the DC/ CD4+ T cell assays,
maximum potentiation of the T cell response was observed at moderate antibody
excess, while no significant increase in proliferation was seen at extreme antibody
excess. In the PBM assays, although the greatest increase in proliferation also occurred
in moderate antibody excess, a significant enhancement of proliferation was also seen
in extreme antibody excess. This difference may be due to variations in the type and
quantity of FcyR expressed on DC and APCs in the PBM population, and therefore the
optimal antibody/ antigen ratio for immune complex uptake, or to alternative pathways
of antigen processing and presentation utilised by different cell types. However, to
compare the two types of assay directly, purified monocytes and CD4+ T cells as





7.1. The Role of DC in the Primary Immune Response
It is generally accepted that DC are essential accessory cells for induction of the primary
immune response to antigen (Inaba et al 1990, Macatonia et al 1989, Steinman 1991).
Direct priming of naive T cells in situ by antigen-bearing DC has been demonstrated,
while other APCs such as B cells and macrophages appear to be incapable of eliciting a
response (McKeever et al 1992, Inaba et al 1990, Liu & MacPherson 1993). Some
murine studies have suggested that B cells are required for T cell priming. However,
animals in these experiments were treated with anti- p. antibody from birth in order to
delete B cells, and this treatment could also have affected DC viability or function
(Janeway et al 1987, Kurt-Jones et al 1988). DC are also required to elicit a primary
antibody response, probably for the activation of specific CD4+ T cells which can then
provide B cell help (Inaba et al 1985). The reasons for the distinctive capabilities of DC
have not been elucidated, although several features of these cells are probably
important.
Interstitial DC, situated in non-lymphoid tissues such as the epidermis, are ideally
situated to encounter and accumulate antigen rapidly on its entry into the body. The
method by which DC take up antigen in a primary response is still unclear, although an
efficient process of antigen accumulation is vital to ensure initiation of the immune
response. Non-specific pinocytosis may account for the uptake of soluble antigens
(Barfoot et al 1989), and a role has been suggested for IgM, detected on the surface of
a variable proportion of DC from sheep afferent lymph (Bujdoso et al 1990). Specific
IgM antibodies, generated during the primary response, may form complexes with
antigen and attach to the DC surface via complement receptors (Steinman 1991, Nestle
et al 1993) or possibly FcqR. "Natural" antibodies of IgM isotype, with multiple
specificities, could act as a concentrating mechanism for antigen before the production
of specific antibodies. The role of cytophilic IgM in antigen uptake by afferent lymph
DC in the primary immune response was investigated in Chapter 3. In vitro studies
assessed DC uptake of FITC-OVA in the presence or absence of purified IgM anti-OVA
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antibodies, or unfractionated serum containing these antibodies. No increase in DC
uptake of labelled antigen was observed in the presence of either serum or purified
antibodies. This may indicate that IgM does not function in the uptake of antigen by DC
in the primary response in vivo; alternatively the in vitro experimental conditions could
have been unsuitable. It is possible that a lack of complement is responsible for the lack
of uptake; 7S subunits of IgM could also be involved, rather than the complete IgM
pentamer. Further experiments would be required to investigate these possibilities.
Although DC are capable of internalising soluble antigens, they are generally thought to
be poorly phagocytic (Steinman 1991), and this raises the question of how a primary
response to particulate antigens and microorganisms is initiated. However, other
reports describe the presence of phagocytic inclusions in afferent lymph DC, and the
uptake of Bacillus Calmette Guerin (BCG) organisms by proliferating DC precursors
from murine bone marrow (Hall & Robertson 1984, Inaba et al 1993). DC pulsed in
vitro with BCG elicited strong T cell responses in vivo, demonstrating that at least at
this stage of differentiation, DC are capable of taking up microorganisms and
processing antigens for presentation in immunogenic form to naive T cells.
After taking up antigen, DC migrate via the afferent lymph or the blood to the draining
lymph node or spleen, where they interact with recirculating T cells. Naive T cells
recirculate through the lymph node, passing from high endothelial venules to T cell
areas of the node and subsequently into the efferent lymph (Mackay et al 1990).
Memory-type T cells, in contrast, tend to migrate through the peripheral tissues and
enter afferent lymph (Pitzalis et al 1988). Activated antigen-specific T cells secrete
cytokines necessary for providing B cell help in antibody production, and for
promoting cell-mediated responses.
The superior accessory ability of DC compared with other APC types is unlikely to be
due to differences in the method or efficiency of antigen uptake. Macrophages, for
example, are far more efficient in the phagocytosis of particulate antigens than DC, and
also accumulate soluble antigens by fluid phase endocytosis. However, macrophages
and monocytes are incapable of activating naive CD4+ T cells (Inaba et al 1990, Levin
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et al 1993). B cells acquire soluble antigens by pinocytosis. Specific antigen,
recognised by the mlg of the B cell, is taken up and presented with great efficiency to T
cell lines (Lanzavecchia 1985), but B cells are not able to activate naive T cells. It is
probable that the pathways of processing and presentation and the costimulatory
characteristics of the different APC types are more important.
Exogenous antigens are generally processed in an endocytic pathway for presentation
by MHC class II molecules, while cytoplasmic antigens are processed via a separate
route and presented in association with MHC class I molecules (Harding 1991). The
class II pathway requires the presence of acidic intracellular compartments and is
blocked by lysosomotropic agents such as chloroquine. There may be differences in the
pathway or in the proteolytic enzymes in DC as compared to other APCs such as
monocytes, enabling DC to produce antigenic peptides for association with MHC class
II molecules more efficiently.
Although DC constitutively express higher levels of MHC class II molecules than other
APCs, this alone is unlikely to account for their unique abilities: no correlation was
found between the level of class II expression by different APC types and their ability
to prime naive CD4+ T cells in vivo (Levin et al 1993). However, there may be
qualitative differences in DC class II molecules or in the array of peptides generated by
DC for association with class II, which increase affinity for the TCR of antigen-specific
T cells. DC have fewer lysosomal enzymes than monocytes (Thomas et al 1993a), and
it is therefore possible that more peptides escape complete degradation and remain
available for interaction with the antigen binding groove of MHC class II molecules.
Monocytes and DC were found to have comparable accessory activity in assay systems
such as those involving anti-CD3 mAb stimulation of T cells, which depend less on the
expression of MHC class II by the APC. Costimulatory molecules were employed
comparably by each cell type in these assays. However, in the MLR, which is
dependent on class II expression, DC were far more effective than monocytes in the
activation of naive and memory T cells, suggesting that differences in the expression of
class II molecules and/or their peptide ligands are likely to be responsible for the
superior ability of DC to activate allogeneic T cells (Thomas et al 1993b). This may be
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important in both primary and secondary responses.
Ligation of the TCR by specific peptide on MHC molecules is necessary but not
sufficient for T cell activation. Costimulation, mediated either by a surface molecule on
an APC interacting with its ligand on the responding cell, or by cytokines produced by
the APC, is required for activation. Lack of a sufficient costimulatory signal can lead to
anergy. The ability of the accessory molecules ICAM-1, LFA-3 and B7 to provide
costimulation through their T cell ligands has been described (Dustin & Springer 1989,
Springer 1990, Young et al 1992). These molecules are present on monocytes and DC,
and the ligand pairs seem to work in an additive manner for optimal T cell activation
(Thomas et al 1993b). DC from ovine afferent lymph also express CD2 which may
contribute an activational stimulus by interaction with LFA-3 on responding cells. B7
has been suggested as the central costimulatory molecule in the activation of responding
cells by DC, due to their constitutive expression of this molecule, while it is found on
other APCs only after activation (Young et al 1992). However, more recent studies
have indicated that DC, like other APCs, acquire B7 expression and function on
activation (Thomas et al 1993b, Hart et al 1993). B7 alone is therefore unlikely to
account for the ability of DC to activate naive T cells and initiate a primary immune
response.
Other characteristics of DC undoubtedly contribute to their accessory functions. Surface
area is increased by the DC's dendritic morphology, enabling multiple interactions with
T cells and the formation of clusters in which specific T cells are activated (Steinman
1991). DC surface molecules are sialated to a lesser degree than those of other cells,
giving the cell membrane a lower negative charge and promoting DC association with
negatively-charged responding cells (Boog et al 1989).
7.2. Accessory Activity of DC in the Secondary Immune Response
Although there is an absolute requirement for antigen presentation by DC for activation
of naive T cells, this is not the case in the secondary response. APCs such as
macrophages and B cells express MHC class II molecules and can act as accessory cells
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for memory or activated CD4+ T cells (Unanue & Allen 1987). Other cell types can be
induced to express class II molecules, although the consequences of class II expression
by cells not specialised for antigen presentation are varied. While class II-bearing
endothelial cells appear to be capable of T cell activation, antigen presentation by
keratinocytes expressing MHC class II molecules leads to anergy (Geppert & Lipsky
1985, Bal et al 1990). T cells express MHC class II on activation (Yu et al 1980), and
there is contradictory evidence concerning their possible role in antigen presentation.
Activated T cells from ovine efferent lymph are effective stimulator cells in the MLR,
but fail to present native protein antigens or peptides. In contrast, ovine T cell lines
generated in vitro are capable of presenting peptides but not native antigens (Hopkins
et al 1993). Activated human T cells can also stimulate responding cells in the MLR,
and presentation of peptides to specific T cell responders has been reported (Damle &
Gupta 1982, Gerrard et al 1985, La Salle et al 1991). The lack of ability to present
native antigens may be due to deficiencies in uptake; when viral antigen binds to a T cell
surface molecule uptake is enhanced and it can be effectively processed and presented
(Lanzavecchia et al 1988).
Conflicting studies describe the induction of anergy, probably due to a lack of adequate
costimulation, when antigen is presented by class II-expressing T cells in the absence
of other APCs (Jenkins & Schwartz 1987, Sidhu et al 1992). Responding T cells could
be activated where peptide was presented on T cell class II molecules, as long as
costimulation was provided by added APCs (Sidhu et al 1992). The significance of
antigen presentation by T cells in vivo is thus still unclear.
Other cell types can therefore act as APCs for activated or memory T cells. However, in
many experimental systems used to assess antigen presentation, DC are the most
efficient accessoiy cells in secondary responses (Van Voorhis et al 1983, McKeever et
al 1991). The factors discussed above (section 7.1.) involving processing and
presentation, and possible differences in DC expression of MHC class II and the
peptides produced by DC as opposed to other APCs, could also contribute to DC
accessory functions in the secondary response.
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7.2.1. The Role of FcyR in Uptake and Presentation of Antigen by DC
The major differences in a secondary as compared to a primary response in vivo are the
presence of memory T and B cells and specific antibody. The latter enables cells
bearing FcR to accumulate and present antigen in complex form with greatly increased
efficiency (Lanzavecchia 1990). The expression of FcyR by DC from different tissues
and those obtained by separate methods of isolation is variable (Section 1.6.). There is
evidence that DC from ovine afferent lymph carry FcyR; these cells formed rosettes
with IgG-coated erythrocytes and took up fluoresceinated antigen with increased
efficiency in the presence of specific antibody both in vitro and in vivo (Harkiss et al
1990, and Chapter 3). The enhancement was dependent on intact Fc portions of
antibody, with F(ab')2 fragments being completely ineffective, and the degree of
increase in the uptake of antigen varied with the antibody/ antigen ratio. The data
strongly suggests the involvement of FcyR on the DC surface in the accumulation of
immune complexes. In accordance with this, an increase in surface IgG levels occurred
when DC were incubated with OVA and anti-OVA antibody of IgG isotype (Chapter
3). This increase in staining was also dependent on the antibody/ antigen ratio, and can
be explained by the presence of anti-OVA antibodies in the form of immune complexes
attached to FcyR on the DC. The IgG detected on afferent lymph DC during these
experiments was of the IgGl isotype; no corresponding increase in IgG2 was
observed. Harkiss et al (1990) reported that anti-OVA antibodies of both IgGl and
IgG2 isotypes were effective in promoting the uptake of OVA; however, the affinity
purified anti-OVA antibodies used in this thesis were all IgGl, as determined by
ELISA.
DC stained positively by flow cytometry with rabbit antisera raised against peptides
from the sequence of bovine FcyRI, and an antiserum raised against a putative ovine
FcyRII (Chapter 4). Although this clearly suggested the presence of FcyR on afferent
lymph DC, it did not distinguish between the various types of FcyR. Western blot
analysis of DC lysates with the anti-FPl antiserum gave two bands at molecular
weights of 40kD and 72kD, which were of the correct sizes for FcyRII and FcyRI as
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described in mice and humans (Ravetch & Kinet 1991). Western blot analysis of ovine
alveolar macrophage lysate with this antiserum also demonstrated two proteins of 40
and 72kD. Affinity purified anti-FPl antibodies reacted with the same two bands, on
lysates of both DC and alveolar macrophages. There is therefore considerable evidence
for the expression of FcyR by ovine afferent lymph DC, and these cells appear to
express both FcyRI and FcyRII.
Evidence for enhanced antigen presentation by DC following the uptake of complexed
antigen via FcyR was obtained in the assays described in Chapter 6. This effect was
observed in experiments with DC and CD4+ T cells from six sheep, with the degree of
enhancement on the addition of antibody ranging from a 5-fold to a 302-fold increase.
As with the uptake experiments, the enhancement was dependent on the antigen/
antibody ratio, being greatest at moderate antibody excess, and required intact specific
antibody. A significant increase in T cell proliferation was also observed at a 3-fold
antigen excess in two of three sheep; however OVA was used at a higher concentration
than in the antibody excess assays and there was a strong response to OVA alone.
Similar results were obtained in functional assays with PBMs, described in Chapter 5.
Again, specific antibody caused a significant increase in the proliferation of PBMs from
a primed sheep to low concentrations of OVA. However, the enhancement of the
response was less than that seen with the DC and CD4+ T cell assays, ranging from a
1.8-fold to a 5.8-fold increase. The smaller increase may be due to the presence of
fewer FcR-expressing APCs in the PBM experiments, or to the different APCs
involved. DC may be more efficient in antigen presentation after uptake via FcR than
monocytes. Further experiments with separated monocytes would be required to
determine the explanation for this difference. F(ab')2 portions of specific antibody had
no effect on PBM proliferation, indicating the requirement for an intact Fc region of the
IgG anti-OVA antibodies. The antibody effect also depended on the antibody/ antigen
ratio, and irrelevant antibodies had no enhancing effect on PBM proliferation to OVA.
Enhanced presentation of antigen in the form of immune complexes has been reported
for various FcR-expressing APCs (Celis & Chang 1984, Schalke et al 1985, Manca et
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al 1991). DC from rat lymph node and thymus were effective at inducing enhanced
proliferation of T cell lines to the acetylcholine receptor from Torpedo californica, in the
presence of monoclonal antibodies specific for this antigen. Pulsing experiments with
antigen and antibodies showed that the effect was at the level of the presenting cells,
and DC incubated with complexes for one hour at 37°C were capable of eliciting a
significant proliferative response from the responding cells. The authors concluded that
a means for the attachment of IgG antibodies in complex form to the DC surface was
involved, although rat splenic and thymic DC were not generally thought to express
FcyR. This work, using rat cells, is the only previous report of enhanced antigen
presentation by DC where the antigen is in the form of immune complexes. However,
the assays used do not compare directly with the experiments described in Chapter 6, as
monoclonal antibodies and T cell lines were used in the work by Schalke et al (1985),
while polyclonal antibodies and a bulk population of CD4+ T cells from a primed
animal were used in this thesis. The latter may more closely represent the situation in
vivo, where antibodies recognising different epitopes of an antigen will be present.
The DC were also obtained from different tissues in each case; from the spleen or
thymus of the rat, and from the afferent lymph of sheep.
Polyclonal antibodies have been used by others to demonstrate the enhanced
proliferation of human T cell clones to hepatitis B surface antigen in the presence of
specific antibodies (Celis & Chang 1984). The CD4+ T cells used in the assays
described in Chapter 6 had been recently isolated from peripheral blood, and not
maintained for long periods in culture as is the case for T cell lines.
The importance of the antigen/ antibody ratio in the enhanced presentation of antigen in
the form of immune complexes has been described (Manca et al 1991). In this study,
the FcyR-expressing APCs were macrophages, and the responding cells were murine
or human T cell clones specific for various antigens. Immune complexes in moderate
antibody excess provided optimal stimulation of T cells, while complexes in extreme
antibody excess or extreme antigen excess did not potentiate the T cell response to
antigen alone. In conditions of extreme antibody excess, the proliferation of T cells to
stimulatory antigen concentrations was actually inhibited. Antigen molecules were
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shielded from degradation within the APC by the presence of many antibody
molecules. This mechanism of shielding by antibody can alter the substrate available for
processing, and may therefore influence which T cell epitopes are dominant in the
response to a particular antigen (Watts & Lanzavecchia 1993).
The DC assays described in Chapter 6 gave similar results in that the maximum increase
in the CD4+ T cell responses to suboptimal levels of OVA occurred at moderate
antibody excess. However, specific antibody did not inhibit the T cell proliferation to
OVA at any of the concentrations used. In the PBM assays described in Chapter 6,
conditions of moderate antibody excess again provided optimal stimulation of the
responding cells. In contrast to the DC and CD4+ T cell assays, and to the work carried
out by Manca et al (1991), PBM proliferation to OVA was also enhanced at extreme
antibody excess, although to a lesser degree than the increase observed at moderate
antibody excess. The reason for this is unclear; it may be due to the different APCs
involved in these experiments; DC and the APCs present in PBMs, likely to be
monocytes. The latter may be more efficient in the uptake, processing and presentation
of immune complexes at extreme antibody excess than DC from afferent lymph.
The antigen/ antibody ratio may be significant in the regulation of cell mediated and
humoral aspects of the secondary response in vivo. A varying ratio in different tissues
and at different stages in the secondary immune response, may mean that complexed
antigen is present in either stimulatory or non-stimulatory form for presentation to
specific T cells. Thus T cells would be efficientiy activated to undergo clonal expansion
and secrete cytokines, in a secondary response where residual antibody complexes with
substimulatory concentrations of antigen for efficient uptake by FcyR-expressing APC.
However, when levels of antibody had increased to give extreme antibody excess, the
same APCs would not be able to stimulate specific T cells and the cell mediated
response would decline. Antigen presentation by specific B cells is several orders of
magnitude more efficient than that by B cells of irrelevant specificity (Lanzavecchia
1987). However, the presence of specific antibodies at extreme excess in vivo would
leave few B cell epitopes of the antigen exposed for interaction with mlg and so the
antibody response would be decreased. Cross-linking of FcyRII and mlg on B cells
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delivers an inhibitory signal to the cell (Phillips & Parker 1984)
FcyR are internalised after immune complex binding, and enter an endocytic
compartment from which both receptor and ligand proceed to lysosomes for
degradation (Ukkonen et al 1986). In the DC assays, at least a proportion of antigen
was subsequently presented on MHC class II molecules, and activated specific CD4+ T
cells. Exogenous antigen is generally processed by the endocytic pathway before being
presented in association with class II molecules, but antigens in the form of SMAA
complexes and ISCOMs may also be presented on class I molecules to CD8+ T cells
for initiation of CTL responses (De Vries et al 1988, Takahashi et al 1990, Randall &
Young 1991). Presentation of viral protein incorporated into ISCOMs by a class II
pathway that is not inhibited by chloroquine has also been demonstrated (Van
Binnendijk et al 1992). In the latter case, ISCOMs are likely to enter the cytoplasm of
the cell where antigenic peptides are produced, before association of these peptides with
class II molecules either in the ER or after entering an endosomal/ lysosmal
compartment in which class II molecules reside. The processing pathway responsible
for presentation of OVA peptides on MHC class II molecules after DC uptake of
antigen in the form of immune complexes was not determined in this thesis; however,
as FcyR enter endosomes on internalisation, it is j>robable that complexes are processed
by the chloroquine-sensitive endosomal pathway. It is possible that some of the antigen
taken up by DC in complex form also enters the class I pathway, and is capable of
eliciting cytotoxic responses from CD8+ T cells. Further experiments involving DC and
purified CD8+ T cells would be required to determine whether this occurs.
Cross-linkage of FcyR causes internalisation, and delivers a signal to the cell. This
signal may be inhibitory as in the case of the cross-linked B cell mlg and FcyR, or
stimulatory as for FcyR on macrophages, monocytes and neutrophils (Van de Winkel
& Capel 1993, Phillips & Parker 1984). Cross-linking FcyRIII on NK cells initiates
cell activation and ADCC effector function. Initial signalling depends on tyrosine
phosphorylation of the y or £ associated subunit of the FcR. This is rapidly followed
by phospholipase C (PLC) activity, and hydrolysis of membrane inositol triphosphate
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and diacylglycerol which mediate the mobilisation of intracellular calcium and the
activation of protein kinase C (Ting et al 1992, Azzoni et al 1992). PLC-derived second
messengers appear to be crucial for the development of ADCC function (Trinchieri
1989), but the protein tyrosine kinase linking FcR stimulation to PLC activation has not
been characterised. Although the y and C, subunits situated with FcyRIII do not possess
intrinsic enzymatic activity, they are associated with a 70kD tyrosine phosphoprotein.
Stimulation of FcyRIII induces increased association of this phosphoprotein with the £
subunit in T and NK cells (Vivier et al 1993). A similar protein located with the £
subunit in T cells has been identified as a tyrosine kinase, and the FcR-associated
dimers may interact with this non-receptor tyrosine kinase to initiate signalling and cell
activation.
There is less information on signalling events following the cross-linkage of FcyRII. A
recent study demonstrated the requirement for tyrosine phosphorylation for the
internalisation of FcyRII and FcyRI in a human monocytic cell line (Ghazizadeh &
Fleit 1994). FcyRII is not generally thought to be associated with any subunits in the
cell membrane, which would imply that tyrosine phosphorylation of the cytoplasmic tail
of the receptor occurs on stimulation. However, FcyRI, FcyRII and FcyRIII on
human myeloid cells all appear to be located with y-y homodimers. 20% of the FcyRII
on cultured human monocytes is associated with these subunits (Masuda & Roos
1993). Signalling may therefore be initiated in a similar way to that described above for
FcyRIII.
The events which follow the cross-linking of FcyRII on afferent lymph DC by immune
complexes have not been determined, and it is not known whether FcyRII on DC has
associated subunits. It is likely, however, that tyrosine phosphorylation of either the
cytoplasmic region of the receptor, or perhaps of an associated y chain, initiates cell
signalling and activation in a similar manner to that seen with FcyRIII on NK and T
cells. Modulation of DC surface molecules, migration to T cell areas in lymphoid
tissues and increased antigen processing and presentation to specific T cells could all be
enhanced by cell activation following FcR ligation. Signalling via FcyR on neutrophils
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and macrophages induces the release of inflammatory mediators such as leukotrienes
and prostaglandins, and the inflammatory cytokines IL-1, EL-6 and TNF-a (Debets et
al 1990, Krutmann et al 1990, Chantry et al 1989). DC may respond in a similar
manner and produce costimulatory cytokines such as IL-1 for enhanced activation of
specific T cells, although DC production of cytokines is still an area of some
controversy (Section 1.5.).
DC may also play a regulatory role in immune responses, by producing soluble forms
of FcyR. Soluble FcyRII is produced by human LC (Astier et al 1994), and could also
be released by afferent lymph DC. Murine IgG binding factors inhibit in vitro
production of antibody in a secondary response, and the soluble FcyRII released by
human LC competes with membrane-associated FcyRII for the binding of immune
complexes (Fridman et al 1992, Astier et al 1994). Thus soluble FcyRII could inhibit
the uptake of immune complexes by macrophages and DC in vivo, which in turn
would lead to less efficient presentation of antigen by these cells and downregulation
of antibody and T cell responses.
7.3. Modulation of DC Phenotype in a Secondary Immune Response
The changes in DC phenotype detected by FACS analysis after administration ofOVA
to a primed sheep were rapid and comprehensive, affecting all of the surface molecules
examined to some extent. Both the number of DC positive for a specific molecule, and
the level of expression on the positive cells, were decreased. This could be due to
downregulation of surface antigens on the same population of DC that is present in
resting lymph, or to a discrete cell population with different characteristics entering the
afferent lymph from the tissues. Similar changes in DC phenotype were observed after
in vitro culture. Although surface markers were downregulated where DC were
cultured with medium only or with OVA, a more pronounced decrease occurred in the
presence of OVA and specific antibody. This suggests that in the in vivo experiment
the same population ofDC may be altering in phenotype, rather than a new population
of cells entering the afferent lymph.
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The cross-linking of FcyR on the DC surface by immune complexes and subsequent
signalling may provide the stimulus for the initial downregulation of surface markers.
After an initial decrease, the number of DC staining with mAbs for particular molecules
returned to around the resting percentage positive after a variable time period. Indeed,
with some molecules such as CD1 and MHC class II, increased expression was
observed 24 hours after antigen administration compared with that at the start of the
experiment. This is in agreement with previous work, in which the number of MHC
class II molecules expressed per DC increased substantially, to twice the original level
two days after antigen administration, and six times the starting level by day 5
following OVA injection in a primed sheep (Hopkins et al 1989). The increased
expression of class II correlated with enhanced ability of DC to present a second
antigen to specific T cells. The initial downregulation of MHC class II may be a
mechanism to turnover those molecules on the DC surface already containing peptides,
so that newly synthesised class II molecules can interact with peptides from the recently
acquired antigen (i.e. OVA) for subsequent presentation to T cells. CD1 levels seem to
alter in a similar manner after antigen administration in vivo and in vitro. Although the
role of CD1 has not been fully elucidated, CD1 molecules have been reported to
function in the presentation of microbial antigens or hsps to T cells bearing y8 TCRs
(Porcelli et al 1989, Haas et al 1993), and also to a{3 T cells which do not express CD4
or CD8 (Porcelli et al 1992). Why CD1 expression should be modulated after
administration of OVA is unclear, although this could be a non-specific consequence of
antigen uptake via FcyR.
FcyR with bound ligands are sorted to lysosomes for degradation, therefore the uptake
of immune complexes by DC should lead to an initial downregulation of receptors on
the cell surface. A subsequent increase could occur following cell activation, to enable
the cell to take up more antigen in complex form. Alternatively the levels of FcyR on
the DC from afferent lymph may be further decreased, as occurs with isolated LC on
culture (Witmer-Pack et al. 1988). DC are capable of retaining antigen in immunogenic
form for a period of up to 2 days in culture (Pure et al 1990); once sufficient antigen
has been obtained downregulation of FcyR could decrease the likelihood of the first
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antigen being displaced by another. In the in vivo experiments involving OVA
administration to primed sheep, the percentage of DC staining with the anti-FPl serum
increased four-fold at the 4 hour time point in one sheep, and two-fold by 24 hours
after antigen administration in another. These increases may reflect an upregulation of
FcyR on the DC surface after antigen injection; however, the antiserum was not
absorbed against OVA, and rabbit anti-OVA antibodies could also be binding to OVA
exposed on the DC membrane. To determine the contribution of the rabbit anti-OVA
antibodies, the experiment could be repeated using rabbit antiserum from which anti-
OVA antibody activity had been removed. A further limitation with the antiserum is that
it appears to react with both FcyRI and FcyRII on the DC surface, as described in the
Western blot analysis in Chapter 4. Monoclonal antibodies specific for each ovine
FcyR type would be required to fully investigate changes in FcyR expression after
immune complex stimulation.
The mechanisms responsible for the alteration in the proportions ofDC expressing the
various surface molecules investigated are unclear. MHC class II molecules recycle
from the cell membrane, through an endocytic compartment and back to the membrane,
and this has been proposed as a means of loading surface class II dimers with fresh
peptides (Reid & Watts 1990). However, only newly synthesised class II molecules
appear to associate with peptides, therefore the recycling of class II may not play a
significant role in antigen presentation to CD4+ T cells (Davidson et al 1991). If class II
molecules on DC are internalised in a similar way and not returned to the cell
membrane, this process could account for the rapid decrease in expression of these
molecules after immune complex administration. Adhesion molecules could also be
internalised and not replaced at the cell surface: alternatively downregulation of both
adhesion and presentational molecules may be achieved by enzyme cleavage.
Alteration in DC expression of adhesion molecules may be necessary to enable the cells
to leave the dermis or epidermis. DC must have some method of remaining in the
tissues, and this is likely to involve interactions both with resident stromal cells and the
extracellular matrix. Some or all of these adhesive interactions probably must be broken
to enable DC to migrate to and enter afferent lymphatics; a decreased association with
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T cells in secondary responses, but they can also elicit CD8+ cytotoxic responses in
vivo and in vitro (Macatonia et al 1989, Nair at al 1993, Takahashi et al 1993).
Although exogenous antigens such as OVA would generally be processed by the
endocytic pathway for presentation on MHC class II molecules to CD4+ T cells,
antigens administered in the form of SMAA complexes and ISCOMs elicit both CD4
and CD8 T cell responses. A proportion of the immune complexes containing OVA
may be presented on class I molecules; this could be determined by experiments with
DC and CD8+ T cells separated from PBMs. Inhibition experiments with Brefeldin A
and chloroquine would distinguish between the class I pathway and the endocytic class
II processing pathway. The types of cells activated by DC in a secondary response in
vivo may be an important factor in determination of the outcome of the immune
response to particular pathogens.
7.5 Final Conclusions
The main findings described in this thesis included the pronounced and rapid
modulation of surface markers on DC obtained from the afferent lymph of primed
sheep after administration of antigen. These alterations in DC phenotype may be
required for efficient processing and presentation of antigen and migration to the T cell
areas of the draining lymph node. Afferent lymph DC were found to express FcyRI
and FcyRII, demonstrated by flow cytometry and Western blot analysis with antiserum
raised against a peptide from the sequence of bovine FcyRI. Functional studies showed
that specific antibody greatly increased the response of CD4+ T cells to substimulatory
concentrations of antigen presented by DC, depending on the antigen/ antibody ratio.
An intact Fc portion of specific antibody was required for potentiation of the T cell
response. These results suggest enhanced presentation of antigen by DC following the
uptake of immune complexes via Fc receptors. Similar observations were made in
experiments with unfractionated PBMs. DC FcyR would play an important role in the
uptake and presentation of antigen in secondary responses in vivo, in which specific
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